REMARKS

The application has been amended to include a Sequence Listing in conformity with 37 C.F.R. § § 1.821-1.825. Submitted herewith is the Sequence Listing, a copy of the Sequence Listing in computer readable form (CRF), as well as a Statement under 37 C.F.R. § § 1.821(f) and 1.825. Appendices A and B also include the Sequence Listing.

It is respectfully requested that no new matter has been added by the amendment. However, if any questions remain after consideration of the instant amendments, the Office is kindly requested to contact applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: September 6, 2002

ACT/TLW/csw

N:\2183\5226\second preliminary amendment.wpd

APPENDIX B

(VERSION OF SUBSTITUTE SPECIFICATION EXCLUDING CLAIMS WITH MARKINGS TO SHOW CHANGES MADE)

(Serial No. 10/040,949)

PATENT
Attorney Docket 2183-5226US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: _____

Date of Deposit with USPS: _____

Person making Deposit: _____

APPLICATION FOR LETTERS PATENT

for

INFECTION WITH ~~CHIMAERIC~~CHIMERIC ADENOVIRUSES OF CELLS NEGATIVE FOR THE ADENOVIRUS SEROTYPE 5 COXSACKI ADENOVIRUS RECEPTOR (CAR)

Inventors:
Menzo Havenga
Ronald Vogels

Attorney:
Allen C. Turner
Registration No. 33,041
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110
(801) 532-1922

~~Title:~~ INFECTION WITH ~~CHIMAERIC~~CHIMERIC ADENOVIRUSES OF CELLS NEGATIVE FOR THE ADENOVIRUS SEROTYPE 5 COXSACKI ADENOVIRUS RECEPTOR (CAR).

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is a continuation of International Application Number PCT/NL00/00481 filed on July 7, 2000 designating the United States of America, International Publication No. WO 01/04334 (January 18, 2001), the contents of the entirety of which is incorporated herein by this reference.

TECHNICAL FIELD

[0002] The invention relates to the field of molecular genetics and medicine. In particular, the invention relates to the field of gene therapy, especially gene therapy involving adenovirus.

BACKGROUND

[0003] In gene therapy, genetic information is delivered to a host cell in order to either correct (supplement) a genetic deficiency in ~~said~~the cell, ~~or~~ to inhibit an unwanted function in ~~said~~the cell, or to eliminate ~~said~~the host cell. Of course, the genetic information can also be intended to provide the host cell with a wanted function, for instance, to supply a secreted protein to treat other cells of the host, etc.

[0004] Thus, basically three different approaches to gene therapy exist. The first is directed towards compensating a deficiency present in a (mammalian) host. The second is directed towards the removal or elimination of unwanted substances (organisms or cells). The third is directed towards providing a cell with a desired function.

[0005] For the purposes of gene therapy, adenoviruses have been proposed as a suitable vehicle to deliver genes to the host. Gene-transfer vectors derived from adenoviruses (so-called "adenoviral vectors") have a number of features that make them particularly useful for gene transfer. 1) Adenovirus biology is characterized in detail. 2) Adenovirus is generally not associated with severe human pathology. 3) Adenovirus is extremely efficient in introducing its DNA into the host cell. 4) Adenovirus can infect a wide variety of cells and has a broad host-

range. 5) Adenovirus can be produced at high virus titers in large quantities. 6) Adenovirus can be rendered replication-defective by deletion of the early-region 1 (El) of the viral genome (Brody et al., 1994).

[0006] However, there are still drawbacks associated with the use of adenoviral vectors, especially the well-investigated serotypes of subgroup C adenoviruses. These serotypes require the presence of the Coxsacki adenovirus receptor (CAR) on cells for successful infection. Although this protein is expressed by many cells and established cell lines, this protein is absent for many other primary cells and cell lines making the latter cells difficult to infect with serotypes 1, 2, 5, and 6.

[0007] The adenovirus genome is a linear double-stranded DNA molecule of approximately 36,000 base pairs. The adenovirus DNA contains identical Inverted Terminal Repeats (ITR) of approximately 90-140 base pairs with the exact length depending on the serotype. The viral origins of replication are within the ITRs exactly at the genome ends.

[0008] Most adenoviral vectors currently used in gene therapy have a deletion in the E1 region, where novel genetic information can be introduced. The E1 deletion renders the recombinant virus replication defective (Levrero et a1, 1991). It has been demonstrated extensively that recombinant adenovirus, in particular serotype 5, is suitable for efficient transfer of genes *in vivo* to the liver, the airway epithelium and solid ~~tumours~~tumors in animal models and human xenografts in immunodeficient mice (Bout, 1996; Blaese et al., 1995). Thus, preferred methods for *in vivo* gene transfer into target cells make use of adenoviral vectors as gene delivery vehicles.

[0009] At present, six different subgroups of human adenoviruses have been proposed which, in total, encompasses 51 distinct adenovirus serotypes. Besides these human adenoviruses, an extensive number of animal adenoviruses have been identified (*see*, Ishibashi et al., 1983).

[0010] A serotype is defined on the basis of its immunological distinctiveness as determined by quantitative ~~neutralisation~~neutralization with animal antisera (*e.g.*, horse, and/or rabbit). If ~~neutralisation~~neutralization shows a certain degree of cross-reaction between two viruses, distinctiveness of serotype is assumed if A) the hemagglutinins are unrelated, as shown by lack of cross-reaction on hemagglutination-inhibition, or B) substantial biophysical/

biochemical differences in DNA exist (Francki et al., 1991). The nine serotypes identified last (*i.e.*, 42-51) were isolated for the first time from HIV–infected patients (Hierholzer et al., 1988; Schnurr et al., 1993; De Jong et al., 1998). For reasons not well understood, most of such immuno-compromised patients shed adenoviruses that were rarely or never isolated from immuno-competent individuals (Hierholzer et al., 1988, 1992; Khoo et al., 1995;; De Jong et al., 1998).

[0011] The adenovirus serotype 5 is most widely used for gene therapy purposes. Similar to serotypes 2, 4 and 7, serotype 5 has a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, it is known that, for instance, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. For a detailed overview of the disease association of the different adenovirus serotypes, see ~~table~~Table 1. The underlying reason for the different natural affiliations of serotypes towards specific organs can be manifold. Such reasons may include, but need not be limited to, the observation that serotypes differ in the route of infection or make use of different receptor molecules or ~~internalisation~~internalization pathways, or that a serotype can infect many tissues/organs but it can only replicate in one organ because of the requirement of certain cellular factors for replication. As mentioned before, it is presently unknown which mechanisms are responsible for the observed differences in human disease association.

[0012] One of the problems associated with the development of effective Gene Therapy protocols for the treatment of disease is the limitation of the current vectors to effectively transduce cells *in vivo*. One of the most effective ways to deliver foreign genetic material to cells *in vivo* is through the use of adenovirus vectors. Although, the vector system is very efficient, the current adenovirus vector technology has its ~~limitation~~limitations, ~~Specifically were~~specifically, where certain cell types need to be transduced that are normally not very efficiently transduced by Adenovirus 2 or 5. Examples of such relatively resistant cell types include endothelial cells, smooth muscle cells, dendritic cells, neuronal cells, glial cells, synovical cells, primary fibroblasts, cells from the amniotic fluid, hemopoietic stem cells, and monocytic/-macrophage cells, etc. Thus, in one aspect, the invention provides a method for delivering a nucleic acid of interest to a host cell by means of a gene delivery vehicle based on adenoviral material, whereby ~~said~~the gene delivery vehicle delivers the nucleic acid to the host

cell by associating with a binding site and/or a receptor present on CAR-negative cells, ~~said~~the binding site and/or receptor being a binding site and/or a receptor for adenovirus subgroups D and/or F. The method may advantageously be used to efficiently transduce cells both *in vitro* and *in vivo*.

SUMMARY OF THE INVENTION

[0013] The present invention was made during research with ~~chimaeric~~chimeric adenoviruses~~.~~, ~~Said~~the ~~chimaeric~~chimeric adenoviruses comprising capsids derived from adenovirus 5 of which at least part of the adenovirus 5 fiber protein was replaced by a fiber protein from a different adenovirus serotype. It was observed that ~~chimaeric~~chimeric adenoviruses ~~comprising~~comprised fiber protein from adenovirus serotypes belonging to subgroup D or subgroup F were capable of efficiently transducing CAR-negative target cells.

[0014] ~~Adenovirus~~Adenoviruses 2 and 5 belong to adenovirus subgroup C. Together with the adenoviruses of subgroups A, and D-F, the subgroup C adenoviruses were, before the present invention, thought to attach to cells via the Coxsacki adenovirus receptor (CAR) (Roelvink et al, 1998).

[0015] It has been shown that adenoviruses of subgroup B such as Ad3 bind to a different receptor than CAR (Defer et al, 1990). Likewise, it was demonstrated that receptor specificity could be altered by exchanging the Ad3 with the Ad-5 knob protein, and vice versa (Krasnykh et al., 1996; Stevenson et al., 1995, 1997).

[0016] A host cell may be any host cell as long at it comprises a binding site and/or a receptor present on CAR-negative cells, ~~said~~the binding site and/or receptor being a binding site and/or a receptor for adenovirus subgroups D and/or F. Preferably, ~~said~~the cell is a human cell. ~~Said~~The cell may be a cell present in a culture dish or be part of a whole organism.

[0017] Preferably ~~said~~the CAR-negative cells are hemopoietic cells or amniotic fluid cells or derivatives thereof. Preferably, ~~said~~the CAR-negative hemopoietic cells are K562 cells. Preferably, ~~said~~the CAR-negative amniotic fluid cells are amniotic villi or chorion villi cells, or derivatives thereof.

[0018] A gene delivery vehicle according to the invention may be any vehicle capable of transferring nucleic acid into cells. Preferably, ~~said~~the gene delivery vehicle is a viral vector particle~~,~~; more preferably, ~~said~~the gene delivery vehicle is an adenoviral vector particle. The word "gene" in the term "gene delivery vehicle" does not reflect a situation wherein always an entire gene is delivered by ~~said~~the vehicle. The word gene, in this respect, merely reflects the presence of a nucleic acid of interest. ~~Said~~The nucleic acid may comprise an entire gene, an artificial sequence, a recombinant nucleic acid, a protein coding domain, a cDNA, or a sequence coding for anti-sense RNA, mRNA and/or other kind of nucleic acid.

[0019] Suitable adenovirus material may comprise an adenovirus capsid or a functional part, derivative and/or analogue thereof. ~~Said~~The adenovirus capsid preferably comprises an adenovirus subgroup D or subgroup F capsid, or a functional part, derivative and/or analogue thereof. ~~Said~~The adenovirus capsid may also be a ~~chimaeric~~chimeric capsid comprising proteins or parts thereof from at least two different adenovirus serotypes or derivatives and/or analogues thereof. Preferably, at least part of a fiber protein of ~~said~~the ~~chimaeric~~chimeric capsid is derived from an adenovirus of subgroup D and/or subgroup F or a functional derivative and/or analogue thereof. Preferably, capsid proteins other ~~then~~than ~~said~~the part of a fiber protein~~,~~ are derived from an adenovirus of subgroup C, preferably of adenovirus 5 or adenovirus 2. Suitable derivatives of ~~said~~the adenovirus capsids may, among other methods, be obtained through so-called silent amino-acid substitution in one or more capsid proteins.

[0020] Preferably, ~~said~~the adenovirus material comprises at least part of an adenovirus fiber protein. Preferably, ~~said~~the adenovirus fiber protein is derived from an adenovirus of subgroup D or subgroup F or a functional part, derivative and/or analogue thereof. Preferably, ~~said~~the part of a fiber protein is a part involved in binding to a receptor and/or a binding site on a target cell. Typically, but not necessarily, ~~said~~the part of an adenovirus fiber protein involved in binding to a receptor and/or a binding site on a target cell is a part of the knob. Adenovirus fiber protein comprises at least three functional regions. One region, the base, is responsible for anchoring the fiber to a penton base of the adenovirus capsid. Another region, the knob, is typically associated with receptor recognition, whereas the shaft region functions as a spacer separating the base from the knob. Various regions may also have other functions. For instance, the shaft is presumably also involved in target cell specificity. Each of the regions

mentioned above may be used to define a part of a fiber. However, regions of a fiber may also be identified in another way. For instance, the knob region comprises ~~of~~ a receptor binding region and a shaft binding region. The base region comprises ~~of~~ a penton base binding region and a shaft binding region. Moreover, the shaft comprises ~~of~~ repeated stretches of amino acids. Each of these repeated stretches may be a part.

[0021] A receptor and/or binding site binding part of a fiber protein may be a single region of a fiber protein or a functional part thereof, or a combination of regions or parts thereof of at least one fiber protein, wherein ~~said~~the receptor and/or binding site binding part of a fiber protein, either alone or in combination with one or more other proteins of a adenovirus capsid, determines the efficiency with which a gene delivery vehicle can transduce a given cell or cell type, preferably, but not necessarily, in a positive way. Needless to say, ~~that said~~the fiber and/or a capsid may comprise further modifications to adapt the fiber protein and/or the capsid to specific other needs, which a person skilled in the art will be capable of doing.

[0022] A receptor and/or a binding site for adenovirus subgroups D and/or F may be any kind of molecule capable of associating with an adenovirus of subgroup D and/or F. In and/or on the surface of a cell, ~~said~~the receptor and/or binding site must be able to associate with ~~said~~the adenovirus of subgroup D and/or F provided to ~~said~~the cell. ~~Said~~The receptor and/or binding site may be part of a complex present in and/or on ~~said~~the cell. ~~Said~~The receptor and/or binding site does not need to be able to associate with an adenovirus of subgroup D and/or F all the time as long as it is capable of doing so some of the time. ~~Said~~The receptor and/or binding site may ~~further~~ also be a receptor and/or binding site for another virus and/or gene delivery vehicle, although this does not have to be so. A person skilled in the art may want to determine whether an adenovirus serotype belonging to ~~another~~a subgroup other than D and/or F can also ~~utilise~~utilize the receptor and/or binding site for adenovirus subgroups D and/or F.

[0023] In another aspect, the invention provides the use of a gene delivery vehicle comprising a nucleic acid of interest and comprising adenoviral material involved in binding to a host cell, ~~said~~the material being from a subgroup D and/or F adenovirus, in delivering ~~said~~the nucleic acid of interest to a CAR-negative cell. With the knowledge of a novel pathway for the transduction of cells using adenovirus material, it becomes possible to approach this novel pathway also through means other ~~means then~~than ~~said~~the material derived from ~~a~~ subgroup D

and/or F. A person skilled in the art ~~recognises~~recognizes this and will be able to devise means to accomplish this, for instance, through the use of antibodies directed toward a crucial component of ~~said~~the pathway, together with a membrane fusion peptide. Such means and methods are also within the scope of the invention.

[0024] In another aspect, the invention provides a gene delivery vehicle being a ~~chimaera~~chimera based on at least two adenoviruses, whereby a cell-~~recognising~~-recognizing element of ~~said~~the gene delivery vehicle is based on adenoviral material from a subgroup D and/or F adenovirus, which material confers the capability of infecting CAR-negative cells.

[0025] Preferably, ~~said~~the adenoviral material is based on the fiber, penton, and/or hexon proteins of a subgroup D and/or subgroup F adenovirus.

[0026] To date, six different subgroups of human adenoviruses have been proposed which, in total, ~~encompasses~~encompass 51 distinct adenovirus serotypes. A serotype is defined on the basis of its immunological distinctiveness as determined by quantitative ~~neutralisation~~neutralization with animal antisera (*e.g.*, horse, rabbit). If ~~neutralisation~~neutralization shows a certain degree of cross-reaction between two viruses, distinctiveness of serotype is assumed if A) the hemagglutinins are unrelated, as shown by lack of cross-reaction on hemagglutination-inhibition, or B) substantial biophysical/ biochemical differences in DNA exist (Francki et al, 1991). The nine serotypes identified last (42-51) were isolated for the first time from HIV-infected patients (Hierholzer et al 1988; Schnurr et al 1993~~;~~). For reasons not well understood, most of such immune-compromised patients shed adenoviruses that were rarely, or never, isolated from immune-competent individuals (Hierholzer et al., 1988, 1992; Khoo et al., 1995~~;~~; De Jong et al., 1998). The usefulness of these adenoviruses, or cross-~~immunising~~immunizing adenoviruses to prepare gene delivery vehicles may be seriously hampered~~,~~ since the individual to which the gene delivery vehicle is provided~~,~~ will raise a ~~neutralising~~neutralizing response to such a vehicle before long.

[0027] There is thus a need in the field of gene therapy to provide gene delivery vehicles, preferably based on adenoviruses, which do not encounter pre-existing immunity and/or which are capable of avoiding or diminishing ~~neutralising~~neutralizing antibody responses. Thus, preferably~~,~~ a gene delivery vehicle of the invention further comprises an element from adenovirus 35 or a functional equivalent thereof, responsible for at least partially avoiding an immune

response against adenovirus 35. A functional equivalent/homologue of adenovirus 35 (element) for the purpose of the present invention is an adenovirus (element) which, like adenovirus 35, encounters pre-existing immunity in less than about 10% of the hosts, at least in a significant geographic region of the world, to which it is administered for the first time, or which is capable in more than about 90% of the hosts, at least in a significant geographic region of the world, to which it is administered to avoid or diminish the immune response. Typical examples of such adenoviruses are adenovirus serotypes 34, 26 and 48.

[0028] In another embodiment, a gene delivery vehicle according to the invention comprises an element of adenovirus 16 or a functional equivalent thereof, which element confers ~~said~~the virus with an enhanced capability to infect smooth muscle cells and/or synoviocytes. A functional equivalent of an element of adenovirus 16 in this respect, is an element from another subgroup B virus. Preferably, ~~said~~the element is a tissue tropism-determining part of a fiber protein. Typically, a tissue tropism-determining part of an adenovirus fiber protein is a part that influences the transduction efficiency of a cell.

[0029] For ~~Gene~~gene ~~Therapeutic~~therapeutic purposes, one typically does not want an adenovirus batch to be administered to a host cell which contains replication competent adenovirus, although this is not always true. In general, ~~therefor~~therefore, it is desired to omit a number of genes (but at least one) from the adenoviral genome on the vector encoding the virus and to supply these genes in the genome of the cell in which the vector is brought to produce adenovirus. Such a cell is usually called a packaging cell. The invention thus also provides a packaging cell for producing an adenovirus according to the invention, comprising, *in trans,* all elements necessary for adenovirus production not present on the adenoviral vector according to the invention. Typically, vector and packaging cells have to be adapted to one another in that they have all the necessary elements, but that they do not have overlapping elements which lead to replication competent virus by recombination. In a preferred embodiment, ~~said~~the packaging cell is, or is derived from, PER.C6 (ECCAC deposit number 96022940).

[0030] In another embodiment, a gene delivery vehicle according to the invention comprises an adenovirus vector. ~~Said~~The adenovirus vector may be a classical adenovirus vector, a minimal adenovirus vector, or an integrating adenovirus such as an Ad/AAV ~~chimaeric~~chimeric vector, a retro-adenovirus or a transposon-adenovirus, or yet another different

kind of adenovirus vector. ~~With an~~An "integrating adenovirus" vector, for the purpose of the invention, ~~is meant~~means a vector comprising nucleic acid derived from an adenovirus and further comprising means for the integration of at least part of the nucleic acid of ~~said~~the vector into the host cell genome. ~~Said~~The means are preferably derived from a nucleic acid with the inherent capacity to integrate into the host cell genome. Such nucleic acid with the inherent capacity to integrate into the host cell genome may be derived from a transposon or transposon-like element, a retrovirus, and/or an adeno-associated virus or a different virus with the capacity to integrate nucleic acid into the host cell genome.

[0031] In a preferred embodiment, ~~said~~the adenovirus vector comprises nucleic acid encoding at least a receptor and/or binding site determining part of a fiber protein of an adenovirus of subgroup D or subgroup F. In a preferred embodiment the invention provides a method for producing ~~said~~the adenovirus vector, comprising welding together, preferably through homologous recombination, two nucleic acid molecules comprising partially overlapping sequences wherein ~~said~~the overlapping sequences allow essentially only one homologous recombination which leads to the generation of a physically linked nucleic acid comprising at least two functional adenovirus inverted terminal repeats, a functional encapsulation signal and a nucleic acid of interest or functional parts, derivatives and/or analogues thereof. In a preferred embodiment, at least one of ~~said~~the at least two nucleic acid molecules comprises nucleic acid encoding at least a receptor and/or binding site determining part of a fiber protein of an adenovirus of subgroup D or subgroup F.

[0032] An important aspect in this embodiment of the invention is that ~~said~~the partially overlapping sequences allow essentially only homologous recombination leading to the generation of a functional adenovirus vector capable of being replicated and packaged into adenovirus particles in the presence of the required transacting functions. With "essentially only one" it is meant that ~~said~~the overlapping sequences in each nucleic acid comprise essentially only one continuous sequence wherein homologous recombination leading to the generation of a functional adenovirus may occur. Within ~~said~~the continuous sequence, the actual number of homologous recombination events may be higher than one. Non-continuous overlapping sequences are not desired because they reduce the reliability of ~~said~~the method. Non-continuous

overlapping sequences are also not desired because they reduce the overall efficiency of ~~said~~the method, presumably due to the generation of undesired homologous recombination products.

[0033] A preferred embodiment of the invention provides a method for generating an adenovirus vector wherein both of ~~said~~the nucleic acid molecules comprise only one adenovirus inverted terminal repeat or a functional part, derivative and/or analogue thereof. In one aspect, one or both of ~~said~~the two nucleic acid molecules have undergone modifications prior to ~~said~~the welding together. ~~Said~~The modification may include the welding together of different nucleic acid molecules, leading to the generation of one or both of ~~said~~the two nucleic acid molecules. In a preferred embodiment, ~~said~~the different nucleic acids are welded together through homologous recombination of partially overlapping sequences. In a further aspect, ~~said~~the welding together is performed in a cell or a functional part, derivative and/or analogue thereof. Preferably, ~~said~~the cell is a mammalian cell. More preferably, ~~said~~the welding together is performed in a cell expressing E1-region-encoded proteins. Preferably, ~~said~~the cell is a PER.C6 cell (ECACC deposit number 96022940) or a derivative thereof. In a preferred embodiment, ~~said~~the nucleic acid molecules are not capable of replicating in ~~said~~the mammalian cell prior to ~~said~~the welding together. ~~Said~~The replication is undesired since it reduces the reliability of the methods of the invention, presumably through providing additional targets for undesired homologous recombination. ~~Said~~The replication is also not desired because it reduces the efficiency of the methods of the invention, presumably because ~~said~~the replication competes for substrate or adenovirus-transacting functions with the replication of ~~said~~the adenovirus vector.

[0034] In a preferred embodiment, one of ~~said~~the nucleic acid molecules is relatively small and the other is relatively large. This configuration is advantageous because it allows easy manipulation of ~~said~~the relatively small nucleic acid molecule allowing, for example, the generation of a large number of small nucleic acid molecules comprising different nucleic ~~acid~~acids of interest, for instance, for the generation of an adenovirus vector library. ~~Said~~The configuration is also desired because it allows the production of a large batch of quality-tested large nucleic acid ~~molecule~~molecules. The amplification of large nucleic acid molecules, for instance, in bacteria, is difficult in terms of obtaining sufficient amounts of ~~said~~the large nucleic acid. The amplification of large nucleic acid molecules, for instance, in bacteria, is also difficult to control because a small modification of ~~said~~the large nucleic acid is not easily detected.

Moreover, for reasons not quite understood, some large vectors are more stable in bacteria or yeasts than others. ~~Said~~The configuration, however, allows the generation of a standard batch of ~~a~~ large nucleic acid ~~molecule~~molecules which can be thoroughly tested, for instance, through generating a control adenovirus of which the efficiency and the reliability of production is known, and determining ~~said~~the parameters of a new batch of large nucleic acid ~~molecule~~molecules. Once validated, ~~said~~the batch may be used for the generation of a large number of different adenovirus vectors through combining ~~said~~the large molecule with a large number of different small nucleic acid molecules. ~~Said~~The system, therefore, also allows for the selection and/or manipulation of vectors comprising a large nucleic acid molecule of the invention to allow a suitable yield of intact large nucleic acid.

[0035] In another embodiment, ~~said~~the cell comprising nucleic acid encoding E1-region proteins, further comprises a nucleic acid encoding an adenovirus E2-region and/or an adenovirus E4-region protein. Preferably, ~~said~~the cell further comprising nucleic acid encoding an adenovirus E2-region and/or an adenovirus E4-region protein is a derivative of PER.C6.

[0036] In another aspect, the invention provides a receptor and/or a binding site for adenoviruses type D and/or F, present on or associated with CAR-negative cells. Preferably, ~~said~~the receptor and/or a binding site is present on K562 cells, amniotic fluid-derived cells, and/or primary fibroblast cells.

[0037] In yet another aspect, the invention provides the use of a receptor and/or a binding site for adenoviruses type D and/or F, present in and/or on a cell, for the delivery of nucleic acid to ~~said~~the cell.

[0038] In yet another embodiment, the invention provides the use of a gene delivery vehicle according to any one of claims 1-14, in a pharmaceutical.

[0039] In another aspect, the invention provides a capsid protein derived from a subgroup D and/or a subgroup F adenovirus or a functional part, derivative and/or analogue thereof. Preferably, ~~said~~the protein is a fiber protein. The invention further provides a nucleic acid encoding a capsid protein of the invention. Preferably, ~~said~~the nucleic acid comprises a fiber sequence from a subgroup D and/or a subgroup F, as depicted in ~~figure~~Figure 7.

BRIEF DESCRIPTION OF THE FIGURES

[0040] Table 1: Association of human adenovirus serotypes with human disease.

[0041] Table 2: Oligonucleotides and degenerate oligonucleotides used for the amplification of DNA encoding for fiber protein derived from alternative human adenovirus serotypes. Bold letters in oligonucleotides A-E (SEQ ID NOS:17-21) represent an NdeI restriction site. Bold letters in oligonucleotides 1-6 (SEQ ID NOS:22-27) and 8 (SEQ ID NO:29) represent an NsiI restriction site. Bold letters in oligonucleotide 7 (SEQ ID NO:28) represents a PacI restriction site.

[0042] Table 3: Production results of fiber chimeric adenoviruses. The number of virus particles per ml was determined using HPLC. The number of infectious units (IU) per milliliter was determined through titration on human 911 cells. For infection experiments, the number of virus particles per milliliter is taken from all chimeric adenoviruses since IU/ml reflects a receptor-mediated process.

[0043] Table 4: Flow cytometric results on expression of integrins $\alpha_v\beta3$ and $\alpha_v\beta5$, the Coxsacki adenovirus receptor (CAR), and MHC class I on the membranes of human cell lines and human primary cells. A549: Human lung carcinoma cell line (ATCC, CCL-1185). K562: Human erythroid leukemia (ATCC, CCL-243). SupT1: Human Lymphoblast hybrid B and T (ATCC, CRL-1991). GM09503: Human primary fibroblasts. HepG2: Human liver carcinoma (ATCC, HB8065). CEM: human lymphoblast cells (ATCC, CRL-1992). HeLa: Human cervix carcinoma (ATCC, CCL-2). Primary amniocytes and chorion villi cells were obtained from the Department of Antropogenetics, Leiden, The Netherlands. Primary smooth muscle cells, human umbilical vein endothelial cells, and synoviocytes were obtained from TNO-PG, Leiden, The Netherlands. Shown is the percentage of cells expressing either molecule on their membrane. ND: not determined. 0% means undetectable expression of the molecule on the membrane of the cell using flow cytometry. 100% means high expression of the molecule on the cell membrane.

[0044] Figure 1: Schematic presentation of adapter plasmid pMLPI.TK.

[0045] Figure 2: Schematic presentation of adapter plasmid pAd/L420-HSA.

[0046] Figure 3: Schematic presentation of adapter plasmid pAd5/CLIP.

[0047] Figure 4: Schematic presentation of plasmid system which requires only one recombinational event to generate recombinant adenoviruses.

[0048] Figure 5: Schematic presentation of plasmid system which requires two recombinational events to generate recombinant adenoviruses.

[0049] Figure 6: Schematic presentation of generation of plasmid pBr/AdBamRDeltaFib in which the Adenovirus type 5 fiber DNA is replaced by a short DNA stretch containing a unique NsiI site.

[0050] Figure 7: Fiber protein sequences of adenovirus serotypes 8 (SEQ ID NO:30), 9 (SEQ ID NO:31), 13 (SEQ ID NO:32), 14 (SEQ ID NO:33), 20 (SEQ ID NO:34), 23 (SEQ ID NO:35), 24 (SEQ ID NO:36), 25 (SEQ ID NO:37), 27 (SEQ ID NO:38), 28 (SEQ ID NO:39), 29 (SEQ ID NO:40), 30 (SEQ ID NO:41), 32 (SEQ ID NO:42), 33 (SEQ ID NO:43), 34 (SEQ ID NO:44), 35 (SEQ ID NO:45), 36 (SEQ ID NO:46), 37 (SEQ ID NO:47), 38 (SEQ ID NO:48), 39 (SEQ ID NO:49), 42 (SEQ ID NO:50), 43 (SEQ ID NO:51), 44 (SEQ ID NO:52), 45 (SEQ ID NO:53), 46 (SEQ ID NO:54), 47 (SEQ ID NO:55), 48 (SEQ ID NO:56), 49 (SEQ ID NO:57), and 51 (SEQ ID NO:58). Bold letters represent part of the tail of adenovirus serotype 5. If bold letters are not present, it means that a PCR fragment was sequenced which does not contain the Ad5 tail. An X present in the sequence means unidentified amino acid due to unidentified nucleotide(s). At the end of the sequence, the stop codon of the fiber is represented by a dot.

[0051] Figure 8: Transduction of human lung carcinoma cells (A549) with a panel of chimeric adenoviruses carrying the fiber of adenovirus 12, 16, 17, 28, 32, 40-L, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500 (*see*, legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per μg of protein.

[0052] Figure 9: Transduction of human erythroid leukemia cells (K562) with a panel of chimeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40-S, 40-L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (*see*, legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per μg of protein. Error bars represent SD.

[0053] Figure 10: Transduction of human primary fibroblasts (GM09503) with a panel of chimeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40-L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per µg of protein. Error bars represent SD.

[0054] Figure 11: Transduction of human lymphoblast cells (SupT1) with a panel of chimeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40-S, 40-L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (*see,* legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per µg of protein. Error bars represent SD.

[0055] Figure 12: Transduction of human chorion villi cells with a panel of chimeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40-L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (*see,* legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per µg of protein. Error bars represent SD.

[0056] Figure 13: Transduction of human hepatic cells (HEPG2) with a panel of chimeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40-S, 40-L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (*see,* legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per µg of protein. Error bars represent SD.

DETAILED DESCRIPTION OF THE INVENTION

~~**Detailed description.**~~

[0057] It has been demonstrated in mice that upon *in vivo* systemic delivery of recombinant adenovirus serotype 5 for gene therapy purposes, approximately 99% of the virus is trapped in the liver (Herz et al., 1993). Therefore, alteration of the adenovirus serotype 5 host cell range to be able to target other organs *in vivo* is a major interest of the invention.

[0058] The initial step for successful infection is binding of adenovirus to its target cell, a process generally thought to be mediated through fiber protein. The fiber protein has a trimeric structure (Stouten et al., 1992) with different lengths, depending on the virus serotype (Signas et al., 1985; Kidd et ~~all~~al. 1993). Different serotypes have polypeptides with structurally similar N- and C-termini, but different middle stem regions. N-terminally, the first 30 amino acids are involved in anchoring of the fiber to the penton base (Chroboczek et al., 1995), especially the conserved FNPVYP region in the tail (Arnberg et al., 1997). The C-terminus, or knob, is generally thought to be responsible for initial interaction with the cellular adenovirus receptor. After this initial binding, secondary binding between the capsid penton base and cell-surface integrins is proposed to lead to ~~internalisation~~internalization of viral particles in coated pits and endocytosis (Morgan et al., 1969; Svensson et al., 1984; Varga et al., 1992; Greber et al., 1993; Wickham et al., 1994).

[0059] Integrins are αβ-heterodimers of which at least 14 α-subunits and 8 β-subunits have been identified (Hynes et al, 1992). The array of integrins expressed in cells is complex and will vary between cell types and cellular environment. Although the knob contains some conserved regions~~,~~ between serotypes, knob proteins show a high degree of variability, indicating that different adenovirus receptors might exist. For instance, it has been demonstrated that adenoviruses of subgroup C (Ad2, Ad5) and adenoviruses of subgroup B (Ad3) bind to different receptors (Defner et al., 1990). By using baculovirus-produced soluble CAR, as well as adenovirus serotype 5 knob protein, Roelvink et ~~al~~al. concluded, via interference studies, that all adenovirus serotypes, except serotypes of subgroup B, enter cells via CAR (Roelvink et al., 1998). The latter, which is now generally accepted in the field, if valid, should thus limit the complexity of using different serotypes for gene therapy purposes.

[0060] Besides the involvement in cell binding, the fiber protein also contains the type-specific γ-antigen, which together with the ε-antigen of the hexon, determines the serotype specificity. The γ-antigen is ~~localised~~localized on the fiber and it is known that it consists of 17 amino acids (Eiz et al., 1997). The anti-fiber antibodies of the host are therefore directed to the trimeric structure of the knob. To obtain re-directed infection of recombinant adenovirus serotype 5, several approaches have been, or still are, under investigation. Wickham et al. has altered the RGD (Arg, Gly, Asp) motif in the penton base, which is believed to be responsible

for the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrin binding to the penton base. They have replaced this RGD motif by another peptide motif which is specific for the $\alpha_4\beta_1$ receptor. In this way, targeting the adenovirus to a specific target cell could be accomplished (Wickham et al., 1995, 1996). Krasnykh et al. has made use of the HI loop available in the knob. This loop is, based on X-ray crystallographics, located on the outside of the knob trimeric structure and, therefore, is thought not to contribute to the intramolecular interactions in the knob (Krasnykh et al., 1998). However, complete CAR-independent infection was not observed.

[0061] It is an object of the present invention to provide a method and means by which an adenovirus can infect cells negative for the CAR protein. Therefore, the generation of ~~chimaeric~~chimeric adenoviruses based on adenovirus serotype 5 with a modified fiber gene is described. For this purpose, two or three plasmids, which together contain the complete adenovirus serotype 5 genome, were constructed. From a plasmid, the DNA encoding the adenovirus serotype 5 fiber protein was essentially removed and replaced by linker DNA sequences which facilitate easy cloning. This plasmid subsequently served as template for the insertion of DNA encoding for fiber protein derived from different adenovirus serotypes (*e.g.*, human or animal). The DNAs derived from the different serotypes were obtained using the polymerase chain reaction technique in combination with (degenerate) oligo-nucleotides. At the former E1 location in the genome of adenovirus serotype 5, any gene of interest can be cloned. A single transfection procedure of the two or three plasmids together resulted in the formation of a recombinant ~~chimaeric~~chimeric adenovirus. Although successful introduction of changes in the adenovirus serotype 5 fiber and penton-base have been reported, the complex structure of the knob and the limited knowledge of the precise amino acids interacting with CAR, render such targeting approaches laborious and difficult.

[0062] To overcome the limitations described above, we used pre-existing adenovirus fibers to ~~maximise~~maximize the chance of obtaining recombinant adenovirus which can normally assemble in the nucleus of a producer cell and which can be produced on pre-existing packaging cells. By generating a ~~chimaeric~~chimeric adenovirus serotype 5-based fiber library containing fiber proteins of all other human adenovirus serotypes, we have developed a technology which enables rapid screening for a recombinant adenoviral vector with preferred infection characteristics.

[0063] In one aspect, this invention describes ~~chimaeric~~chimeric adenoviruses and methods to generate these viruses that have ~~an~~a tropism different from that of adenovirus serotype 5. This ~~chimaeric~~chimeric adenovirus serotype 5 is able to infect cell types which do not express the CAR protein much more efficiently both *in vitro* and *in vivo* than the adenovirus serotype 5. Such cells include, but are not limited to, endothelial cells, smooth muscle cells, dendritic cells, neuronal cells, glial cells, synovical cells, primary fibroblasts, cells from the amniotic fluid, hemopoietic stem cells, and monocytic/ macrophage cells, etc.

[0064] In another aspect, the invention describes the construction and use of plasmids consisting of distinct parts of adenovirus serotype 5 in which the gene encoding for fiber protein has been replaced with DNA derived from alternative human or animal serotypes. This set of constructs, in total encompassing the complete adenovirus genome, allows for the construction of unique ~~chimaeric~~chimeric adenoviruses ~~customised~~customized for transduction of particular cell types or organ(s).

[0065] In all aspects of the invention, the ~~chimaeric~~chimeric adenoviruses may, or may not, contain deletions in the E1 region and insertions of heterologous genes linked either or not to a promoter. Furthermore, ~~chimaeric~~chimeric adenoviruses may, or may not, contain deletions in the E3 region and insertions of heterologous genes linked to a promoter. Furthermore, ~~chimaeric~~chimeric adenoviruses may, or may not, contain deletions in the E2 and/-or E4 region and insertions of heterologous genes linked to a promoter. In the latter case, E2-and/-or E4-complementing cell lines are required to ~~generated~~generate recombinant adenoviruses.

Example 1: Generation of adenovirus serotype 5 genomic plasmid clones

[0066] The complete genome of adenovirus serotype 5 has been cloned into various plasmids or cosmids to allow easy modification of parts of the adenovirus serotype 5 genome, while still retaining the capability to produce recombinant virus. For this purpose the following plasmids were generated:

1. pBr/Ad.Bam-rITR (ECACC deposit P97082122)

[0067] In order to facilitate blunt-end cloning of the ITR sequences, wild-type human adenovirus type 5 (Ad5) DNA was treated with Klenow enzyme in the presence of excess

dNTPs. After inactivation of the Klenow enzyme and purification by phenol/chloroform extraction followed by ethanol precipitation, the DNA was digested with BamHI. This DNA preparation was used without further purification in a ligation reaction with pBr322-derived vector DNA prepared as follows: pBr322 DNA was digested with EcoRV and BamHI, dephosphorylated by treatment with TSAP enzyme (Life Technologies) and purified on LMP agarose gel (SeaPlaque GTG). After transformation into competent *E.coli* DH5a (Life ~~Techn.~~Technologies) and analysis of ~~ampicilline~~ampicillin-resistant colonies, one clone was selected that showed a digestion pattern as expected for an insert extending from the BamHI site in Ad5 to the right ITR.

[0068] Sequence analysis of the cloning border at the right ITR revealed that the most 3' G residue of the ITR was missing, and the remainder of the ITR was found to be correct. ~~Said~~The missing G residue is complemented by the other ITR during replication.

2. pBr/Ad.Sal-rITR (ECACC deposit P97082119)

[0069] pBr/Ad.Bam-rITR was digested with BamHI and SalI. The vector fragment including the adenovirus insert was isolated in LMP agarose gel (SeaPlaque GTG) and ligated to a 4.8 kb SalI-BamHI fragment obtained from wt Ad5 DNA and purified with the Geneclean II kit (Bio 101, Inc.). One clone was chosen and the integrity of the Ad5 sequences was determined by restriction enzyme analysis. Clone pBr/Ad.Sal-rITR contains adeno type 5 sequences from the SalI site at ~~bp~~base pair 16746 up to and including the rITR (missing the most 3' G residue).

3. pBr/Ad.Cla-Bam (ECACC deposit P97082117)

[0070] wt Adeno type 5 DNA was digested with ClaI and BamHI, and the 20.6 kb fragment was isolated from gel by electro-elution. pBr322 was digested with the same enzymes and purified from agarose gel by Geneclean. Both fragments were ligated and transformed into competent DH5a. The resulting clone, pBr/Ad.Cla-Bam, was ~~analyse~~analyzed by restriction enzyme digestion and shown to contain an insert with adenovirus sequences from ~~bp~~base pairs 919 to 21566.

4. pBr/Ad.AflII-Bam (ECACC deposit P97082114)

[0071] Clone pBr/Ad.Cla-Bam was ~~linearised~~linearized with EcoRI (in pBr322) and partially digested with AflII. After heat inactivation of AflII for 20' at 65^0C, the fragment ends were filled in with Klenow enzyme. The DNA was then ligated to a blunt double-stranded oligo linker containing a PacI site (5'-AATTGTCTTAATTAACCGCTTAA-3' (SEQ ID NO:1)). This linker was made by annealing the following two oligonucleotides: 5'-AATTGTCTTAATTAACCGC-3' (SEQ ID NO:2) and 5'-AATTGCGGTTAATTAAGAC-3' (SEQ ID NO:3), followed by blunting with Klenow enzyme. After precipitation of the ligated DNA to change buffer, the ligations were digested with an excess PacI enzyme to remove concatameres of the oligo. The 22016 ~~bp~~base pair partial fragment containing Ad5 sequences from ~~bp~~base pair 3534 up to 21566 and the vector sequences, was isolated in LMP ~~agarose~~agarose gel (SeaPlaque GTG), religated and transformed into competent DH5a. One clone that was found to contain the PacI site and that had retained the large adeno fragment was selected and sequenced at the 5' end to verify correct insertion of the PacI linker in the (lost) AflII site.

5. pBr/Ad.Bam-rITRpac#2 (ECACC deposit P97082120) and pBr/Ad.Bam-rITR#8 (ECACC deposit P97082121)

[0072] To allow insertion of a PacI site near the ITR of Ad5 in clone pBr/Ad.Bam-rITR, about 190 nucleotides were removed between the ClaI site in the pBr322 backbone and the start of the ITR sequences. This was done as follows: pBr/Ad.Bam-rITR was digested with ClaI and treated with nuclease Bal31 for varying lengths of time (2', 5', 10' and 15'). The extent of nucleotide removal was followed by separate reactions on pBr322 DNA (also digested at the ClaI site), using identical buffers and conditions. Bal31 enzyme was inactivated by incubation at 75^0C for 10 minutes, and the DNA was precipitated and resuspended in a smaller volume of TE buffer. To ensure blunt ends, DNAs were further treated with T4 DNA polymerase in the presence of excess dNTPs. After digestion of the (control) pBr322 DNA with SalI, satisfactory degradation (~150 ~~bp~~base pairs) was observed in the samples treated for 10' or 15'. The 10' or 15' treated pBr/Ad.Bam-rITR samples were then ligated to the above-described blunted PacI linkers (~~See~~*see*, pBr/Ad.AflII-Bam). Ligations were purified by precipitation, digested with excess PacI and separated from the linkers on an LMP agarose gel. After religation, DNAs were transformed

into competent DH5a and colonies ~~analyse~~analyzed. Ten clones were selected that showed a deletion of approximately the desired length and these were further ~~analyse~~analyzed by T-track sequencing (T7 sequencing kit, Pharmacia Biotech). Two clones were found with the PacI linker inserted just downstream of the rITR. After digestion with PacI, clone #2 has 28 ~~bp~~base pairs and clone #8 has 27 ~~bp~~base pairs attached to the ITR.

6. pWE/Ad.AflII-rITR (ECACC deposit P97082116)

[0073] Cosmid vector pWE15 (Clontech) was used to clone larger Ad5 inserts. First, a linker containing a unique PacI site was inserted in the EcoRI sites of pWE15, creating pWE.pac. To this end, the double-stranded PacI oligo, as described for pBr/Ad.AflII-BamHI, was used but now with its EcoRI protruding ends. The following fragments were then isolated by electro-elution from agarose gel: pWE.pac digested with PacI, pBr/AflII-Bam digested with PacI and BamHI and pBr/Ad.Bam-rITR#2 digested with BamHI and PacI. These fragments were ligated together and packaged using ~~l~~one-phage packaging extracts (Stratagene) according to the ~~manufacturers~~manufacturer's protocol. After infection into host bacteria, colonies were grown on plates and ~~analyse~~analyzed for presence of the complete insert. pWE/Ad.AflII-rITR contains all adenovirus type 5 sequences from ~~bp~~base pair 3534 (AflII site) up to and including the right ITR (missing the most 3' G residue).

7. pBr/Ad.lITR-Sal(9.4) (ECACC deposit P97082115)

[0074] Adeno 5 wt DNA was treated with Klenow enzyme in the presence of excess dNTPs and subsequently digested with SalI. Two of the resulting fragments, designated left ITR-Sal(9.4) and Sal(16.7)-right ITR, respectively, were isolated in LMP ~~agarose~~agarose gel (Seaplaque GTG). pBr322 DNA was digested with EcoRV and SalI and treated with phosphatase (Life Technologies). The vector fragment was isolated using the Geneclean method (BIO 101, Inc.) and ligated to the Ad5 SalI fragments. Only the ligation with the 9.4 kb fragment gave colonies with an insert. After analysis and sequencing of the cloning border, a clone was chosen that contained the full ITR sequence and extended to the SalI site at ~~bp~~base pair 9462.

8. pBr/Ad.lITR-Sal(16.7) (ECACC deposit P97082118)

[0075] pBr/Ad.lITR-Sal(9.4) ~~is~~was digested with SalI and dephosphorylated (TSAP, Life Technologies). To extend this clone up to the third SalI site in Ad5, pBr/Ad.Cla-Bam was ~~linearised~~linearized with BamHI and partially digested with SalI. A 7.3 kb SalI fragment containing adenovirus sequences from base pairs 9462-16746 was isolated in LMP agarose gel and ligated to the SalI-digested pBr/Ad.lITR-Sal(9.4) vector fragment.

9. pWE/Ad.AflII-EcoRI

[0076] pWE.pac was digested with ClaI and 5' protruding ends were filled using Klenow enzyme. The DNA was then digested with PacI and isolated from agarose gel. pWE/AflII-rITR was digested with EcoRI and, after treatment with Klenow enzyme, digested with PacI. The large 24 kb fragment containing the adenoviral sequences was isolated from agarose gel and ligated to the ClaI-digested and blunted pWE.pac vector using the Ligation Express^{tm} kit from Clontech. After transformation of Ultracompetent XL10-Gold cells from Stratagene, clones were identified that contained the expected insert. pWE/AflII-EcoRI contains Ad5 sequences from ~~bp~~base pairs 3534-27336.

Construction of new adapter plasmids

[0077] The absence of sequence overlap between the recombinant adenovirus and E1 sequences in the packaging cell line is essential for safe, RCA-free generation and propagation of new recombinant viruses. The adapter plasmid pMLPI.TK (~~figure~~Figure~~.~~ 1) is an example of an adapter plasmid designed for use according to the invention in combination with the improved packaging cell lines of the invention. This plasmid was used as the starting material to make a new vector in which nucleic acid molecules comprising specific promoter and gene sequences can be easily exchanged.

[0078] First, a PCR fragment was generated from pZipΔMo+PyF101(N^-) template DNA (described in PCT/NL96/00195) with the following primers: LTR-1: 5'-CTG TAC GTA CCA GTG CAC TGG CCT AGG CAT GGA AAA ATA CAT AAC TG-3' (SEQ ID NO:4) and LTR-2: 5'-GCG GAT CCT TCG AAC CAT GGT AAG CTT GGT ACC GCT AGC GTT AAC CGG GCG ACT CAG TCA ATC G-3' (SEQ ID NO:5). Pwo DNA polymerase (Boehringer Mannheim) was used according to ~~manufacturers~~manufacturer's protocol with the following

temperature cycles: once 5' at 95^{0}C; 3' at 55^{0}C; and 1' at 72^{0}C, and 30 cycles of 1' at 95^{0}C, 1' at 60^{0}C, 1' at 72^{0}C, followed by once 10' at 72^{0}C. The PCR product was then digested with BamHI and ligated into pMLP10 (Levrero *et al.*, 1991) vector digested with PvuII and BamHI, thereby generating vector pLTR10. This vector contains adenoviral sequences from ~~bp~~base pair 1 up to ~~bp~~base pair 454 followed by a promoter consisting of a part of the Mo-MuLV LTR having its wild-type enhancer sequences replaced by the enhancer from a mutant polyoma virus (PyF101). The promoter fragment was designated L420. Next, the coding region of the murine HSA gene was inserted. pLTR10 was digested with BstBI followed by Klenow treatment and digestion with NcoI. The HSA gene was obtained by PCR amplification on pUC18-HSA (Kay *et al.*, 1990) using the following primers: HSA1, 5'-GCG CCA CCA TGG GCA GAG CGA TGG TGG C-3' (SEQ ID NO:6) and HSA2, 5'-GTT AGA TCT AAG CTT GTC GAC ATC GAT CTA CTA ACA GTA GAG ATG TAG AA-3' (SEQ ID NO:7). The 269 bp amplified fragment was subcloned in a shuttle vector using the NcoI and BglII sites. Sequencing confirmed incorporation of the correct coding sequence of the HSA gene, but with an extra TAG insertion directly following the TAG stop codon. The coding region of the HSA gene, including the TAG duplication, was then excised as ~~a~~an NcoI (sticky)-SalI (blunt) fragment and cloned into the 3.5 kb NcoI(sticky)/BstBI(blunt) fragment from pLTR10, resulting in pLTR-HSA10.

[0079] Finally, pLTR-HSA10 was digested with EcoRI and BamHI, after which the fragment containing the left ITR, packaging signal, L420 promoter and HSA gene was inserted into vector pMLPI.TK digested with the same enzymes, ~~and~~ thereby replacing the promoter and gene sequences. This resulted in the new adapter plasmid pAd/L420-HSA (~~figure~~Figure ~~.~~ 2) that contains convenient recognition sites for various restriction enzymes around the promoter and gene sequences. SnaBI and AvrII can be combined with HpaI, NheI, KpnI, or HindIII to exchange promoter sequences, while the latter sites can be combined with the ClaI or BamHI sites 3' from HSA coding region to replace genes in this construct.

[0080] Another adapter plasmid that was designed to allow easy exchange of nucleic acid molecules was made by replacing the promoter, gene and poly A sequences in pAd/L420-HSA with the CMV promoter, a multiple cloning site, an intron and a poly-A signal. For this purpose, pAd/L420-HSA was digested with AvrII and BglII followed by treatment with Klenow to obtain blunt ends. The 5.1 kb fragment with pBr322 vector and adenoviral sequences was

isolated and ligated to a blunt 1570 bp fragment from pcDNA1/amp (Invitrogen) obtained by digestion with HhaI and AvrII followed by treatment with T4 DNA polymerase. This adapter plasmid was named pCLIP (~~figure~~Figure~~.~~ 3).

Generation of recombinant adenoviruses

[0081] To generate E1-~~-~~deleted recombinant adenoviruses with the new plasmid-based system, the following constructs are prepared:

a) An adapter construct containing the expression cassette with the gene of interest ~~linearised~~linearized with a restriction enzyme that cuts at the 3' side of the overlapping adenoviral genome fragment, preferably not containing any pBr322 vector sequences, and

b) ~~A~~a complementing adenoviral genome construct pWE/Ad.AflII-rITR digested with PacI.

[0082] These two DNA molecules are further purified by phenol/ chloroform extraction and EtOH precipitation. Co-transfection of these plasmids into an adenovirus packaging cell line, preferably a cell line according to the invention, generates recombinant replication-~~-~~deficient adenoviruses by a one-step homologous recombination between the adapter and the complementing construct (~~figure~~Figure~~.~~ 4).

[0083] Alternatively, ~~in stead~~instead of pWE/Ad.AflII-rITR, other fragments can be used, *e.g.*, pBr/Ad.Cla-Bam digested with EcoRI and BamHI or pBr/Ad.AflII-BamHI digested with PacI and BamHI can be combined with pBr/Ad.Sal-rITR digested with SalI. In this case, three plasmids are combined and two homologous recombinations are needed to obtain a recombinant adenovirus (~~figure~~Figure~~.~~ 5). It is to be understood that those skilled in the art may use other combinations of adapter and complementing plasmids without departing from the present invention.

[0084] A general protocol as outlined below and meant as a non-limiting example of the present invention, has been performed to produce several recombinant adenoviruses using various adapter plasmids and the Ad.AflII-rITR fragment. Adenovirus packaging cells (PER.C6) were seeded in ~25 cm^2 flasks and the next day, when they were at ~80% confluency, transfected with a mixture of DNA and lipofectamine agent (Life ~~Techn.~~Technologies) as described by the manufacturer. Routinely, 40 µl lipofectamine, 4 µg adapter plasmid and 4 µg of the

complementing adenovirus genome fragment AflII- rITR (or 2 μg of all three plasmids for the double homologous recombination) are used. Under these conditions transient transfection efficiencies of ~50% (48 hrs post-transfection) are obtained as determined with control transfections using a pAd/CMV-LacZ adapter. Two days later, cells are passaged to ~80 cm^2 flasks and further cultured. Approximately five (for the single homologous recombination) to eleven days (for the double homologous recombination) later, a cytopathogenic effect (CPE) is seen, indicating that functional adenovirus has formed. Cells and medium are harvested upon full CPE and recombinant virus is released by freeze-thawing. An extra amplification step in an 80 cm^2 flask is routinely performed to increase the yield since, at the initial stage, the titers are found to be variable despite the occurrence of full CPE. After amplification, viruses are harvested and plaque purified on PER.C6 cells. Individual plaques are tested for viruses with active transgenes.

[0085] Besides replacements in the E1 region, it is possible to delete or replace (part of) the E3 region in the adenovirus because E3 functions are not necessary for the replication, packaging and infection of the (recombinant) virus. This creates the opportunity to use a larger insert or to insert more than one gene without exceeding the maximum package size (approximately 105% of wt genome length). This can be done, *e.g.*, by deleting part of the E3 region in the pBr/Ad.Bam-rITR clone by digestion with XbaI and religation. This removes Ad5 wt sequences 28592-30470 including all known E3 coding regions. Another example is the precise replacement of the coding region of gp19K in the E3 region with a polylinker allowing insertion of new sequences. This, 1) leaves all other coding regions intact and 2) obviates the need for a heterologous promoter since the transgene is driven by the E3 promoter and pA sequences, leaving more space for coding sequences.

[0086] To this end, the 2.7 kb EcoRI fragment from wt Ad5 containing the 5' part of the E3 region was cloned into the EcoRI site of pBluescript (KS^-) (Stratagene). Next, the HindIII site in the polylinker was removed by digestion with EcoRV and HincII and subsequent religation. The resulting clone, pBS.Eco-Eco/ad5DHIII, was used to delete the gp19K coding region. Primers 1 (5'-GGG TAT TAG GCC AA AGG CGC A-3' SEQ ID NO:8)) and 2 (5'-GAT CCC ATG GAA GCT TGG GTG GCG ACC CCA GCG-3' (SEQ ID NO:9)) were used to amplify a sequence from pBS.Eco-Eco/Ad5DHIII corresponding to sequences 28511 to 28734 in wt Ad5

DNA. Primers 3 (5'-GAT CCC ATG GGG ATC CTT TAC TAA GTT ACA AAG CTA-3' (SEQ ID NO:10)) and 4 (5'-GTC GCT GTA GTT GGA CTG G-3' (SEQ ID NO:11)) were used on the same DNA to amplify Ad5 sequences from base pairs 29217 to 29476. The two resulting PCR fragments were ligated together by virtue of the ~~new~~newly introduced NcoI site and subsequently digested with XbaI and MunI. This fragment was then ligated into the pBS.Eco-Eco/ad5ΔHIII vector that was digested with XbaI (partially) and MunI, generating pBS.Eco-Eco/ad5ΔHIII.Δgp19K. To allow insertion of foreign genes into the HindIII and BamHI site, an XbaI deletion was made in pBS.Eco-Eco/ad5ΔHIII.Δgp19K to remove the BamHI site in the Bluescript polylinker. The resulting plasmid, pBS.Eco-Eco/ad5ΔHIIIΔgp19KΔXbaI, contains unique HindIII and BamHI sites corresponding to sequences 28733 (HindIII) and 29218 (BamHI) in Ad5. After introduction of a foreign gene into these sites, either the deleted XbaI fragment is re-introduced, or the insert is recloned into pBS.Eco-Eco/ad5ΔHIII.Δgp19K using HindIII and, for example, MunI. Using this procedure, we have generated plasmids expressing HSV-TK, hIL-1a, rat IL-3, luciferase or LacZ. The unique SrfI and NotI sites in the pBS.Eco-Eco/ad5ΔHIII.Δgp19K plasmid (with or without inserted gene of interest) are used to transfer the region comprising the gene of interest into the corresponding region of pBr/Ad.Bam-rITR, yielding construct pBr/Ad.Bam-rITRΔgp19K (with or without inserted gene of interest). This construct is used as described *supra* to produce recombinant adenoviruses. In the viral context, expression of inserted genes is driven by the adenovirus E3 promoter.

[0087] Recombinant viruses that are both E1 and E3 deleted are generated by a double homologous recombination procedure as described above for E1-replacement vectors using a plasmid-based system consisting of:

a) an adapter plasmid for E1 replacement according to the invention, with or without insertion of a first gene of interest,

b) the pWE/Ad.AflII-EcoRI fragment, and

c) the pBr/Ad.Bam-rITRΔgp19K plasmid with or without insertion of a second gene of interest.

[0088] In addition to manipulations in the E3 region, changes of (parts of) the E4 region can be accomplished easily in pBr/Ad.Bam-rITR. Generation and propagation of such a virus, however, in some cases demands complementation *in trans*.

Example 2: Generation of adenovirus serotype 5-based viruses with ~~chimaeric~~chimeric fiber proteins

[0089] The method described *infra* may be used to generate recombinant adenoviruses by co-transfection of two~~,~~ or more ~~separate~~separately cloned adenovirus sequences. One of these cloned adenovirus sequences was modified such that the adenovirus serotype 5 fiber DNA was deleted and substituted for unique restriction sites, thereby generating ~~i~~ "template clones~~i~~" which allow for the easy introduction of DNA sequences encoding for fiber protein derived from other adenovirus serotypes.

Generation of adenovirus template clones lacking DNA encoding for fiber

[0090] The fiber-coding sequence of adenovirus serotype 5 is located between nucleotides 31042 and 32787. To remove the adenovirus serotype 5 DNA encoding fiber, we started with construct pBr/Ad.Bam-rITR. First ~~a~~an NdeI site was removed from this construct. For this purpose, pBr322 plasmid DNA was digested with NdeI, after which protruding ends were filled using Klenow enzyme. This pBr322 plasmid was then ~~re-ligated~~religated, digested with NdeI and transformed into *E.coli* DH5α. The obtained pBr/ΔNdeI plasmid was digested with ScaI and SalI and the resulting 3198 bp vector fragment was ligated to the 15349 bp ScaI-SalI fragment derived from pBr/Ad.BamrITR, resulting in plasmid pBr/Ad.Bam-rITRΔNdeI, which hence contained a unique NdeI site. Next, a PCR was performed with oligonucleotides NY-up: 5'-CGA **CAT ATG** TAG ATG CAT TAG TTT GTG TTA TGT TTC AAC GTG-3' (SEQ ID NO:12), ~~And~~ and NY-down:5'-GGA GAC CAC TGC CAT GTTG-3' (SEQ ID NO:13) (~~figure~~Figure 6). During amplification, both ~~a~~an NdeI (bold face) and ~~a~~an NsiI restriction site (underlined) were introduced to facilitate cloning of the amplified fiber DNAs. Amplification consisted of 25 cycles of each 45 sec. at 94^{0}C, 1 min. at 60^{0}C, and 45 sec. at 72^{0}C. The PCR reaction contained 25 pmol of oligonucleotides NY-up or NY-down, 2mM dNTP, PCR buffer with 1.5 mM $MgCl_2$, and 1 unit of Elongase heat-stable polymerase (Gibco, The Netherlands). One-tenth of the PCR product was run on an agarose gel which demonstrated that the expected DNA fragment of ± 2200 bp was amplified. This PCR fragment was subsequently purified using Geneclean kit system (Bio101 Inc.). Then, both the construct pBr/Ad.Bam-rITRΔNdeI, as well as

the PCR product, were digested with restriction enzymes NdeI and SbfI. The PCR fragment was subsequently cloned using T4 ligase enzyme into the NdeI- and SbfI--digested pBr/Ad.Bam-rITR ΔNdeI, generating pBr/Ad.BamRΔFib. This plasmid allows insertion of any PCR--amplified fiber sequence through the unique NdeI and NsiI sites that are inserted in place of the removed fiber sequence. Viruses can be generated by a double homologous recombination in packaging cells described *infra* using an adapter plasmid, construct pBr/Ad.AflII-EcoRI digested with PacI and EcoRI and a pBr/Ad.BamRΔFib construct in which heterologous fiber sequences have been inserted. To increase the efficiency of virus generation, the construct pBr/Ad.BamRΔFib was modified to generate a PacI site flanking the right ITR. Hereto, pBr/Ad.BamRΔFib was digested with AvrII and the 5 kb adeno fragment was isolated and introduced into the vector pBr/Ad.Bam-rITR.pac#8, replacing the corresponding AvrII fragment. The resulting construct was named pBr/Ad.BamRΔFib.pac. Once a heterologous fiber sequence is introduced in pBr/Ad.BamRΔ Fib.pac, the fiber--modified right--hand adenovirus clone may be introduced into a large cosmid clone as described for pWE/Ad.AflII-rITR in ~~example~~Example 1. Such a large cosmid clone allows generation of adenovirus by only one homologous recombination, making the process extremely efficient.

Amplification of fiber sequences from adenovirus serotypes

[0091] To enable amplification of the DNAs encoding fiber protein derived from alternative serotypes,- degenerate oligonucleotides were ~~synthesised~~synthesized. For this purpose, first, known DNA sequences encoding for fiber protein of alternative serotypes were aligned to identify conserved regions in both the tail-region as well as the knob-region of the fiber protein. From the alignment, which contained the nucleotide sequence of 19 different serotypes representing all 6 subgroups, (degenerate) oligonucleotides were ~~synthesised~~synthesized (*see*, ~~table~~Table 2). Also shown in ~~table~~Table 3 is the combination of oligonucleotides used to amplify the DNA--encoding fiber protein of a specific serotype. The amplification reaction (50 µl) contained 2 mM dNTPs, 25 pmol of each oligonucleotide, standard 1x PCR buffer, 1,.5 mM $MgCl_2$, and 1 Unit Pwo heat--stable polymerase (Boehringer) per reaction. The cycler program contained 20 cycles, each consisting of 30 sec. at 94^0C, 60 sec. at 60-64^0C, and 120 sec. ~~At~~at 72^0C. One-tenth of the PCR product was run on an agarose gel, which demonstrated that a DNA

fragment was amplified. Of each different template, two independent PCR reactions were performed, after which the independent PCR fragments obtained were sequenced to determine the nucleotide sequence. From 11 different serotypes, the nucleotide sequence could be compared to sequences present in Genbank. Of all other serotypes, the DNA-encoding fiber protein was previously unknown and was therefore aligned with known sequences from other subgroup members to determine homology, *i.e.*, sequence divergence. Of the 51 human serotypes known to date, all fiber sequences, except for serotypes 1, 6, and 26, have been amplified and sequenced. The protein sequences of the fiber from different adenovirus serotypes is given in ~~figure~~Figure 7.

Generation of fiber ~~chimaeric~~chimeric adenoviral DNA constructs

[0092] All amplified fiber DNAs as well as the vector (pBr/Ad.BamRΔFib) were digested with NdeI and NsiI. The digested DNAs ~~was~~were subsequently run on a agarose gel, after which the fragments were isolated from the gel and purified using the Geneclean kit (Bio101 Inc). The PCR fragments were then cloned into the NdeI and NsiI sites of pBr/AdBamR ΔFib, thus generating pBr/AdBamRFibXX (where XX stands for the serotype number of which the fiber DNA was isolated). So far, the fiber sequence of serotypes 5/ 7/ 8/ 9/ 10/ 11/ 12/ 13/ 14/ 16/ 17/ 19/ 21/ 24/ 27/ 28/ 29/ 30/ 32/ 33/ 34/ 35/ 36/ 37/ 38/ 40-S/ 40-L/ 41-S/ 42/45/ 47/ 49/ 51 have been cloned into pBr/AdBamRFibXX. From pBr/AdBamRFibXX (where XX is 5/ 8/ 9/ 10/ 11/ 13/ 16/ 17/ 24/ 27/ 30/ 32/ 33/ 34/ 35/ 38/ 40-S/ 40-L/ 45/ 47/ 49/ 51) ~~an~~a 6 kb AvrII fragment encompassing the fiber sequence was isolated via gel electrophoresis and Geneclean. This AvrII fragment was subsequently cloned in plasmid pBr/Ad.Bam-rITR.pac (*see*, ~~example~~Example 1) which was digested to completion with AvrII and dephosphorylated as described previously, leading to the generation of the plasmid pBr/Ad.Bam-rITR.pac.fibXX. This plasmid was subsequently used to generate a cosmid clone with a modified fiber using the constructs pWE.pac, pBr/AflII-Bam and pBr/Ad.Bam-rITR.pac.fibXX. This cosmid cloning resulted in the formation of construct pWE/Ad.AflII-rITR/FibXX (where XX stands for the serotype number of which the fiber DNA was isolated).

Generation of pAd5/L420.HSA, pAd5/Clip and pAd5/Clipsal

[0093] pMLPI.TK was used to make a new vector in which nucleic acid molecules comprising specific promoter and gene sequences can be easily exchanged.

[0094] First, a PCR fragment was generated from pZipΔMo+PyF101(N$^-$) template DNA (described in PCT/NL96/00195) with the following primers: LTR-1: 5'-CTG TAC GTA CCA GTG CAC TGG CCT AGG CAT GGA AAA ATA CAT AAC TG-3' (SEQ ID NO:4) and LTR-2: 5'-GCG GAT CCT TCG AAC CAT GGT AAG CTT GGT ACC GCT AGC GTT AAC CGG GCG ACT CAG TCA ATC G-3' (SEQ ID NO:5). Pwo DNA polymerase (Boehringer Mannheim) was used according to ~~manufacturers~~manufacturer's protocol with the following temperature cycles: once 5' at 95°C; 3' at 55°C; and 1' at 72°C, and 30 cycles of 1' at 95°C, 1' at 60°C, 1' at 72°C, followed by once 10' at 72°C. The PCR product was then digested with BamHI and ligated into pMLP10 (Levrero et al., 1991; Gene 101, 195-202) digested with PvuII and BamHI, thereby generating vector pLTR10. This vector contains adenoviral sequences from ~~bp~~base pair 1 up to ~~bp~~base pair 454 followed by a promoter consisting of a part of the Mo-MuLV LTR having its wild-type enhancer sequences replaced by the enhancer from a mutant polyoma virus (PyF101). The promoter fragment was designated L420. Sequencing confirmed correct amplification of the LTR fragment; however, ~~the~~ most 5' bases in the PCR fragment were missing so that the PvuII site was not restored. Next, the coding region of the murine HSA gene was inserted. pLTR10 was digested with BstBI followed by Klenow treatment and digestion with NcoI. The HSA gene was obtained by PCR amplification on pUC18-HSA (Kay et al., 1990; J. Immunol. 145, 1952-1959) using the following primers: HSA1, 5'-GCG CCA CCA TGG GCA GAG CGA TGG TGG C-3' (SEQ ID NO:6) and HSA2, 5'-GTT AGA TCT AAG CTT GTC GAC ATC GAT CTA CTA ACA GTA GAG ATG TAG AA-3' SEQ ID NO:7). The 269 bp amplified fragment was subcloned in a shuttle vector using the NcoI and BglII sites. Sequencing confirmed incorporation of the correct coding sequence of the HSA gene, but with an extra TAG insertion directly following the TAG stop codon. The coding region of the HSA gene, including the TAG duplication, was then excised as ~~a~~an NcoI(sticky)-SalI(blunt) fragment and cloned into the 3.5 kb NcoI(sticky)/BstBI(blunt) fragment from pLTR10, resulting in pLTR-HSA10.

[0095] Finally, pLTR-HSA10 was digested with EcoRI and BamHI, after which the fragment containing the left ITR, packaging signal, L420 promoter and HSA gene was inserted

into vector pMLPI.TK digested with the same enzymes, ~~and~~ thereby replacing the promoter and gene sequences. This resulted in the new adapter plasmid pAd5/L420-HSA that contains convenient recognition sites for various restriction enzymes around the promoter and gene sequences. SnaBI and AvrII can be combined with HpaI, NheI, KpnI, or HindIII to exchange promoter sequences, while the latter sites can be combined with the ClaI or BamHI sites 3' from HSA coding region to replace genes in this construct.

[0096] Another adapter plasmid that was designed to allow easy exchange of nucleic acid molecules was made by replacing the promoter, gene and polyA sequences in pAd5/L420-HSA with the CMV promoter, a multiple cloning site, an intron and a polyA signal. For this purpose, pAd5/L420-HSA was digested with AvrII and BglII followed by treatment with Klenow to obtain blunt ends. The 5.1 kb fragment with pBr322 vector and adenoviral sequences was isolated and ligated to a blunt 1570 bp fragment from pcDNA1/amp (Invitrogen) obtained by digestion with HhaI and AvrII followed by treatment with T4 DNA polymerase. This adapter plasmid was named pAd5/Clip. To enable removal of vector sequences from the adenoviral fragment, pAd5/Clip was partially digested with EcoRI and the linear fragment was isolated. An oligo of the sequence 5' TTAAGTCGAC-3' (SEQ ID NO:14) was annealed to itself, resulting in a linker with ~~a~~an SalI site and EcoRI overhang. The linker was ligated to the partially digested pAd5/Clip vector and clones were selected that had the linker inserted in the EcoRI site 23 bp upstream of the left adenovirus ITR in pAd5/Clip, resulting in pAd5/Clipsal.

Generation of pAd5Clip.LacZ, pAd5Clip.Luc, pAd5Clip.TK and pAd5Clipsal.Luc

[0097] The adapter plasmid pAd5/Clip.LacZ was generated as follows: The E.coli LacZ gene was amplified from the plasmid pMLP.nlsLacZ (EP 95-202 213) by PCR with the primers 5'GGGGTGGCCAGGGTACCTCTAGGCTTTTGCAA (SEQ ID NO:15) and 5'GGGGGGATCCATAAACAAGTTCAGAATCC (SEQ ID NO:16). The PCR reaction was performed Ex Taq (Takara) according to the ~~suppliers~~supplier's protocol at the following amplification program: 5 minutes at 94°C, 1 cycle; 45 seconds at 94°C and 30 seconds at 60°C and 2 minutes at 72°C, 5 cycles; 45 seconds at 94°C and 30 seconds at 65°C and 2 minutes at 72°C, 25 cycles; 10 minutes at 72°C; 45 seconds at 94°C and 30 seconds at 60°C and 2 minutes at 72°C, 5 cycles, I cycle. The PCR product was subsequently digested with Kpn1 and BamHI and

the digested DNA fragment was ligated into KpnI/BamHI-digested pcDNA3 (Invitrogen), giving rise to pcDNA3.nlsLacZ. Next, the plasmid pAd5/Clip was digested with SpeI. The large fragment containing part of the 5' part of the CMV promoter and the adenoviral sequences was isolated. The plasmid pcDNA3.nlsLacZ was digested with SpeI and the fragment containing the 3'part of the CMV promoter and the ~~lacZ~~LacZ gene was isolated. Subsequently, the fragments were ligated, giving rise to pAd/Clip.LacZ. The reconstitution of the CMV promoter was confirmed by restriction digestion.

[0098] The adapter plasmid pAd5/Clip.Luc was generated as follows: The plasmid pCMV.Luc (EP 95-202 213) was digested with HindIII and BamHI. The DNA fragment containing the luciferase gene was isolated. The adapter plasmid pAd5/Clip was digested with HindIII and BamHI, and the large fragment was isolated. Next, the isolated DNA fragments were ligated, giving rise to pAd5/Clip.Luc. The adapter pClipsal.Luc was generated in the same way but using the adapter pClipsal digested with HIII and BamHI as vector fragment. Likewise, the TK-containing HIII-BamHI fragment from pCMV.TK (EP 95-202 213) was inserted in pClipsal to generate pAd5/Clip.TK. The presence of the SalI site just upstream of the left ITR enables liberation of vector sequences from the adeno insert. Removal of these vector sequences enhances frequency of vector generation during homologous recombination in PER.C6.

Generation of recombinant adenovirus ~~chimaeric~~chimeric for fiber protein

[0099] To generate recombinant Ad-5 virus carrying the fiber of ~~serotype~~serotypes 12, 16, 28, 40-L, 51, and 5, three constructs, pCLIP.Luc, pWE/AdAflII-Eco and pBr/AdBamrITR.pac/fibXX (XX = 12, 16, 28, 40-L, 51, and 5), were transfected into adenovirus producer cells. To generate recombinant Ad-5 virus carrying the fiber of 5/ 7/ 8/ 9/ 10/ 11/ 12/ 13/ 14/ 16/ 17/ 19/ 21/ 24/ 27/ 28/ 29/ 30/ 32/ 33/ 34/ 35/ 36/ 37/ 38/ 40-S/ 40-L/ 41-S/ 42/45/ 47/ 49/ 51, two constructs, pCLIP.Luc and pWE/Ad.AflII-rITR/FibXX, were transfected into adenovirus producer cells.

For transfection, 2 µg of pCLIP.Luc, and 4 µg of both pWE/AdAflII-Eco and pBr/AdBamrITR.pac/fibXX (or in case of cosmids: 4 µg of pCLIP.Luc plus 4 µg of pWE/Ad.AflII-rITR/FibXX) were diluted in serum-free DMEM to 100 µl total volume. To this DNA suspension 100 µl 1x diluted lipofectamine (Gibco) was added. After 30 minutes at room

temperature, the DNA-lipofectamine complex solution was added to 2.5 ml of serum-free DMEM, which was subsequently added to a T25 cm^2 tissue culture flask. This flask contained $2x10^6$ PER.C6 cells that were seeded 24-hours prior to transfection. Two hours later, the DNA-lipofectamine complex-containing medium was diluted once by the addition of 2.5 ml DMEM supplemented with 20% ~~foetal~~fetal calf serum. Again 24 hours later, the medium was replaced by fresh DMEM supplemented with 10% ~~foetal~~fetal calf serum. Cells were cultured for 6-8 days, subsequently harvested, and freeze/thawed 3 times. Cellular debris was removed by centrifugation for 5 minutes at 3000 rpm at room temperature. Of the supernatant (12.5 ml), 3-5 ml was used to ~~infect~~ again infect PER.C6 cells (T80 cm^2 tissue culture flasks). This re-infection results in full cytopathogenic effect (CPE) after 5-6 days, after which the adenovirus is harvested as described above.

Example 3: Production, purification, and titration of fiber ~~chimaeric~~chimeric adenoviruses

[0100] Of the supernatant obtained from transfected PER.C6 cells, typically 10 ml was used to inoculate a 1 litre fermentor which contained 1—1.5 x 10^6 cells/-ml PER.C6 -that were specifically adapted to grow in suspension. Three days after inoculation, the cells were harvested and pelleted by centrifuging for 10 min at 1750 rpm at room temperature. The ~~chimaeric~~chimeric adenoviruses present in the pelleted cells were subsequently extracted and purified using the following downstream processing protocol. The pellet was dissolved in 50 ml 10 mM $NaPO_4^-$ and frozen at -20^{0}C. After thawing at 37^{0}C, 5.6 ml deoxycholate (5% w/v) was added, after which the solution was homogenated. The solution was subsequently incubated for 15 minutes at 37^{0}C to completely crack the cells. After ~~homogenising~~homogenizing the solution, 1875 µ?l (1M) $MgCl_2^-$ ~~was added~~ and 5 ml 100% glycerol were added. After the addition of 375 µ?l DNase (10 mg/ ml), the solution was incubated for 30 minutes at 37^{0}C. Cell debris was removed by centrifugation at 1880xg for 30 minutes at room temperature without the brake on. The supernatant was subsequently purified from proteins by loading on 10 ml of freon. Upon centrifugation for 15 minutes at 2000 rpm without brake at room temperature, three bands are visible of which the upper band represents the adenovirus. This band was isolated by pipetting, after which it was loaded on a Tris/HCl (1M) buffered caesiumchloride blockgradient (range: 1.2 to 1.4 gr./ml). Upon centrifugation at 21000 rpm for 2.5 hours at 10^{0}C, the virus was purified

from remaining protein and cell debris since the virus, in contrast to the other components, ~~-~~does not migrate into the 1.4 gr~~.~~/~~-~~ml caesium~~_~~chloride solution. The virus band is isolated~~,~~ after which a second purification using a Tris/ HCl (1M) buffered ~~continues~~ gradient of 1.33 gr~~.~~/ml of caesium~~_~~chloride is performed. After virus loading on top of this gradient~~,~~ the virus is centrifuged for 17 hours at 55000 rpm at 10^0C. Subsequently~~,~~ the virus band is isolated and after the addition of 30 ~~?~~µl of sucrose (50 w/v)~~,~~ excess caesium~~_~~chloride is removed by three rounds of dialysis, each round comprising ~~of~~ 1 hour. For dialysis~~,~~ the virus is transferred to dialysis slides (Slide-a-lizer, cut~~-~~off 10000 kDa, Pierce, USA). The buffers used for dialysis are PBS which are supplemented with an increasing concentration of sucrose (~~round~~rounds 1 to 3~~:~~-30 ml, 60 ml, and 150 ml sucrose (50% w/v)/-1.5 litre PBS, all supplemented with 7.5 ml 2% (w/v) $CaMgCl_2$). After dialysis, the virus is removed from the ~~slide~~Slide-a-lizer after which it is aliquoted in portions of 25 and 100 ~~?~~µl~~,~~ ~~upon~~after which the virus is stored at -85^0C.

[0101] To determine the number of virus particles per ~~millilitre~~milliliter, 100 ~~?~~µl of the virus batch is run on ~~an~~a high~~-~~pressure liquid chromatograph (HPLC). The adenovirus is bound to the column (anion exchange)~~,~~ after which it is eluted using ~~a~~an NaCl gradient (range 300-600 mM). By determining the area under the virus peak~~,~~ the number of virus particles can be calculated. To determine the number of infectious units (IU) per ml present in a virus batch, titrations are performed on 911 cells. For this purpose, $4x10^4$ 911 cells are seeded per well of 96-well plates in rows B, D, and F in a total volume of 100 ~~?~~µl per well. Three hours after seeding~~,~~ the cells are attached to the plastic support~~,~~ after which the medium can be removed. To the cells a volume of 200 ~~?~~µl is added, in duplicate, containing different dilutions of virus (range: 10^2 times diluted to $2x10^9$). By screening for CPE~~,~~ the highest virus dilution which still renders CPE after 14 days is considered to contain at least one infectious unit. Using this observation, together with the calculated amount of virus volume present in these wells~~,~~ renders the number of infectious units per ml of a given virus batch. The production results~~,~~ *i.e.*~~,~~ virus particles per ml and IU per ml or those ~~chimaeric~~chimeric adenoviruses that were produced so far, are shown in ~~table~~Table 3.

Example 4: Presence of Ad5 Receptor molecules on human cells

[0102] To investigate the importance of the presence of CAR on target cells for infection with ~~chimaeric~~chimeric adenoviruses, ~~-~~a panel of human cell lines and primary cells were tested for the presence and/~~-~~or absence of CAR, MHC class I, and integrins (~~?~~αv~~?~~β3, ~~?~~αv~~?~~β5). For this purpose, $1x10^5$ target cells ~~or~~ were transferred to tubes (4 tubes per cell type) designed for flow cytometry. Cells were washed once with PBS/-0.5% BSA, after which the cells were pelleted by centrifugation for 5 minutes at 1750 rpm at room temperature. Subsequently, 10 ~~?~~µl of a 100 times diluted ~~?~~α_v~~?~~β3 antibody (Mab 1961, Brunswick ~~chemie~~Chemie, Amsterdam, The Netherlands), a 100 times diluted antibody ~~?~~α_v~~?~~β5 ~~(antibody~~ (Mab 1976, Brunswick ~~chemie~~Chemie, Amsterdam, The Netherlands), or 2000 times diluted CAR antibody ~~(was~~ a kind gift of Dr. Bergelson, Harvard Medical School, Boston, USA (Hsu et al.)) was added to the cell pellet, after which the cells were incubated for 30 minutes at 4^0C in a dark environment. After this incubation, cells were washed twice with PBS/0.5% BSA and again pelleted by centrifugation for 5 minutes at 1750 rpm at room temperature. To label the cells, 10 ~~?~~µl of rat anti~~-~~mouse IgG1 ~~labelled~~labeled with phycoerythrin (PE) was added to the cell pellet upon which the cells were again incubated for 30 minutes at 4^0C in a dark environment. Finally, the cells were washed twice with PBS/0.5% BSA and ~~analyse~~analyzed on a flow cytometer. The results of flow cytometric analysis of these experiments are shown in ~~table~~Table 4. These results show that human erythroid leukemia cells (K562, ATCC: CCL-243), human primary fibroblasts (GM09503), human primary smooth muscle cells, and primary human synoviocytes do not express detectable levels of the CAR receptor. In contrast, human lung carcinoma cells (A549, ATCC: CCL-1185), human lymphoblast cells (SupT1 ~~(~~B and T cell hybrid, ATCC, CRL-1991), and human liver cells (~~HEPG2~~HepG2, ATCC, HB8065) express high amounts of CAR protein. Human lymphoblast cells (CEM, ATCC: CRL-1992), primary human umbilical vein endothelial cells (HUVEC), and human primary chorion villi express low amounts of CAR protein.

Example 5: Infection of CAR negative cells with fiber ~~chimaeric~~chimeric adenovirus

[0103] Several of the cell types described in ~~example~~Example 4, *i.e.*, A549, K562, GM09503, SupT1, chorion villi, and HepG2, were infected with a panel of ~~chimaeric~~chimeric adenoviruses. This panel consists of adenovirus serotype 5 (subgroup C), ~~and~~ of adenovirus

serotype 5 containing the fiber of serotypes 16 and 51 (subgroup B), of 28, 32, and 49 (subgroup D), of 12 (subgroup A), and of 40 (40-S and/or 40-L: subgroup F). For this purpose, target cells are seeded at a concentration of 10^5 cells per well of 6-well plates in 2 ml Dulbecco's modified Eagles medium (DMEM, Life Technologies, The Netherlands) supplemented with 10% ~~Foetal~~Fetal calf serum. Twenty-four hours later, the medium is replaced by fresh medium containing the different ~~chimaeric~~chimeric adenoviruses at an increasing MOI of 0, 10, 50, 250, 1250, 2500, 5000 (MOI based on virus particles per ~~millilitre~~milliliter). Approximately 2 hours after the addition of virus the medium containing the virus is discarded, cells are washed once with PBS, and subsequently 2 ml of fresh medium (not containing virus) is added to each well. ~~Forthy~~Forty-eight hours later, cells are harvested, washed and pelleted by centrifuging 5 minutes at 1500 rpm. Cells are subsequently lysed in 0,1 ml lysis buffer (1% Triton-X-100, 15% Glycerol, 2 mM EDTA, 2 mM DTT, and 25 mM $MgCl_2$ in Tris-phosphate buffer pH 7.8) after which the total protein concentration of the lysate is measured (Biorad, protein standard II). To determine marker gene expression (luciferase activity), 20 µl of the protein sample is mixed with 100 µl of a luciferase substrate (Luciferine, Promega, The Netherlands) and subsequently measured on a Lumat LB 9507 apparatus (EG & G Berthold, The Netherlands). The results of these infection experiments, given as the amount of luciferase activity (RLU) per µg protein, are shown in ~~figure~~Figures 8-14. From these infection experiments, several conclusions can be drawn. The infection of A549 cells (~~figure~~Figure 8) demonstrates that all ~~chimaeric~~chimeric adenoviruses tested infect with relative high efficiency these cells. The infection of K562 cells (~~figure~~Figure 9) demonstrates that these cells cannot be transduced with adenovirus serotype 5 (subgroup C) or the fiber chimera 12 (subgroup A). All other ~~chimaeric~~chimeric adenoviruses (16/ 51: subgroup B; 28/ 32/ 49: subgroup D; 40-L: subgroup F) are able to infect these cells with different efficiencies. The infection of GM09503 primary human fibroblasts (~~figure~~Figure 10) demonstrates that these cells can be transduced with all fiber chimeras, including Adenovirus serotype 5, albeit with different efficiencies. The infection of SupT1 cells (~~figure~~Figure 11) demonstrates that these cells can be transduced with all fiber chimeras albeit with different efficiencies except for fiber chimera 49, which does not infect these human lymphoblast cells. The infection of human chorion villi cells (~~figure~~Figure 12) shows a similar transduction pattern as observed with K562 cells except for adenovirus chimera 49 which does not infect these cells.

The infection of ~~HEPG2~~HEPG2 cells (~~figure~~Figure 13) shows a similar transduction pattern as observed with A549 cells. By ~~Linking~~linking the CAR expression data of these cells to the infection efficiency data obtained, several conclusions can be drawn. 1) Infection of adenovirus serotype 5 is correlated with the presence of CAR (~~figure~~Figures 8-13). 2) In the absence of CAR but in the presence of a high amount of MHC class I, poor infection is observed using adenovirus serotype 5, indicating that MHC class I is a worse receptor for adenovirus serotype 5 as compared to CAR (~~figure~~Figure 10). 3) In the absence of CAR, adenovirus fiber chimeras 16 and 51 (subgroup B), as well as chimeras 28 and 32 (subgroup D) as well as chimera 40-L (subgroup F), can infect cells with high efficiency, indicating that these viruses can ~~utilise~~utlilze receptors other than CAR (~~figure~~Figures 9 and 12). 4) A comparison of the infection data of the ~~chimaeric~~chimeric adenoviruses carrying the fiber of 28, 32~~,~~ and 49 teaches that, within an adenovirus subgroup, differences in transduction efficiencies exist, indicating that either adenovirus members of one subgroup ~~either~~ have different affinities for the same receptor, or that different adherence molecules can be used (~~figure~~Figures 8-13) by members of an adenovirus subgroup.

Example 6: Complexity of receptor recognition of adenovirus serotypes

[0104] To investigate the complexity and/or the number of different adherence molecules which can be used by human adenoviruses from different subgroups or between members within one subgroup, the following strategies are designed.

1) Interference studies with total ~~chimaeric~~chimeric viruses

[0105] Via infection experiments described in ~~example~~Example 5, cell lines are identified that are poorly transducible with ~~a chimaeric~~chimeric viruses carrying the fiber protein of, for example, serotype 49 (subgroup D), indicating that such a cell expresses low levels of the adherence molecule required for D group adenovirus infection. Next, ~~chimaeric~~chimeric adenoviruses carrying the fiber protein of other members of subgroup D are mixed in different concentrations with the fiber 49 ~~chimaeric~~chimeric adenovirus and subsequently added to the cells. Since the fiber 49 ~~chimaeric~~chimeric adenovirus carries a transgene other than the other subgroup D ~~chimaeric~~chimeric adenoviruses (including but not limited to LacZ, Green

Fluorescent Protein, Yellow Fluorescent Protein, luciferase, etc.), interference of infection can be ~~visualised~~visualized. As a positive control, two fiber 49 ~~chimaeric~~chimeric adenoviruses carrying different marker genes ~~is~~are used. Identical to the example for subgroup D described above, experiments are conducted with different members of ~~subgroup~~subgroups A, B, C, E, and F. These experiments show if the fiber protein of members of the same adenovirus subgroup ~~recognise~~ recognize the same adherence molecules on a cell membrane. Naturally, this approach is also used to investigate inter-subgroup variation, for example, usage of adherence molecules by subgroup D and B members.

2) Interference studies with fiber protein--derived peptides

[0106] Peptides of 6-12 amino acids are synthetically ~~synthesised~~ synthesized which together form the complete knob domain of a fiber from a subgroup D, for example, 49. Next, one or more peptides are mixed in various concentrations with the fiber 49 ~~chimaeric~~chimeric adenovirus, after which the mixture is added to the cells. Using this approach, one or more peptides are identified which block, at a certain concentration, the infection of the fiber 49 ~~chimaeric~~chimeric adenovirus. This peptide (or these peptides) are subsequently used to investigate whether the infection of other subgroup D members is blocked by addition of the peptide(s) and whether inhibition of infection occurs using the same concentration of peptide. Identical to the example for subgroup D described above, peptides are ~~synthesised~~ synthesized using the knob domain of a member of ~~subgroup~~subgroups A, B, C, E, and F. These experiments show not only which adherence molecules are used but also which part of the fiber protein is directly involved in binding to target cells. Naturally, these peptides are also used to investigate inter-subgroup variation.

3) Interference studies with baculovirus--produced recombinant knob proteins

[0107] Of each adenovirus subgroup, the knob region of one member is amplified by PCR. The forward oligonucleotide ~~hybridises~~ hybridizes to the final repeat of the shaft part of the fiber just upstream of the start of the knob protein. This oligonucleotide contains a restriction site to facilitate cloning, a Histidine (6x) tag for purification after production, and a mutation, thereby introducing a Methionine start codon. The reverse oligonucleotide ~~hybridises~~ hybridizes after the

polyA signal and contains a restriction site to facilitate cloning into a baculovirus expression construct. After generation of recombinant baculovirus, insect cells, for instance, Sf9, are infected. ~~4-6~~Four to six days after infection, cells are cracked by 3 cycles of freeze/-thaw. Recombinant knob protein is purified from the supernatant using an antibody specifically ~~recognising~~ recognizing the His tag. The recombinant knobs are subsequently used in interference studies to investigate the complexity of adenovirus binding between members of different subgroups as well as members within one subgroup.

Example 7: ~~identification~~ Identification of adherence molecules involved in adenovirus ~~subgroups~~subgroups B, D~~,~~ and F binding and ~~internalisation~~internalization

[0108] To investigate what adherence molecules are involved in binding and ~~internalisation~~ internalization of adenovirus serotypes from different subgroups, in particular, subgroups B, D~~,~~ and F, the following strategies are designed~~.~~:

1) Phage display libraries

[0109] Phage display libraries, containing random 6-12 amino ~~acids~~acid peptides are~~ i~~ "~~mixedî~~" with synthetically ~~synthesised~~ synthesized peptides which have been identified to block infection of one or more members of ~~either subgroups~~subgroups B, D, and/-or F. Mixing of phages with peptide(s) is performed in an ELISA setting in which the peptide(s) are coated to a plastic support. Several rounds of mixing, washing and elution are performed to obtain an enrichment for phages that truly and specifically- ~~bind~~binds to the peptide(s). Finally, the phages retrieved are amplified and plaque purified, after which approximately 20 are sequenced to establish the nature of the peptide insert of the phages. From the consensus sequence of all 20 phages, a (degenerate) oligonucleotide is ~~synthesised~~ synthesized which, together with a polyA ~~hybridising~~ hybridizing oligonucleotide, is used for the amplification of cDNA sequences both from cells which can or cannot (negative control) be infected with a subgroup B, D, and/or F ~~chimaeric~~chimeric adenovirus. Amplified cDNAs are cloned, sequenced and aligned, amongst others, against existing Genbank sequences.

2) cDNA expression library screening

[0110] cDNA libraries, either commercially available or generated using a CAR-negative cell line which is highly transducible with ~~chimaeric~~chimeric adenoviruses carrying the fiber protein of members of, for example, subgroup D or subgroup F, are used for expression library screening using either ~~radiolabelled~~ radiolabeled adenovirus or recombinant produced knob proteins as probes. Clones or plaques which bind to the probe are picked, amplified and ~~re-tested~~ retested for enrichment of probe binding. Finally, phages are picked, after which the cDNA content is elucidated by sequence analysis. Retrieved cDNAs are cloned, sequenced and aligned, amongst others, against existing Genbank sequences.

3) Peptidase treatment of cells after adenovirus binding

[0111] Cells which are highly transducible with ~~chimaeric~~chimeric adenoviruses carrying the fiber protein of members of, for example, subgroup D~~,~~ are treated with different peptidases after binding of the ~~chimaeric~~chimeric adenovirus. The panel of suited peptidases ~~suited~~ is first tested on the ~~chimaeric~~chimeric adenovirus only to ensure that capsid proteins of the ~~chimaeric~~chimeric virus is not cleaved. ~~Peptidae~~ Peptidase-treated cells are spun down, after which the supernatant is added to 24-well plates precoated with anti-adenovirus hexon and/-or penton antibodies. After binding of adenovirus to the precoated plastic support, wells are washed extensively with PBS. Upon washing, the adenovirus is harvested, after which either protein gel electrophoresis or Malditoff is used to identify whether parts of a cellular protein ~~is~~are bound to the fiber protein or whether extra protein bands are visible as compared to protein gel electrophoresis or Malditoff of a purified batch of adenovirus only. As a negative control for the above-described experiments, cells negative for infection with a ~~chimaeric~~chimeric adenovirus carrying a fiber of a member of subgroup D can be used. Alternatively, cells which are highly transducible with ~~chimaeric~~chimeric adenoviruses carrying the fiber protein of members of, for example, subgroup D, are first treated with peptidases, after which the medium is incubated with adenoviruses bound to a plastic support.

[0112] The above-described examples encompasses the construction of recombinant adenoviral vectors ~~chimaeric~~chimeric for the fiber protein which results in an altered infection host-range. The alteration of the infection host-range results in highly efficient infection of cells

negative for the CAR protein, which is the protein required by adenovirus serotype 5 for efficient infection. These vectors are generated for the purpose of gene transfer and recombinant DNA vaccines. These vectors are thus ideally suited for gene transfer to tissues, and/or organs of which ~~de~~the cells do not express detectable levels of CAR.

Figure and table legends

[0113] Table 1: Association of human adenovirus serotypes with human disease.

[0114] Table 2: Oligonucleotides and degenerate oligonucleotides used for the amplification of DNA encoding for fiber protein derived from alternative human adenovirus serotypes. Bold letters in oligonucleotides A-E represent an NdeI restriction site. Bold letters in oligonucleotides 1-6 and 8 represent an NsiI restriction site. Bold letters in oligonucleotide 7 represents a PacI restriction site.

[0115] Table 3: Production results of fiber chimaeric adenoviruses. The number of virus particles per ml were determined using HPLC. The number of infectious units (IU) per millilitre were determined through titration on human 911 cells. For infection experiments, the number of virus particles per millilitre is taken from all chimaeric adenoviruses since IU/ml reflects a receptor mediated process.

[0116] Table 4: Flow cytometric results on expression of integrins $?_v?3$ and $?_v?5$, the Coxsacki adenovirus receptor (CAR), and MHC class I on the membranes of human cell lines and human primary cells. A549: Human lung carcinoma cell line (ATCC, CCL 1185). K562: Human erythroid leukemia (ATCC, CCL 243). SupT1: Human Lymphoblast hybrid B and T (ATCC, CRL 1991). GM09503: Human primary fibroblasts. HEPG2HEPG2: Human liver carcinoma (ATCC, HB8065). CEM: human lymphoblast cells (ATCC, CRL 1992). HeLa: Human cervix carcinoma (ATCC, CCL 2). Primary amniocytes and chorion villi cells were obtained from department of antropogenetics, Leiden, The Netherlands. Primary Smooth muscle cells, Human umbilical vein endothelial cells, and synoviocytes were obtained from TNO-PG, Leiden, The Netherlands. Shown is the percentage of cells expressing either molecule on their membrane. ND: not determined. 0% means undetectable expression of the molecule on the membrane of the cell using flow cytometry. 100% means high expression of the molecule on the cell membrane.

[0117] Figure 1: Schematic presentation of adapter plasmid pMLPI.TK.

[0118] Figure 2: Schematic presentation of adapter plasmid pAd/L420-HAS.

[0119] Figure 3: Schematic presentation of adapter plasmid pAd5/CLIP

[0120] Figure 4: Schematic presentation of plasmid system which requires only one recombinational event to generate recombinant adenoviruses.

[0121] ~~Figure 5: Schematic presentation of plasmid system which requires two recombinational events to generate recombinant adenoviruses.~~

[0122] ~~Figure 6: Schematic presentation of generation of plasmid pBr/AdBamRDeltaFib in which the Adenovirus type 5 fiber DNA is replaced by a short DNA stretch containing an unique NsiI site.~~

[0123] ~~Figure 7: Fiber protein sequences of adenovirus serotypes 8, 9, 13, 14,20, 23, 24, 25, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 42, 43, 44, 45, 46, 47, 48, 49, and 51. Bold letters represent part of the tail of adenovirus serotype 5. If bold letters not present it means that a PCR fragment was sequenced which does not contain the Ad5 tail. An X, present in the sequence means unidentified amino acid due to unidentified nucleotide. At the end of the sequence the stop codon of the fiber is presented by a dot.~~

[0124] ~~Figure 8: Transduction of human lung carcinoma cells (A549) with a panel of chimaeric adenoviruses carrying the fiber of adenovirus 12, 16, 17, 28, 32, 40 L, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per ?g of protein.~~

[0125] ~~Figure 9: Transduction of human erythroid leukemia cells (K562) with a panel of chimaeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40 S, 40 L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per ?g of protein. Error bars represent SD.~~

[0126] ~~Figure 10: Transduction of human primary fibroblasts (GM09503) with a panel of chimaeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40 L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per ?g of protein. Error bars represent SD.~~

[0127] ~~Figure 11: Transduction of human lymphoblast cells (SupT1) with a panel of chimaeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40 S, 40 L, 49, or 51.~~

~~Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per ?g of protein. Error bars represent SD.~~

[0128] ~~Figure 12: Transduction of human chorion villi cells with a panel of chimaeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40 L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per ?g of protein. Error bars represent SD.~~

[0129] ~~Figure 13: Transduction of human hepatic cells (HEPG2) with a panel of chimaeric adenoviruses carrying the fiber of adenovirus 12, 16, 28, 32, 40 S, 40 L, 49, or 51. Adenovirus 5 served as reference. Cells were infected with increasing MOI based on virus particles per cell: 10, 50, 250, 1250, 2500, 5000 (see legend on the right of graph). Luciferase transgene expression is expressed as relative light units (RLU) per ?g of protein. Error bars represent SD.~~

REFERENCES

Arnberg N., Mei Y. and Wadell G., 1997. Fiber genes of adenoviruses with tropism for the eye and the genital tract. Virology 227: 239-244.

Bout A., 1997. Gene therapy, p. 167-182. In: D.J.A. Crommelin and R.D. Sindelar (ed.), Pharmaceutical biotechnology , Harwood Academic Publishers.

Bout, A. 1996. Prospects for human Gene therapy. Eur. J. drug Met. And Pharma. 2, 175-179.

Blaese et al., Cancer Gene Ther., 2 (1995):291-297).

Brody and Crystal, Ann. N. Y. Acad. Sci. 716(1994):90-101.

Chroboczek J., Ruigrok R.W.H., and Cusack S., 1995. Adenovirus fiber, p. 163-200. In: W. Doerfler and P. Bohm (ed.), The molecular repertoire of adenoviruses, I. Springer-Verlag, Berlin.

Defer C., Belin M., Caillet-Boudin M. and Boulanger P., 1990. Human adenovirus-host cell interactions; comparative study with members of subgroup B and C. Journal of Virology 64 (8): 3661-3673.

De Jong, J.C., Wermenbol, A.G., Verweij-Uijterwaal, M.W., Slaterus, K.W., Wertheim-van Dillen, P., van Doornum, G.J.J., Khoo, S.H., and Hierholzer, J.C. (1998). Adenoviruses from HIV-infected patients, including two new candidate serotypes Ad50 and Ad51 of Subgenus D and B1 respectively. In preparation.

Eisenlohr, L.C., Gerard, W., and Hackett, C.J. (1987). Role of receptor-binding activity of the viral hemagglutin molecule in the presentation of influenza virus antigens to helper T-cells. J. Virol 61, 1375-1383.

Eiz B and Pring-~~kerblom~~Kerblom P., 1997. Molecular characterization of the type-specific g-determinant located on the adenovirus fiber. Journal of Virology 71: 6576-6581.

Francki, R.I.B., Fauquet, C.M., Knudson, D.L. and Brown, F. (1991~~)~~). Classification and nomenclature of viruses. Fifth report of the international Committee on taxonomy of viruses. Arch. Virol. Suppl. 2, 140-144.

GahÈry-SÈgard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P. and Guillet J., 1998.Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. Journal of Virology 72: 2388-2397.

Gall J., Kass-Eisler A., Leinwand L. and Falck-Pedersen E., 1996. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralisation epitopes. Journal of Virology 70 (4): 2116-2123.

Greber, U.F., Willets, M., Webster, P., and Helenius, A. (1993). Stepwise dismanteling of adenovirus 2 during entry into cells. Cell 75, 477-486.

Hynes, R.O. (1992~~)~~). Integrins: versatility, modulation and signalling in cell adhesion. Cell 69, 11-25.

Herz and Gerard, Proc. Natl. Acad. Sci. U.S.A., 96 (1993):2812-2816.

Hierholzer, J.C. (1992~~)~~). Adenovirus in the immunocompromised host. Clin. Microbiol Rev. 5, 262-274.

Hierholzer, J.C., Wigand, R., Anderson, L.J., Adrian, T., and Gold, J.W.M. (1988). Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types43-47). J. Infect. Dis. 158, 804-813.

Ishibashi, M. and Yasue (1983). in Adenoviruses of Animals, Chapter 12, p497-561.

Kay, R., Takei, F., and Humphries, R.K. (1990). Expression cloning of a cDNA encoding M1/69-J11d heat-stable antigens. J. Immunol. 145 (6), 1952-1959.

Khoo, S.H., Bailey, A.S., De Jong, J.C., and Mandal, B.K. (1995). Adenovirus infections in human immunodeficiency virus-positive patients: Clinical features and molecular epidemiology. J. Infect. Dis 172, 629-637.

Kidd, A.H., Chrboczek, J., Cusack, S., and Ruigrok, R.W.lH. (1993). Adenovirus type 40 virions containtwo distinct fibers. Virology 192, 73-84.

Krasnykh V.N., Mikheeva G.V., Douglas J.T. and Curiel D.T., 1996.Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. Journal of Virology **70**(10): 6839-6846.

Krasnykh V., Dmitriev I., Mikheeva G., Miller C.R., Belousova N. and Curiel D.T.,1998.

Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. Journal of Virology **72**(3): 1844-1852.

Leopold, P.L., Ferris, B., Grinberg, I., Worgall, S., Hackett, N.R., and Crystal, R.G. (1998). Fluorescent virions: Dynamic tracking of the pathway of adenoviral vectors in living cells. Hum. Gene Ther. 9, 367-378.

Levrero, M., Barban, V., Manteca, S., Ballay, A., Balsamo, C., Avantaggiata, M.L., Natoli, G., Skellekens, H., Tiollais, P., and Perricaudet, M. (1991(. Defective and non-defective adenovirus vectors for expression foreign genes in vitro and in vivo. Gene 101, 195-202.

Matlin, K.S., Reggio, H., Helenius, A., and Simons, K. (1981). Infectious entry pathway of influenza virus in a canine kidney cell line. J. Cell Biol. 91, 601-613.

Morgan, C., Rozenkrantz, H.S., and Mednis, B. (1969(Structure and development of viruses as observed in the electron microscope.X. Entry and uncoating of adenovirus. J.Virol 4, 777-796.

Roelvink, P.W., Lizonova, A.,Lee, J.G.M., Li, Y., Bergelson, J.M. Finberg, R.W., Brough, D.E., Kovesdi, I., and Wickham, T.J. (1998). The Coacksackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A,C,D,E, and F. J. Virology 72 (No. 10), 7909-7915.

Richman, D.D., Hostetler, K.Y., Yazaki, P.J., and Clark, S. (1986). Fate of influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine. Virology 151, 200-210.

Stevenson S.C., Rollence M., White B., Weaver L. and McClelland A., 1995.
Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. Journal of Virology 69(5): 2850-2857.

Stevenson S.C., Rollence M., Marshall-Neff J. and McClelland A., 1997.Selective targeting of human cells by a ~~chimaeric~~chimeric adenovirus vector containing a modified fiber protein. Journal of Virology 71(6): 4782-4790.

Signas, G., Akusjarvi, G., and Petterson, U. (1985). Adenovirus 3 fiberpolypeptide gene: Complications for the structure of the fiber protein. J. Virol. 53, 672-678.

Stouten, P.W.F., Sander, C., Ruigrok, R.W.H., and Cusack, S. (1992). New triple helical model for the shaft of the adenovirus fiber. J. Mol. Biol. 226, 1073-1084.

Schulick, A.H., Vassalli, G., Dunn, P.F., Dong, G., Rade, J.J., Zamarron, C. and Dichek, D.A. (1997). Established immunity precludes adenovirus-mediated gene transfer inrat carotid arteries.

Schnurr, D and Dondero, M.E. (1993). Two new candidate adenovirus serotypes Intervirol. 36, 79-83.

Svensson, V. and Persson, R. (1984). Entry of adenovirus 2 into Hela cells. J. Virol. 51, 687-694.

Varga, M.J., Weibull, C., and Everitt, E. (1991). Infectious entry pathway of adenovirus type 2. J. Virol 65, 6061-6070.

Wickham T.J., Carrion M.E. and Kovesdi I., 1995. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Therapy **2**: 750-756.

Wickham T.J., Segal, D.M., Roelvink, P.W., Carrion M.E., Lizonova, A., Lee, G-M., and Kovesdi, I. (1996). Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70 (10), 6831-6838.

Wickham, T.J., Mathias, P., Cherish, D.A., and Nemerow, G.R. (1993). Integrins avb3 and avb5 promote adenovirus internalisation but not virus attachment. Cell 73, 309-319.

[0130] Table 1

~~Syndrom~~Syndrome	Subgenus	Serotype
Respiratory illness	A	31
	B	3, 7, 11, 14, 21, 34, 35, 51
	C	1, 2, 5, 6
	D	39, 42-48
	E	4
Keratoconjunctivitis (eye)	B	11
	D	8, 19, 37, 50
Hemorrhagic cystitis (Kidney)	B	7, 11, 14, 16, 21, 34, 35
And urogenital tract infections	C	5
	D	39, 42-48
Sexual transmission	C	2
	D	19, 37
Gastroenteritis	A	31
	B	3
	C	1, 2, 5
	D	28
	F	40, 41
CNS disease	A	12, 31
	B	3, 7
	C	2, 5, 6
	D	32, 49
Hepatitis	A	31
	C	1, 2, 5
Disseminated	A	31
	B	3, 7, 11, 21
	D	30, 43-47
None (???)	A	18
	D	9, 10, 13, 15 17, 20, 22-29, 33, 36, 38

[0131] Table 2

Serotype	Tail oligonucleotide	Knob oligonucleotide
4	A	1
8	B	2
9	B	2
12	E	3
16	C	4
19p	B	2
28	B	2
32	B	2
36	B	2
37	B	2
40-1	D	5
40-2	D	6
41-s	D	5
41-l	D	7
49	B	2
50	B	2
51	C	8

A: 5'- CCC GTG TAT C**CA TAT G**AT GCA GAC AAC GAC CGA CC- 3' (SEQ ID NO:17)

B: 5'- CCC GTC TAC C**CA TAT G**GC TAC GCG CGG- 3' (SEQ ID NO:18)

C: 5'- CCK GTS TAC C**CA TAT G**AA GAT GAA AGC- 3' (SEQ ID NO:19)

D: 5'- CCC GTC TAC C**CA TAT G**AC ACC TYC TCA ACT C- 3' (SEQ ID NO:20)

E: 5'- CCC GTT TAC C**CA TAT G**AC CCA TTT GAC ACA TCA GAC- 3' (SEQ ID NO:21)

1: 5"'- CCG **ATG CAT** TTA TTG TTG GGC TAT ATA GGA - 3' (SEQ ID NO:22)

2: 5'- CCG **ATG CAT** TYA TTC TTG GGC RAT ATA GGA - 3' (SEQ ID NO:23)

3: 5'- CCG **ATG CAT** TTA TTC TTG GGR AAT GTA WGA AAA GGA - 3' (SEQ ID NO:24)

4: 5'- CCG **ATG CAT** TCA GTC ATC TTC TCT GAT ATA - 3' (SEQ ID NO:25)

5: 5'- CCG **ATG CAT** TTA TTG TTC AGT TAT GTA GCA - 3' (SEQ ID NO:26)

6: 5'- GCC **ATG CAT** TTA TTG TTC TGT TAC ATA AGA - 3' (SEQ ID NO:27)

7: 5'-- CCG **TTA ATT AAG** CCC TTA TTG TTC TGT TAC ATA AGA A - 3' (SEQ ID NO:28)

8: 5'- CCG **ATG CAT** TCA GTC ATC YTC TWT AAT ATA - 3' (SEQ ID NO:29)

[0132] Table 3

Adenovirus	Virus particles/ ml	Infectious units/ ml
Ad5Fib5	2.2×10^{12}	6.8×10^{11}
Ad5Fib12	4.4×10^{12}	1.9×10^{12}
Ad5Fib16	1.4×10^{12}	3.0×10^{10}
Ad5Fib17	9.3×10^{11}	9.5×10^{9}
Ad5Fib28	5.4×10^{10}	2.8×10^{8}
Ad5Fib32	2.0×10^{12}	1.1×10^{12}
Ad5Fib40-S	3.2×10^{10}	1.0×10^{10}
Ad5Fib40-L	2.0×10^{12}	6.4×10^{11}
Ad5Fib49	1.2×10^{12}	4.3×10^{11}
Ad5Fib51	5.1×10^{12}	1.0×10^{12}

[0133] Table 4

Cell line	$\alpha_v\beta3$	$\alpha_v\beta5$	CAR	MHC class I
A549	17%	98%	100%	ND
K562	12%	55%	0%	15%
GM09503	20%	50%	0%	100%
CEM	0%	0%	3%	100%
SupT1	5%	1%	70%	100%
Smooth muscle cells	100%	70%	0%	15%
HUVEC	100%	15%	10%	90%
Synoviocytes	30%	40%	0%	100%
1^0chorionvilli	100%	0%	12%	100%
HepG2	0%	10%	100%	80%

SEQUENCE LISTING

<110> Introgene BV
Havenga, Menzo
Vogels, Ronald

<120> Infection with chimeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)

<130> 2183-52226US

<140> 10/040,949
<141> 2002-01-07

<150> WO01/04334
<151> 2000-07-07

<150> EP 99202234.3
<151> 1999-07-08

<150> US 60/142,557
<151> 2000-07-07

<160> 58

<170> PatentIn version 3.1

<210> 1
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligo linker

<220>
<221> misc feature
<222> (1)..(23)
<223> linker contains a PacI restriction site at positions 8-15

<400> 1
aattgtctta attaaccgct taa 23

<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>

<221> misc feature
<222> (1)..(19)
<223> oligonucleotide contains a PacI restriction site at positions 8-15

<400> 2
aattgtctta attaaccgc 19

<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide
<220>
<221> misc feature
<222> (1)..(19)
<223> oligonucleotide contains a PacI restriction site at positions 9-16

<400> 3
aattgcggtt aattaagac 19

<210> 4
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(47)
<223> primer LTR-1

<400> 4
ctgtacgtac cagtgcactg gcctaggcat ggaaaaatac ataactg 47

<210> 5
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(64)
<223> primer LRT-2

<400> 5
gcggatcctt cgaaccatgg taagcttggt accgctagcg ttaaccgggc
gactcagtca 60

atcg 64

<210> 6
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(28)
<223> primer HSA1

<400> 6
gcgccaccat gggcagagcg atggtggc 28

<210> 7
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(50)
<223> primer HSA2

<400> 7
gttagatcta agcttgtcga catcgatcta ctaacagtag agatgtagaa 50

<210> 8
<211> 21

<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(21)
<223> primer 1

<400> 8
gggtattagg ccaaaggcgc a 21

<210> 9
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(33)
<223> primer 2

<400> 9
gatcccatgg aagcttgggt ggcgacccca gcg 33

<210> 10
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> misc feature
<222> (1)..(36)
<223> primer 3

<400> 10
gatcccatgg ggatccttta ctaagttaca aagcta 36

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
<220>
<221> misc feature
<222> (1)..(19)
<223> primer 4

<400> 11
gtcgctgtag ttggactgg 19

<210> 12
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> primer bind
<222> (1)..(42)
<223> primer NY-up

<400> 12
cgacatatgt agatgcatta gtttgtgtta tgtttcaacg tg 42

<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> primer bind
<222> (1)..(19)
<223> primer NY-down

<400> 13
ggagaccact gccatgttg 19

<210> 14
<211> 10
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo linker

<400> 14
ttaagtcgac 10

<210> 15
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> primer_bind
<222> (1)..(32)
<223> LacZ primer 1

<400> 15
ggggtggcca gggtacctct aggcttttgc aa 32

<210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<220>
<221> primer_bind
<222> (1)..(29)
<223> LacZ primer 2

<400> 16
gggggatcc ataaacaagt tcagaatcc 29

<210> 17
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc_feature
<222> (1)..(35)
<223> tail oligonucleotide

<220>
<221> misc feature
<222> (11)..(16)
<223> contains a NdeI restriction site at positions 11-16

<400> 17
cccgtgtatc catatgatgc agacaacgac cgacc 35

<210> 18
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(27)
<223> tail oligonucleotide

<220>
<221> misc feature
<222> (1)..(27)
<223> tail oligonucleotide

<220>
<221> misc feature
<222> (11)..(16)
<223> contains a NdeI restriction site at positions 11-16

<400> 18
cccgtctacc catatggcta cgcgcgg 27

<210> 19
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(27)
<223> tail oligonucleotide

<220>

<221> misc feature
<222> (11)..(16)
<223> contains a NdeI restriction site at positions 11-16

<220>
<221> misc feature
<222> (3)
<223> 'k' at position 3 indicates a nucleotide that may be either g or t

<220>
<221> misc feature
<222> (6)

<223> 's' at position 6 indicates a nucleotide that may be either g or c

<400> 19
cckgtstacc catatgaaga tgaaagc 27

<210> 20
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(31)
<223> tail oligonucleotide

<220>
<221> misc feature
<222> (23)

<223> 'y' at position 23 indicates a nucleotide that may be either t or c

<220>
<221> misc feature
<222> (11)..(16)
<223> contains a NdeI restriction site at positions 11-16

<400> 20
cccgtctacc catatgacac ctyctcaact c 31

<210> 21

<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc_feature
<222> (1)..(36)
<223> tail oligonucleotide

<220>
<221> misc_feature
<222> (11)..(16)
<223> contains a NdeI restriction site at positions 11-16

<400> 21
cccgtttacc catatgaccc atttgacaca tcagac 36

<210> 22
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc_feature
<222> (1)..(30)
<223> knob oligonucleotide

<220>
<221> misc_feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 22
ccgatgcatt tattgttggg ctatatagga 30

<210> 23
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(30)
<223> knob oligonucleotide

<220>
<221> misc feature

<222> (11)
<223> 'y' at position 11 indicates a nucleotide that may be either t or c

<220>
<221> misc feature
<222> (22)..(22)
<223> 'r' at position 22 indicates a nucleotide that may be either g or a

<220>
<221> misc feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 23
ccgatgcatt yattcttggg cratatagga 30

<210> 24
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(36)
<223> knob oligonucleotide

<220>
<221> misc feature
<222> (28)
<223> 'w' at position 28 indicates a nucleotide that may be either a or t

<220>
<221> misc feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 24
ccgatgcatt tattcttggg raatgtawga aaagga 36

<210> 25
<211> 30
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc_feature
<222> (1)..(30)
<223> knob oligonucleotide

<220>
<221> misc_feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 25
ccgatgcatt cagtcatctt ctctgatata 30

<210> 26
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc_feature
<222> (1)..(30)
<223> knob oligonucleotide

<220>
<221> misc_feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 26
ccgatgcatt tattgttcag ttatgtagca 30

<210> 27
<211> 30

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(30)
<223> knob oligonucleotide

<220>
<221> misc feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 27
gccatgcatt tattgttctg ttacataaga 30

<210> 28
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>
<221> misc feature
<222> (1)..(37)
<223> knob oligonucleotide

<220>
<221> misc feature
<222> (4)..(11)
<223> contains a PacI restriction site at positions 4-11

<400> 28
ccgttaatta agcccttatt gttctgttac ataagaa 37

<210> 29
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<220>

<221> misc feature
<222> (1)..(30)
<223> knob oligonucleotide

<220>
<221> misc feature
<222> (19)
<223> 'y' at position 19 indicates a nucleotide that may be either t or c

<220>
<221> misc feature
<222> (23)
<223> 'w' at position 23 indicates a nucleotide that may be either a or t

<220>
<221> misc feature
<222> (4)..(9)
<223> contains a NsiI restriction site at positions 4-9

<400> 29
ccgatgcatt cagtcatcyt ctwtaatata 30

<210> 30
<211> 377
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(377)
<223> Serotype 8 fiber protein

<400> 30

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val
35 40 45

Ser Ser Asn Gly Phe Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Thr Ile Asn Asn Gln Asn Val Ser Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Thr Leu Gln Glu Glu Thr Gly Lys Leu Thr Val Asn
85 90 95

Thr Glu Pro Pro Leu His Leu Thr Asn Asn Lys Leu Gly Ile Ala Leu
100 105 110

Asp Ala Pro Phe Asp Val Ile Asp Asn Lys Leu Thr Leu Leu Ala Gly
115 120 125

His Gly Leu Ser Ile Ile Thr Lys Glu Thr Ser Thr Leu Pro Gly Leu
130 135 140

Val Asn Thr Leu Val Val Leu Thr Gly Lys Gly Ile Gly Thr Asp Leu
145 150 155 160

Ser Asn Asn Gly Gly Asn Ile Cys Val Arg Val Gly Glu Gly Gly Gly
165 170 175

Leu Ser Phe Asn Asp Asn Gly Asp Leu Val Ala Phe Asn Lys Lys Glu
180 185 190

Asp Lys Arg Thr Leu Trp Thr Thr Pro Asp Thr Ser Pro Asn Cys Arg
195 200 205

Ile Asp Gln Asp Lys Asp Ser Lys Leu Thr Leu Val Leu Thr Lys Cys
210 215 220

Gly Ser Gln Ile Leu Ala Asn Val Ser Leu Ile Val Val Ala Gly Arg
225 230 235 240

Tyr Lys Ile Ile Asn Asn Asn Thr Asn Pro Ala Leu Lys Gly Phe Thr

245 250 255

Ile Lys Leu Leu Phe Asp Lys Asn Gly Val Leu Met Glu Ser Ser Asn
260 265 270

Leu Gly Lys Ser Tyr Trp Asn Phe Arg Asn Gln Asn Ser Ile Met Ser
275 280 285

Thr Ala Tyr Glu Lys Ala Ile Gly Phe Met Pro Asn Leu Val Ala Tyr
290 295 300

Pro Lys Pro Thr Thr Gly Ser Lys Lys Tyr Ala Arg Asp Ile Val Tyr
305 310 315 320

Gly Asn Ile Tyr Leu Gly Gly Lys Pro His Gln Pro Val Thr Ile Lys
325 330 335

Thr Thr Phe Asn Gln Glu Thr Gly Cys Glu Tyr Ser Ile Thr Phe Asp
340 345 350

Phe Ser Trp Ala Lys Thr Tyr Val Asn Val Glu Phe Glu Thr Thr Ser
355 360 365

Phe Thr Phe Ser Tyr Ile Ala Gln Glu
370 375

<210> 31
<211> 377
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(377)
<223> Serotype 9 fiber protein

<400> 31

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys	Arg	Ala	Arg	Pro	Ser	Glu	Asp	Thr	Phe	Asn	Pro	Val	Tyr	Pro	Tyr
			20					25					30		

Gly	Tyr	Ala	Arg	Asn	Gln	Asn	Ile	Pro	Phe	Leu	Thr	Pro	Pro	Phe	Val
		35					40					45			

Ser	Ser	Asp	Gly	Phe	Gln	Asn	Phe	Pro	Pro	Gly	Val	Leu	Ser	Leu	Lys
	50					55					60				

Leu	Ala	Asp	Pro	Ile	Ala	Ile	Val	Asn	Gly	Asn	Val	Ser	Leu	Lys	Val
65					70					75					80

Gly	Gly	Gly	Leu	Thr	Leu	Gln	Asp	Gly	Thr	Gly	Lys	Leu	Thr	Val	Asn
				85					90					95	

Ala	Asp	Pro	Pro	Leu	Gln	Leu	Thr	Asn	Asn	Lys	Leu	Gly	Ile	Ala	Leu
			100					105					110		

Asp	Ala	Pro	Phe	Asp	Val	Ile	Asp	Asn	Lys	Leu	Thr	Leu	Leu	Ala	Gly
		115					120					125			

His	Gly	Leu	Ser	Ile	Ile	Thr	Lys	Glu	Thr	Ser	Thr	Leu	Pro	Gly	Leu
	130					135					140				

Ile	Asn	Thr	Leu	Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Thr	Glu	Ser
145					150					155					160

Thr	Asp	Asn	Gly	Gly	Ser	Val	Cys	Val	Arg	Val	Gly	Glu	Gly	Gly	Gly
				165					170					175	

Leu	Ser	Phe	Asn	Asn	Asp	Gly	Asp	Leu	Val	Ala	Phe	Asn	Lys	Lys	Glu
			180					185					190		

Asp	Lys	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp	Thr	Ser	Pro	Asn	Cys	Lys
		195					200					205			

Ile Asp Gln Asp Lys Asp Ser Lys Leu Thr Leu Val Leu Thr Lys Cys
210 215 220

Gly Ser Gln Ile Leu Ala Asn Val Ser Leu Ile Val Val Ala Gly Lys
225 230 235 240

Tyr Lys Ile Ile Asn Asn Asn Thr Gln Pro Ala Leu Lys Gly Phe Thr
245 250 255

Ile Lys Leu Leu Phe Asp Glu Asn Gly Val Leu Met Glu Ser Ser Asn
260 265 270

Leu Gly Lys Ser Tyr Trp Asn Phe Arg Asn Glu Asn Ser Ile Met Ser
275 280 285

Thr Ala Tyr Glu Lys Ala Ile Gly Phe Met Pro Asn Leu Val Ala Tyr
290 295 300

Pro Lys Pro Thr Ala Gly Ser Lys Lys Tyr Ala Arg Asp Ile Val Tyr
305 310 315 320

Gly Asn Ile Tyr Leu Gly Gly Lys Pro Asp Gln Pro Val Thr Ile Lys
325 330 335

Thr Thr Phe Asn Gln Glu Thr Gly Cys Glu Tyr Ser Ile Thr Phe Asp
340 345 350

Phe Ser Trp Ala Lys Thr Tyr Val Asn Val Glu Phe Glu Thr Thr Ser
355 360 365

Phe Thr Phe Ser Tyr Ile Ala Gln Glu
370 375

<210> 32
<211> 391
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(391)
<223> Serotype 13 fiber protein

<220>
<221> MISC FEATURE
<222> (1)..(5)
<223> 'Xaa' at positions 1-5 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (23)
<223> 'Xaa' at position 23 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (41)
<223> 'Xaa' at position 41 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (43)
<223> 'Xaa' at position 43 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (49)
<223> 'Xaa' at position 49 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (385)
<223> 'Xaa' at position 385 indicates an unidentified amino acid due to unidentified nucleotide(s)

<400> 32

Xaa Xaa Xaa Xaa Xaa Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Ser Ser Xaa Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly	Tyr	Ala	Arg	Asn	Gln	Asn	Ile	Xaa	Phe	Xaa	Thr	Pro	Pro	Phe	Val
		35					40					45			

Xaa	Ser	Asp	Gly	Phe	Lys	Asn	Phe	Pro	Pro	Gly	Val	Leu	Ser	Leu	Lys
	50					55					60				

Leu	Ala	Asp	Pro	Ile	Thr	Ile	Ala	Asn	Gly	Asp	Val	Ser	Leu	Lys	Val
65					70					75					80

Gly	Gly	Gly	Leu	Thr	Leu	Gln	Glu	Gly	Ser	Leu	Thr	Val	Asp	Pro	Lys
				85					90					95	

Ala	Pro	Leu	Gln	Leu	Ala	Asn	Asp	Lys	Lys	Leu	Glu	Leu	Val	Tyr	Asp
			100					105					110		

Asp	Pro	Phe	Glu	Val	Ser	Thr	Asn	Lys	Leu	Ser	Leu	Lys	Val	Gly	His
		115					120					125			

Gly	Leu	Lys	Val	Leu	Asp	Asp	Lys	Ser	Ala	Gly	Gly	Leu	Lys	Asp	Leu
	130					135					140				

Ile	Gly	Lys	Leu	Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Ile	Glu	Asn
145					150					155					160

Leu	Gln	Asn	Asp	Asp	Gly	Ser	Ser	Arg	Gly	Val	Gly	Ile	Asn	Val	Arg
				165					170					175	

Leu	Gly	Thr	Asp	Gly	Gly	Leu	Ser	Phe	Asp	Arg	Lys	Gly	Glu	Leu	Val
			180					185					190		

Ala	Trp	Asn	Arg	Lys	Asp	Asp	Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp
		195					200					205			

Pro	Ser	Pro	Asn	Cys	Lys	Ala	Glu	Thr	Glu	Lys	Asp	Ser	Lys	Leu	Thr
	210					215					220				

Leu Val Leu Thr Lys Cys Gly Ser Gln Ile Leu Ala Thr Val Ser Ile
225 230 235 240

Ile Val Leu Lys Gly Lys Tyr Glu Phe Val Lys Lys Glu Thr Glu Pro
245 250 255

Lys Ser Phe Asp Val Lys Leu Leu Phe Asp Ser Lys Gly Val Leu Leu
260 265 270

Pro Thr Ser Asn Leu Ser Lys Glu Tyr Trp Asn Tyr Arg Ser Tyr Asp
275 280 285

Asn Asn Ile Gly Thr Pro Tyr Glu Asn Ala Val Pro Phe Met Pro Asn
290 295 300

Leu Lys Ala Tyr Pro Lys Pro Thr Lys Thr Ala Ser Asp Lys Ala Glu
305 310 315 320

Asn Lys Ile Ser Ser Ala Lys Asn Lys Ile Val Ser Asn Phe Tyr Phe
325 330 335

Gly Gly Gln Ala Tyr Gln Pro Gly Thr Ile Ile Ile Lys Phe Asn Glu
340 345 350

Glu Ile Asp Glu Thr Cys Ala Tyr Ser Ile Thr Phe Asn Phe Gly Trp
355 360 365

Gly Lys Val Tyr Asp Asn Pro Phe Pro Phe Asp Thr Thr Ser Phe Thr
370 375 380

Xaa Ser Tyr Ile Ala Gln Glu
385 390

<210> 33
<211> 290
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(290)
<223> Serotype 14 fiber protein

<400> 33

His	Pro	Phe	Ile	Asn	Pro	Gly	Phe	Ile	Ser	Pro	Asn	Gly	Phe	Thr	Gln
1				5				10				15			

Ser	Pro	Asp	Gly	Val	Leu	Thr	Leu	Lys	Cys	Leu	Thr	Pro	Leu	Thr	Thr
		20					25					30			

Thr	Gly	Gly	Ser	Leu	Gln	Leu	Lys	Val	Gly	Gly	Gly	Leu	Thr	Val	Asp
		35					40					45			

Asp	Thr	Asp	Gly	Thr	Leu	Gln	Glu	Asn	Ile	Gly	Ala	Thr	Thr	Pro	Leu
	50					55					60				

Val	Lys	Thr	Gly	His	Ser	Ile	Gly	Leu	Ser	Leu	Gly	Ala	Gly	Leu	Gly
65				70				75						80	

Thr	Asp	Glu	Asn	Lys	Leu	Cys	Thr	Lys	Leu	Gly	Glu	Gly	Leu	Thr	Phe
				85					90					95	

Asn	Ser	Asn	Asn	Ile	Cys	Ile	Asp	Asp	Asn	Ile	Asn	Thr	Leu	Trp	Thr
			100					105					110		

Gly	Val	Asn	Pro	Thr	Glu	Ala	Asn	Cys	Gln	Met	Met	Asp	Ser	Ser	Glu
		115					120					125			

Ser	Asn	Asp	Cys	Lys	Leu	Ile	Leu	Thr	Leu	Val	Lys	Thr	Gly	Ala	Leu
	130					135					140				

Val	Thr	Ala	Phe	Val	Tyr	Val	Ile	Gly	Val	Ser	Asn	Asn	Phe	Asn	Met
145				150					155					160	

Leu	Thr	Thr	Tyr	Arg	Asn	Ile	Asn	Phe	Thr	Ala	Glu	Leu	Phe	Phe	Asp
				165					170					175	

Ser Ala Gly Asn Leu Leu Thr Ser Leu Ser Ser Leu Lys Thr Pro Leu
180 185 190

Asn His Lys Ser Gly Gln Thr Trp Leu Leu Val Pro Leu Leu Met Leu
195 200 205

Lys Val Ser Cys Pro Ala Gln Leu Leu Ile Leu Ser Ile Ile Ile Leu
210 215 220

Glu Lys Asn Lys Thr Thr Phe Thr Glu Leu Val Thr Thr Gln Leu Val
225 230 235 240

Ile Thr Leu Leu Phe Pro Leu Thr Ile Ser Val Met Leu Asn Gln Arg
245 250 255

Ala Ile Arg Ala Asp Thr Ser Tyr Cys Ile Arg Ile Thr Trp Ser Trp
260 265 270

Asn Thr Gly Asp Ala Pro Glu Gly Gln Thr Ser Ala Thr Thr Leu Val
275 280 285

Thr Ser
290

<210> 34
<211> 345
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(345)
<223> Serotype 20 fiber protein

<400> 34

Ile Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly
1 5 10 15

Leu Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro

			20				25				30				
Ile	Ala	Ile	Val	Asn	Gly	Asn	Val	Ser	Leu	Lys	Val	Gly	Gly	Gly	Ile
		35				40				45					
Thr	Val	Glu	Gln	Asp	Ser	Gly	Gln	Leu	Ile	Ala	Asn	Pro	Lys	Ala	Pro
	50				55				60						
Leu	Gln	Val	Ala	Asn	Asp	Lys	Leu	Glu	Leu	Ser	Tyr	Ala	Tyr	Pro	Phe
65				70				75							80
Glu	Thr	Ser	Ala	Asn	Lys	Leu	Ser	Leu	Lys	Val	Gly	Gln	Gly	Leu	Lys
			85				90					95			
Val	Leu	Asp	Glu	Lys	Asp	Ser	Gly	Gly	Leu	Gln	Asn	Leu	Leu	Gly	Lys
		100				105				110					
Leu	Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Val	Glu	Glu	Leu	Lys	Asn
	115				120				125						
Pro	Asp	Asn	Thr	Asn	Arg	Gly	Val	Gly	Ile	Asn	Val	Arg	Leu	Gly	Lys
130				135				140							
Asp	Gly	Gly	Leu	Ser	Phe	Asn	Lys	Asn	Gly	Glu	Leu	Val	Ala	Trp	Asn
145				150				155							160
Lys	His	Asn	Asp	Thr	Gly	Thr	Leu	Trp	Thr	Thr	Pro	Asp	Pro	Ser	Pro
			165				170					175			
Asn	Cys	Lys	Ile	Glu	Glu	Val	Lys	Asp	Ser	Lys	Leu	Thr	Leu	Val	Leu
		180				185				190					
Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Thr	Met	Ala	Phe	Gln	Val	Val
	195				200				205						
Lys	Gly	Thr	Tyr	Glu	Asn	Ile	Ser	Lys	Asn	Thr	Ala	Lys	Asn	Ser	Phe
210				215				220							

Ser Ile Lys Leu Leu Phe Asp Asp Asn Gly Lys Leu Leu Glu Gly Ser
225 230 235 240

Ser Leu Asp Lys Asp Tyr Trp Asn Phe Arg Ser Asp Asp Ser Ile Ile
245 250 255

Pro Asn Gln Tyr Asp Asn Ala Val Pro Phe Met Pro Asn Leu Lys Ala
260 265 270

Tyr Pro Lys Pro Ser Thr Val Leu Pro Ser Thr Asp Lys Asn Ser Asn
275 280 285

Gly Lys Asn Thr Ile Val Ser Asn Leu Tyr Leu Glu Gly Lys Ala Tyr
290 295 300

Gln Pro Val Ala Val Thr Ile Thr Phe Asn Lys Glu Ile Gly Cys Thr
305 310 315 320

Tyr Ser Ile Thr Phe Asp Phe Gly Trp Ala Lys Thr Tyr Asp Val Pro
325 330 335

Ile Pro Phe Asp Ser Ser Ser Phe Thr
340 345

<210> 35
<211> 346
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(346)
<223> Serotype 23 fiber protein

<400> 35

Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe
1 5 10 15

Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile

20 25 30

Ala Ile Thr Asn Gly Asp Val Ser Leu Lys Val Gly Gly Gly Leu Thr
35 40 45

Val Glu Gln Asp Ser Gly Asn Leu Lys Val Asn Thr Lys Ala Pro Leu
50 55 60

Gln Val Ala Ala Asp Lys Gln Leu Glu Ile Ala Leu Ala Asp Pro Phe
65 70 75 80

Glu Val Ser Lys Gly Arg Leu Gly Ile Lys Ala Gly His Gly Leu Lys
85 90 95

Val Ile Asp Asn Ser Ile Ser Gly Leu Glu Gly Leu Val Gly Thr Leu
100 105 110

Val Val Leu Thr Gly His Gly Ile Gly Thr Glu Asn Leu Leu Asn Asn
115 120 125

Asp Gly Ser Ser Arg Gly Val Gly Ile Asn Val Arg Leu Gly Lys Asp
130 135 140

Gly Gly Leu Ser Phe Asp Lys Lys Gly Asp Leu Val Ala Trp Asn Lys
145 150 155 160

Lys Tyr Asp Thr Arg Thr Leu Trp Thr Thr Pro Asp Pro Ser Pro Asn
165 170 175

Cys Lys Val Ile Glu Ala Lys Asp Ser Lys Leu Thr Leu Val Leu Thr
180 185 190

Lys Cys Gly Ser Gln Ile Leu Ala Asn Met Ser Leu Leu Ile Leu Lys
195 200 205

Gly Thr Tyr Glu Tyr Ile Ser Asn Ala Ile Ala Asn Lys Ser Phe Thr
210 215 220

Ile Lys Leu Leu Phe Asn Asp Lys Gly Val Leu Met Asp Gly Ser Ser
225 230 235 240

Leu Asp Lys Asp Tyr Trp Asn Tyr Lys Ser Asp Asp Ser Val Met Ser
245 250 255

Lys Ala Tyr Glu Asn Ala Val Pro Phe Met Pro Asn Leu Lys Ala Tyr
260 265 270

Pro Asn Pro Thr Thr Ser Thr Thr Asn Pro Ser Thr Asp Lys Lys Ser
275 280 285

Asn Gly Lys Asn Ala Ile Val Ser Asn Val Tyr Leu Glu Gly Arg Ala
290 295 300

Tyr Gln Pro Val Ala Ile Thr Ile Thr Phe Asn Lys Glu Thr Gly Cys
305 310 315 320

Thr Tyr Ser Met Thr Phe Asp Phe Gly Trp Ser Lys Val Tyr Asn Asp
325 330 335

Pro Ile Pro Phe Asp Thr Ser Ser Leu Thr
340 345

<210> 36
<211> 390
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(390)
<223> Serotype 24 fiber protein

<400> 36

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val
35 40 45

Ser Ser Asp Gly Phe Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Ala Ile Thr Asn Gly Asp Val Ser Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Thr Val Glu Lys Asp Ser Gly Asn Leu Lys Val Asn
85 90 95

Pro Lys Ala Pro Leu Gln Val Thr Thr Asp Lys Gln Leu Glu Ile Ala
100 105 110

Leu Ala Tyr Pro Phe Glu Val Ser Asn Gly Lys Leu Gly Ile Lys Ala
115 120 125

Gly His Gly Leu Lys Val Ile Asp Lys Ile Ala Gly Leu Glu Gly Leu
130 135 140

Ala Gly Thr Leu Val Val Leu Thr Gly Lys Gly Ile Gly Thr Glu Asn
145 150 155 160

Leu Glu Asn Ser Asp Gly Ser Ser Arg Gly Val Gly Ile Asn Val Arg
165 170 175

Leu Ala Lys Asp Gly Gly Leu Ser Phe Asp Lys Lys Gly Asp Leu Val
180 185 190

Ala Trp Asn Lys His Asp Asp Arg Arg Thr Leu Trp Thr Thr Pro Asp
195 200 205

Pro Ser Pro Asn Cys Thr Ile Asp Gln Glu Arg Asp Ser Lys Leu Thr

210 215 220

Leu Val Leu Thr Lys Cys Gly Ser Gln Ile Leu Ala Asn Val Ser Leu
225 230 235 240

Leu Val Val Lys Gly Lys Phe Ser Asn Ile Asn Asn Asn Thr Asn Pro
245 250 255

Thr Asp Lys Lys Ile Thr Val Lys Leu Leu Phe Asn Glu Lys Gly Val
260 265 270

Leu Met Asp Ser Ser Thr Leu Lys Lys Glu Tyr Trp Asn Tyr Arg Asn
275 280 285

Asp Asn Ser Thr Val Ser Gln Ala Tyr Asp Asn Ala Val Pro Phe Met
290 295 300

Pro Asn Ile Lys Ala Tyr Pro Lys Pro Thr Thr Asp Thr Ser Ala Lys
305 310 315 320

Pro Glu Asp Lys Lys Ser Ala Ala Lys Arg Tyr Ile Val Ser Asn Val
325 330 335

Tyr Ile Gly Gly Leu Pro Asp Lys Thr Val Val Ile Thr Ile Lys Phe
340 345 350

Asn Ala Glu Thr Glu Cys Ala Tyr Ser Ile Thr Phe Glu Phe Thr Trp
355 360 365

Ala Lys Thr Phe Glu Asp Val Gln Phe Asp Ser Ser Ser Phe Thr Phe
370 375 380

Ser Tyr Ile Ala Gln Glu
385 390

<210> 37
<211> 375
<212> PRT

<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(375)
<223> Serotype 25 fiber protein

<220>
<221> MISC_FEATURE
<222> (141)
<223> 'Xaa' at position 41 indicates an unidentified amino acid due to unidentified nucleotide(s)

<400> 37

Ser	Cys	Ser	Cys	Pro	Ser	Ala	Pro	Thr	Ile	Phe	Met	Leu	Leu	Gln	Met
1				5				10						15	

Lys	Arg	Ala	Arg	Pro	Ser	Glu	Asp	Thr	Phe	Asn	Pro	Val	Tyr	Pro	Tyr
			20					25					30		

Gly	Tyr	Ala	Arg	Asn	Gln	Asn	Ile	Pro	Phe	Leu	Thr	Pro	Pro	Phe	Val
		35					40					45			

Ser	Ser	Asp	Gly	Phe	Gln	Asn	Phe	Pro	Pro	Gly	Val	Leu	Ser	Leu	Lys
	50					55					60				

Leu	Ala	Asp	Pro	Ile	Thr	Ile	Ser	Asn	Gly	Asp	Val	Ser	Leu	Lys	Val
65					70					75					80

Gly	Gly	Gly	Leu	Thr	Val	Glu	Gln	Asp	Ser	Gly	Asn	Leu	Ser	Val	Asn
				85					90					95	

Pro	Lys	Ala	Pro	Leu	Gln	Val	Gly	Thr	Asp	Lys	Lys	Leu	Glu	Leu	Ala
			100					105					110		

Leu	Ala	Pro	Pro	Phe	Asn	Val	Lys	Asp	Asn	Lys	Leu	Asp	Leu	Leu	Val
		115					120					125			

Gly	Asp	Gly	Leu	Lys	Val	Ile	Asp	Lys	Ser	Ile	Ser	Xaa	Leu	Pro	Gly
	130					135					140				

Leu	Leu	Asn	Tyr	Leu	Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Asn	Glu
145					150					155					160

Glu	Leu	Lys	Asn	Asp	Asp	Gly	Ser	Asn	Lys	Gly	Val	Gly	Leu	Cys	Val
				165					170					175	

Arg	Ile	Gly	Glu	Gly	Gly	Gly	Leu	Thr	Phe	Asp	Asp	Lys	Gly	Tyr	Leu
			180					185					190		

Val	Ala	Trp	Asn	Lys	Lys	His	Asp	Ile	Arg	Thr	Leu	Trp	Thr	Thr	Leu
		195					200					205			

Asp	Pro	Ser	Pro	Asn	Cys	Arg	Ile	Asp	Val	Asp	Lys	Asp	Ser	Lys	Leu
	210					215					220				

Thr	Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Asn	Val	Ser
225					230					235					240

Leu	Leu	Val	Val	Lys	Gly	Arg	Phe	Gln	Asn	Leu	Asn	Tyr	Lys	Thr	Asn
				245					250					255	

Pro	Asn	Leu	Pro	Lys	Thr	Phe	Thr	Ile	Lys	Leu	Leu	Phe	Asp	Glu	Asn
			260					265					270		

Gly	Ile	Leu	Lys	Asp	Ser	Ser	Asn	Leu	Asp	Lys	Asn	Tyr	Trp	Asn	Tyr
		275					280					285			

Arg	Asn	Gly	Asn	Ser	Ile	Leu	Ala	Glu	Gln	Tyr	Lys	Asn	Ala	Val	Gly
	290					295					300				

Phe	Met	Pro	Asn	Leu	Ala	Ala	Tyr	Pro	Lys	Ser	Thr	Thr	Thr	Gln	Ser
305					310					315					320

Lys	Leu	Tyr	Ala	Arg	Asn	Thr	Ile	Phe	Gly	Asn	Ile	Tyr	Leu	Asp	Ser
				325					330					335	

Gln Ala Tyr Asn Pro Val Val Ile Lys Ile Thr Phe Asn Gln Glu Ala
340 345 350

Asp Ser Ala Tyr Ser Ile Thr Leu Asn Tyr Ser Trp Gly Lys Asp Tyr
355 360 365

Glu Asn Ile Pro Phe Asp Ser
370 375

<210> 38
<211> 335
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(335)
<223> Serotype 27 fiber protein

<400> 38

Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe Lys Asn
1 5 10 15

Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile Thr Ile
20 25 30

Thr Asn Gly Asp Val Ser Leu Lys Val Gly Gly Gly Leu Val Val Glu
35 40 45

Lys Glu Ser Gly Lys Leu Ser Val Asp Pro Lys Thr Pro Leu Gln Val
50 55 60

Ala Ser Asp Asn Lys Leu Glu Leu Ser Tyr Asn Ala Pro Phe Lys Val
65 70 75 80

Glu Asn Asp Lys Leu Ser Leu Asp Val Gly His Gly Leu Lys Val Ile
85 90 95

Gly Asn Glu Val Ser Ser Leu Pro Gly Leu Ile Asn Lys Leu Val Val

			100				105				110				
Leu	Thr	Gly	Lys	Gly	Ile	Gly	Thr	Glu	Glu	Leu	Lys	Glu	Gln	Asn	Ser
		115				120				125					
Asp	Lys	Ile	Ile	Gly	Val	Gly	Ile	Asn	Val	Arg	Ala	Arg	Gly	Gly	Leu
	130				135				140						
Ser	Phe	Asp	Asn	Asp	Gly	Tyr	Leu	Val	Ala	Trp	Asn	Pro	Lys	Tyr	Asp
145				150				155							160
Thr	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp	Thr	Ser	Pro	Asn	Cys	Lys	Met
			165					170					175		
Leu	Thr	Lys	Lys	Asp	Ser	Lys	Leu	Thr	Leu	Thr	Leu	Thr	Lys	Cys	Gly
		180					185					190			
Ser	Gln	Ile	Leu	Gly	Asn	Val	Ser	Leu	Leu	Ala	Val	Ser	Gly	Lys	Tyr
	195					200					205				
Leu	Asn	Met	Thr	Lys	Asp	Glu	Thr	Gly	Val	Lys	Ile	Ile	Leu	Leu	Phe
210					215					220					
Asp	Arg	Asn	Gly	Val	Leu	Met	Gln	Glu	Ser	Ser	Leu	Asp	Lys	Glu	Tyr
225				230					235						240
Trp	Asn	Tyr	Arg	Asn	Asp	Asn	Asn	Val	Ile	Gly	Thr	Pro	Tyr	Glu	Asn
			245					250					255		
Ala	Val	Gly	Phe	Met	Pro	Asn	Leu	Val	Ala	Tyr	Pro	Lys	Pro	Thr	Ser
		260					265					270			
Ala	Asp	Ala	Lys	Asn	Tyr	Ser	Arg	Ser	Lys	Ile	Ile	Ser	Asn	Val	Tyr
	275					280					285				
Leu	Lys	Gly	Leu	Ile	Tyr	Gln	Pro	Val	Ile	Ile	Ile	Ala	Ser	Phe	Asn
290					295					300					

Gln Glu Thr Thr Asn Gly Cys Val Tyr Ser Ile Ser Phe Asp Phe Thr
305 310 315 320

Cys Ser Lys Asp Tyr Thr Gly Gln Gln Phe Asp Val Thr Ser Phe
325 330 335

<210> 39
<211> 374
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(374)
<223> Serotype 28 fiber protein

<400> 39

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val
35 40 45

Ser Ser Asp Gly Phe Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Thr Ile Ala Asn Gly Asp Val Ser Leu Lys Leu
65 70 75 80

Gly Gly Gly Leu Thr Val Glu Lys Glu Ser Gly Asn Leu Thr Val Asn
85 90 95

Pro Lys Ala Pro Leu Gln Val Ala Ser Gly Gln Leu Glu Leu Ala Tyr
100 105 110

Tyr Ser Pro Phe Asp Val Lys Asn Asn Met Leu Thr Leu Lys Ala Gly
115 120 125

His Gly Leu Ala Val Val Thr Lys Asp Asn Thr Asp Leu Gln Pro Leu
130 135 140

Met Gly Thr Leu Val Val Leu Thr Gly Lys Gly Ile Gly Thr Gly Thr
145 150 155 160

Ser Ala His Gly Gly Thr Ile Asp Val Arg Ile Gly Lys Asn Gly Ser
165 170 175

Leu Ala Phe Asp Lys Asn Gly Asp Leu Val Ala Trp Asp Lys Glu Asn
180 185 190

Asp Arg Arg Thr Leu Trp Thr Thr Pro Asp Thr Ser Pro Asn Cys Lys
195 200 205

Met Ser Glu Val Lys Asp Ser Lys Leu Thr Leu Ile Leu Thr Lys Cys
210 215 220

Gly Ser Gln Ile Leu Gly Ser Val Ser Leu Leu Ala Val Lys Gly Glu
225 230 235 240

Tyr Gln Asn Met Thr Ala Ser Thr Asn Lys Asn Val Lys Ile Thr Leu
245 250 255

Leu Phe Asp Ala Asn Gly Val Leu Leu Glu Gly Ser Ser Leu Asp Lys
260 265 270

Glu Tyr Trp Asn Phe Arg Asn Asn Asp Ser Thr Val Ser Gly Lys Tyr
275 280 285

Glu Asn Ala Val Pro Phe Met Pro Asn Ile Thr Ala Tyr Lys Pro Val
290 295 300

Asn Ser Lys Ser Tyr Ala Arg Ser His Ile Phe Gly Asn Val Tyr Ile

305 310 315 320

Asp Ala Lys Pro Tyr Asn Pro Val Val Ile Lys Ile Ser Phe Asn Gln
325 330 335

Glu Thr Gln Asn Asn Cys Val Tyr Ser Ile Ser Phe Asp Tyr Thr Cys
340 345 350

Ser Lys Glu Tyr Thr Gly Met Gln Phe Asp Val Thr Ser Phe Thr Phe
355 360 365

Ser Tyr Ile Ala Gln Glu
370

<210> 40
<211> 343
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(343)
<223> Serotype 29 fiber protein

<400> 40

Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe
1 5 10 15

Lys Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile
20 25 30

Ala Ile Thr Asn Gly Asp Val Ser Leu Lys Val Gly Gly Gly Leu Thr
35 40 45

Val Glu Gln Asp Ser Gly Asn Leu Ser Val Asn Pro Lys Ala Pro Leu
50 55 60

Gln Val Gly Thr Asp Lys Lys Leu Glu Leu Ala Leu Ala Pro Pro Phe
65 70 75 80

Asp	Val	Arg	Asp	Asn	Lys	Leu	Ala	Ile	Leu	Val	Gly	Asp	Gly	Leu	Lys
				85					90					95	

Val	Ile	Asp	Arg	Ser	Ile	Ser	Asp	Leu	Pro	Gly	Leu	Leu	Asn	Tyr	Leu
			100					105					110		

Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Asn	Glu	Glu	Leu	Lys	Asn	Asp
		115					120					125			

Asp	Gly	Ser	Asn	Lys	Gly	Val	Gly	Leu	Cys	Val	Arg	Ile	Gly	Glu	Gly
	130					135					140				

Gly	Gly	Leu	Thr	Phe	Asp	Asp	Lys	Gly	Tyr	Leu	Val	Ala	Trp	Asn	Asn
145					150					155					160

Lys	His	Asp	Ile	Arg	Thr	Leu	Trp	Thr	Thr	Leu	Asp	Pro	Ser	Pro	Asn
				165					170					175	

Cys	Lys	Ile	Asp	Ile	Glu	Lys	Asp	Ser	Lys	Leu	Thr	Leu	Val	Leu	Thr
			180					185					190		

Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Asn	Val	Ser	Leu	Ile	Ile	Val	Asn
		195					200					205			

Gly	Lys	Phe	Lys	Ile	Leu	Asn	Asn	Lys	Thr	Asp	Pro	Ser	Leu	Pro	Lys
	210					215					220				

Ser	Phe	Asn	Ile	Lys	Leu	Leu	Phe	Asp	Gln	Asn	Gly	Val	Leu	Leu	Glu
225					230					235					240

Asn	Ser	Asn	Ile	Glu	Lys	Gln	Tyr	Leu	Asn	Phe	Arg	Ser	Gly	Asp	Ser
				245					250					255	

Ile	Leu	Pro	Glu	Pro	Tyr	Lys	Asn	Ala	Ile	Gly	Phe	Met	Pro	Asn	Leu
			260					265					270		

Leu Ala Tyr Ala Lys Ala Thr Thr Asp Gln Ser Lys Ile Tyr Ala Arg
275 280 285

Asn Thr Ile Tyr Gly Asn Ile Tyr Leu Asp Asn Gln Pro Tyr Asn Pro
290 295 300

Val Val Ile Lys Ile Thr Phe Asn Asn Glu Ala Asp Ser Ala Tyr Ser
305 310 315 320

Ile Thr Phe Asn Tyr Ser Trp Thr Lys Asp Tyr Asp Asn Ile Pro Phe
325 330 335

Asp Ser Thr Ser Phe Thr Ser
340

<210> 41
<211> 386
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(386)
<223> Serotype 30 fiber protein

<220>
<221> MISC_FEATURE
<222> (23)
<223> 'Xaa' at position 23 indicates unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC_FEATURE
<222> (43)
<223> 'Xaa' at position 43 indicates unidentified amino acid due to Unidentified nucleotide(s)

<220>
<221> MISC_FEATURE

<222> (49)
<223> 'Xaa' at position 49 indicates unidentified amino acid due to unidentified nucleotide(s)

<220>

<221> MISC FEATURE
<222> (97)
<223> 'Xaa' at position 97 indicates unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (152)
<223> 'Xaa' at position 152 indicates unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (186)..(786)
<223> 'Xaa' at position 186 indicates unidentified amino acid due to unidentified nucleotide(s)

<400> 41

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Xaa Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Xaa Thr Pro Pro Phe Val
35 40 45

Xaa Ser Asp Gly Phe Lys Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Ala Ile Thr Asn Gly Asp Val Ser Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Thr Val Glu Gln Asp Ser Gly Asn Leu Ser Val Asn
85 90 95

Xaa Lys Ala Pro Leu Gln Val Gly Thr Asp Lys Lys Leu Glu Leu Ala
100 105 110

Leu Ala Pro Pro Phe Asp Val Arg Asp Asn Lys Leu Ala Ile Leu Val
115 120 125

Gly	Asp	Gly	Leu	Lys	Val	Ile	Asp	Arg	Ser	Ile	Ser	Asp	Leu	Pro	Gly
	130					135					140				

Leu	Leu	Asn	Tyr	Leu	Val	Val	Xaa	Thr	Gly	Lys	Gly	Ile	Gly	Asn	Glu
145					150					155					160

Glu	Leu	Lys	Asn	Asp	Asp	Gly	Ser	Asn	Lys	Gly	Val	Gly	Leu	Cys	Val
				165					170					175	

Arg	Ile	Gly	Glu	Gly	Gly	Gly	Leu	Thr	Xaa	Asp	Asp	Lys	Gly	Tyr	Leu
			180					185					190		

Val	Ala	Trp	Asn	Asn	Lys	His	Asp	Ile	Arg	Thr	Leu	Trp	Thr	Thr	Leu
		195					200					205			

Asp	Pro	Ser	Pro	Asn	Cys	Lys	Ile	Asp	Ile	Glu	Lys	Asp	Ser	Lys	Leu
	210					215					220				

Thr	Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Asn	Val	Ser
225					230					235					240

Leu	Ile	Ile	Val	Asn	Gly	Lys	Phe	Lys	Ile	Leu	Asn	Asn	Lys	Thr	Asp
				245					250					255	

Pro	Ser	Leu	Pro	Lys	Ser	Phe	Asn	Ile	Lys	Leu	Leu	Phe	Asp	Gln	Asn
			260					265					270		

Gly	Val	Leu	Leu	Glu	Asn	Ser	Asn	Ile	Glu	Lys	Gln	Tyr	Leu	Asn	Phe
		275					280					285			

Arg	Ser	Gly	Asp	Ser	Ile	Leu	Pro	Glu	Pro	Tyr	Lys	Asn	Ala	Ile	Gly
	290					295					300				

Phe	Met	Pro	Asn	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Thr	Thr	Asp	Gln	Ser
305					310					315					320

Lys Ile Tyr Ala Arg Asn Thr Ile Tyr Gly Asn Ile Tyr Leu Asp Asn
325 330 335

Gln Pro Tyr Asn Pro Val Val Ile Lys Ile Thr Phe Asn Asn Glu Ala
340 345 350

Asp Ser Ala Tyr Ser Ile Thr Phe Asn Tyr Ser Trp Thr Lys Asp Tyr
355 360 365

Asp Asn Ile Pro Phe Asp Ser Thr Ser Phe Thr Phe Ser Tyr Ile Ala
370 375 380

Gln Glu
385

<210> 42
<211> 391
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(391)
<223> Serotype 32 fiber protein

<400> 42

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val
35 40 45

Ser Ser Asp Gly Phe Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Thr Ile Ala Asn Gly Asn Val Ser Leu Lys Val
65 70 75 80

Gly	Gly	Gly	Leu	Thr	Leu	Glu	Gln	Asp	Ser	Gly	Lys	Leu	Ile	Val	Asn
				85					90					95	

Pro	Lys	Ala	Pro	Leu	Gln	Val	Ala	Asn	Asp	Lys	Leu	Glu	Leu	Ser	Tyr
			100					105					110		

Ala	Asp	Pro	Phe	Glu	Thr	Ser	Ala	Asn	Lys	Leu	Ser	Leu	Lys	Val	Gly
		115					120					125			

His	Gly	Leu	Lys	Val	Leu	Asp	Glu	Lys	Asn	Ala	Gly	Gly	Leu	Lys	Asp
	130					135					140				

Leu	Ile	Gly	Thr	Leu	Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Val	Glu
145					150					155					160

Glu	Leu	Lys	Asn	Ala	Asp	Asn	Thr	Asn	Arg	Gly	Val	Gly	Ile	Asn	Val
				165					170					175	

Arg	Leu	Gly	Lys	Asp	Gly	Gly	Leu	Ser	Phe	Asp	Lys	Lys	Gly	Asp	Leu
			180					185					190		

Val	Ala	Trp	Asn	Lys	His	Asp	Asp	Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro
		195					200					205			

Asp	Pro	Ser	Pro	Asn	Cys	Thr	Ile	Asp	Glu	Glu	Arg	Asp	Ser	Lys	Leu
	210					215					220				

Thr	Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Asn	Val	Ser
225					230					235					240

Leu	Leu	Val	Val	Lys	Gly	Lys	Phe	Ser	Asn	Ile	Asn	Asn	Asn	Thr	Asn
				245					250					255	

Pro	Thr	Asp	Lys	Lys	Ile	Thr	Val	Lys	Leu	Leu	Phe	Asn	Glu	Lys	Gly
			260					265					270		

Val Leu Met Asp Ser Ser Ser Leu Lys Lys Glu Tyr Trp Asn Tyr Arg
275 280 285

Asn Asp Asn Ser Thr Val Ser Gln Ala Tyr Asp Asn Ala Val Pro Phe
290 295 300

Met Pro Asn Ile Lys Ala Tyr Pro Lys Pro Thr Thr Asp Thr Ser Ala
305 310 315 320

Lys Pro Glu Asp Lys Lys Ser Ala Ala Lys Arg Tyr Ile Val Ser Asn
325 330 335

Val Tyr Ile Gly Gly Leu Pro Asp Lys Thr Val Val Ile Thr Ile Lys
340 345 350

Leu Asn Ala Glu Thr Glu Ser Ala Tyr Ser Met Thr Phe Glu Phe Thr
355 360 365

Trp Ala Lys Thr Phe Glu Asn Leu Gln Phe Asp Ser Ser Ser Phe Thr
370 375 380

Phe Ser Tyr Ile Ala Gln Glu
385 390

<210> 43
<211> 391
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(391)
<223> Serotype 33 fiber protein

<400> 43

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr

				20				25				30			
Gly	Tyr	Ala	Arg	Asn	Gln	Asn	Ile	Pro	Phe	Leu	Thr	Pro	Pro	Phe	Val
		35					40					45			
Ser	Ser	Asp	Gly	Phe	Lys	Asn	Phe	Pro	Pro	Gly	Val	Leu	Ser	Leu	Lys
	50					55					60				
Leu	Ala	Asp	Pro	Ile	Thr	Ile	Thr	Asn	Gly	Asp	Val	Ser	Leu	Lys	Val
65					70					75					80
Gly	Gly	Gly	Leu	Thr	Leu	Gln	Glu	Gly	Ser	Leu	Thr	Val	Asn	Pro	Lys
				85					90					95	
Ala	Pro	Leu	Gln	Leu	Ala	Asn	Asp	Lys	Lys	Leu	Glu	Leu	Val	Tyr	Asp
			100					105					110		
Asp	Pro	Phe	Glu	Val	Ser	Thr	Asn	Lys	Leu	Ser	Leu	Lys	Val	Gly	His
		115					120					125			
Gly	Leu	Lys	Val	Leu	Asp	Asp	Lys	Ser	Ala	Gly	Gly	Leu	Gln	Asp	Leu
	130					135					140				
Ile	Gly	Lys	Leu	Val	Val	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Ile	Glu	Asn
145					150					155					160
Leu	Gln	Asn	Asp	Asp	Gly	Ser	Ser	Arg	Gly	Val	Gly	Ile	Asn	Val	Arg
				165					170					175	
Leu	Gly	Thr	Asp	Gly	Gly	Leu	Ser	Phe	Asp	Arg	Lys	Gly	Glu	Leu	Val
			180					185					190		
Ala	Trp	Asn	Arg	Lys	Asp	Asp	Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp
		195					200					205			
Pro	Ser	Pro	Asn	Cys	Lys	Ala	Glu	Thr	Glu	Lys	Asp	Ser	Lys	Leu	Thr
	210					215					220				

Leu Val Leu Thr Lys Cys Gly Ser Gln Ile Leu Ala Thr Val Ser Ile
225 230 235 240

Ile Val Leu Lys Gly Lys Tyr Glu Phe Val Lys Lys Glu Thr Glu Pro
245 250 255

Lys Ser Phe Asp Val Lys Leu Leu Phe Asp Ser Lys Gly Val Leu Leu
260 265 270

Pro Thr Ser Asn Leu Ser Lys Glu Tyr Trp Asn Tyr Arg Ser Tyr Asp
275 280 285

Asn Asn Ile Gly Thr Pro Tyr Glu Asn Ala Val Pro Phe Met Pro Asn
290 295 300

Leu Lys Ala Tyr Pro Lys Pro Thr Lys Thr Ala Ser Asp Lys Ala Glu
305 310 315 320

Asn Lys Ile Ser Ser Ala Lys Asn Lys Ile Val Ser Asn Phe Tyr Phe
325 330 335

Gly Gly Gln Ala Tyr Gln Pro Gly Thr Ile Ile Ile Lys Phe Asn Glu
340 345 350

Glu Ile Asp Glu Thr Cys Ala Tyr Ser Ile Thr Phe Asn Phe Gly Trp
355 360 365

Gly Lys Val Tyr Asp Asn Pro Phe Pro Phe Asp Thr Thr Ser Phe Thr
370 375 380

Phe Ser Tyr Ile Ala Gln Glu
385 390

<210> 44
<211> 338
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(338)
<223> Serotype 34 fiber protein

<400> 44

Ser	Cys	Ser	Cys	Pro	Ser	Ala	Pro	Thr	Ile	Phe	Met	Leu	Leu	Gln	Met
1				5				10						15	

Lys	Arg	Ala	Arg	Pro	Ser	Glu	Asp	Thr	Phe	Asn	Pro	Val	Tyr	Pro	Tyr
			20					25					30		

Glu	Asp	Glu	Ser	Thr	Ser	Gln	His	Pro	Phe	Ile	Asn	Pro	Gly	Phe	Ile
		35					40					45			

Ser	Pro	Asn	Gly	Phe	Thr	Gln	Ser	Pro	Asp	Gly	Val	Leu	Thr	Leu	Lys
	50					55					60				

Cys	Leu	Thr	Pro	Leu	Thr	Thr	Thr	Gly	Gly	Ser	Leu	Gln	Leu	Lys	Val
65					70					75					80

Gly	Gly	Gly	Leu	Thr	Val	Asp	Asp	Thr	Asp	Gly	Thr	Leu	Gln	Lys	Asn
			85					90					95		

Ile	Arg	Ala	Thr	Thr	Pro	Ile	Thr	Lys	Asn	Asn	His	Ser	Val	Glu	Leu
			100					105					110		

Thr	Ile	Gly	Asn	Gly	Leu	Glu	Thr	Gln	His	Asn	Lys	Leu	Cys	Ala	Lys
		115					120					125			

Leu	Gly	Asn	Gly	Leu	Lys	Phe	Asn	Asn	Gly	Asp	Ile	Cys	Ile	Lys	Asp
	130					135					140				

Ser	Ile	Asn	Thr	Leu	Trp	Thr	Gly	Ile	Asn	Pro	Pro	Pro	Asn	Cys	Gln
145					150					155					160

Ile	Val	Glu	Asn	Thr	Asn	Thr	Asn	Asp	Gly	Lys	Leu	Thr	Leu	Val	Leu
			165					170					175		

Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val Ser Leu Val Gly Val
180 185 190

Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys Thr Ala Asn Ile Gln
195 200 205

Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu Leu Thr Asp Glu Ser
210 215 220

Asp Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser Thr Ala Thr Ser Glu
225 230 235 240

Thr Val Ala Ser Ser Lys Ala Phe Met Pro Ser Thr Thr Ala Tyr Pro
245 250 255

Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr Ile His Gly Ile Cys
260 265 270

Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Phe Pro Leu Asn Ile Ser
275 280 285

Ile Met Leu Asn Ser Arg Met Ile Ser Ser Asn Val Ala Tyr Ala Ile
290 295 300

Gln Phe Glu Trp Asn Leu Asn Ala Ser Glu Ser Pro Glu Lys Gln His
305 310 315 320

Met Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser Tyr Ile Ile Glu Asp
325 330 335

Asp Asn

<210> 45
<211> 338
<212> PRT
<213> adenoviridae

<220>

<221> VARIANT

<222> (1)..(338)
<223> Serotype 35 fiber protein

<400> 45

Ser	Cys	Ser	Cys	Pro	Ser	Ala	Pro	Thr	Ile	Phe	Met	Leu	Leu	Gln	Met
1				5				10					15		

Lys	Arg	Ala	Arg	Pro	Ser	Glu	Asp	Thr	Phe	Asn	Pro	Val	Tyr	Pro	Tyr
			20					25					30		

Glu	Asp	Glu	Ser	Thr	Ser	Gln	His	Pro	Phe	Ile	Asn	Pro	Gly	Phe	Ile
		35					40					45			

Ser	Pro	Asn	Gly	Phe	Thr	Gln	Ser	Pro	Asp	Gly	Val	Leu	Thr	Leu	Lys
	50					55					60				

Cys	Leu	Thr	Pro	Leu	Thr	Thr	Thr	Gly	Gly	Ser	Leu	Gln	Leu	Lys	Val
65				70					75					80	

Gly	Gly	Gly	Leu	Thr	Val	Asp	Asp	Thr	Asp	Gly	Thr	Leu	Gln	Glu	Asn
			85					90					95		

Ile	Arg	Ala	Thr	Ala	Pro	Ile	Thr	Lys	Asn	Asn	His	Ser	Val	Glu	Leu
			100					105					110		

Ser	Ile	Gly	Asn	Gly	Leu	Glu	Thr	Gln	Asn	Asn	Lys	Leu	Cys	Ala	Lys
		115					120					125			

Leu	Gly	Asn	Gly	Leu	Lys	Phe	Asn	Asn	Gly	Asp	Ile	Cys	Ile	Lys	Asp
	130					135					140				

Ser	Ile	Asn	Thr	Leu	Trp	Thr	Gly	Ile	Asn	Pro	Pro	Pro	Asn	Cys	Gln
145				150					155					160	

Ile	Val	Glu	Asn	Thr	Asn	Thr	Asn	Asp	Gly	Lys	Leu	Thr	Leu	Val	Leu
				165					170					175	

Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val Ser Leu Val Gly Val
180 185 190

Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys Thr Ala Asn Ile Gln
195 200 205

Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu Leu Thr Glu Glu Ser
210 215 220

Asp Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser Thr Ala Thr Ser Glu
225 230 235 240

Thr Val Ala Ser Ser Lys Ala Phe Met Pro Ser Thr Thr Ala Tyr Pro
245 250 255

Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr Ile His Gly Ile Cys
260 265 270

Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Phe Pro Leu Asn Ile Ser
275 280 285

Ile Met Leu Asn Ser Arg Met Ile Ser Ser Asn Val Ala Tyr Ala Ile
290 295 300

Gln Phe Glu Trp Asn Leu Asn Ala Ser Glu Ser Pro Glu Ser Asn Ile
305 310 315 320

Met Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser Tyr Ile Thr Glu Asp
325 330 335

Asp Asn

<210> 46
<211> 392
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(392)
<223> Serotype 36 fiber protein

<400> 46

Ser	Cys	Ser	Cys	Pro	Ser	Ala	Pro	Thr	Ile	Phe	Met	Leu	Leu	Gln	Met
1				5				10						15	

Lys	Arg	Ala	Arg	Pro	Ser	Glu	Asp	Thr	Phe	Asn	Pro	Val	Tyr	Pro	Tyr
			20					25					30		

Gly	Tyr	Ala	Arg	Asn	Gln	Asn	Ile	Pro	Phe	Leu	Thr	Pro	Pro	Phe	Val
		35					40					45			

Ser	Ser	Asp	Gly	Phe	Lys	Asn	Phe	Pro	Pro	Gly	Val	Leu	Ser	Leu	Lys
	50					55					60				

Leu	Ala	Asp	Pro	Ile	Ala	Ile	Val	Asn	Gly	Asp	Val	Ser	Leu	Lys	Val
65					70					75					80

Gly	Gly	Gly	Leu	Thr	Val	Glu	Gln	Asp	Ser	Gly	Lys	Leu	Lys	Val	Asn
				85					90					95	

Pro	Lys	Ile	Pro	Leu	Gln	Val	Val	Asn	Asp	Gln	Leu	Glu	Leu	Ala	Thr
			100					105					110		

Asp	Lys	Pro	Phe	Lys	Ile	Glu	Asn	Asn	Lys	Leu	Ala	Leu	Asp	Val	Gly
		115					120					125			

His	Gly	Leu	Lys	Val	Ile	Asp	Lys	Thr	Ile	Ser	Asp	Leu	Gln	Gly	Leu
	130					135					140				

Val	Gly	Lys	Leu	Val	Val	Leu	Thr	Gly	Val	Gly	Ile	Gly	Thr	Glu	Thr
145					150					155					160

Leu	Lys	Asp	Lys	Asn	Asp	Lys	Val	Ile	Gly	Ser	Ala	Val	Asn	Val	Arg
				165					170					175	

Leu Gly Lys Asp Gly Gly Leu Asp Phe Asn Lys Lys Gly Asp Leu Val
180 185 190

Ala Trp Asn Arg Tyr Asp Asp Arg Arg Thr Leu Trp Thr Thr Pro Asp
195 200 205

Pro Ser Pro Asn Cys Lys Val Ser Glu Ala Lys Asp Ser Lys Leu Thr
210 215 220

Leu Val Leu Thr Lys Cys Gly Ser Gln Ile Leu Ala Ser Val Ala Leu
225 230 235 240

Leu Ile Val Lys Gly Lys Tyr Gln Thr Ile Ser Glu Ser Thr Ile Pro
245 250 255

Lys Asp Gln Arg Asn Phe Ser Val Lys Leu Met Phe Asp Glu Lys Gly
260 265 270

Lys Leu Leu Asp Lys Ser Ser Leu Asp Lys Glu Tyr Trp Asn Phe Arg
275 280 285

Ser Asn Asp Ser Val Val Gly Thr Ala Tyr Asp Asn Ala Val Pro Phe
290 295 300

Met Pro Asn Leu Lys Ala Tyr Pro Lys Asn Thr Thr Thr Ser Ser Thr
305 310 315 320

Asn Pro Asp Asp Lys Ile Ser Ala Gly Lys Lys Asn Ile Val Ser Asn
325 330 335

Val Tyr Leu Glu Gly Arg Val Tyr Gln Pro Val Ala Leu Thr Val Lys
340 345 350

Phe Asn Ser Glu Asn Asp Cys Ala Tyr Ser Ile Thr Phe Asp Phe Val
355 360 365

Trp Ser Lys Thr Tyr Glu Ser Pro Val Ala Phe Asp Ser Ser Ser Phe

370 375 380

Thr Phe Ser Tyr Ile Ala Gln Glu
385 390

<210> 47
<211> 380
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(380)
<223> Serotype 37 fiber protein

<400> 47

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val
35 40 45

Ser Ser Asp Gly Phe Lys Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Thr Ile Thr Asn Gly Asp Val Ser Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Thr Leu Gln Asp Gly Ser Leu Thr Val Asn Pro Lys
85 90 95

Ala Pro Leu Gln Val Asn Thr Asp Lys Lys Leu Glu Leu Ala Tyr Asp
100 105 110

Asn Pro Phe Glu Ser Ser Ala Asn Lys Leu Ser Leu Lys Val Gly His
115 120 125

Gly Leu Lys Val Leu Asp Glu Lys Ser Ala Ala Gly Leu Lys Asp Leu
130 135 140

Ile Gly Lys Leu Val Val Leu Thr Gly Lys Gly Ile Gly Thr Glu Asn
145 150 155 160

Leu Glu Asn Thr Asp Gly Ser Ser Arg Gly Ile Gly Ile Asn Val Arg
165 170 175

Ala Arg Glu Gly Leu Thr Phe Asp Asn Asp Gly Tyr Leu Val Ala Trp
180 185 190

Asn Pro Lys Tyr Asp Leu Arg Thr Leu Trp Thr Thr Pro Asp Thr Ser
195 200 205

Pro Asn Cys Thr Ile Ala Gln Asp Lys Asp Ser Lys Leu Thr Leu Val
210 215 220

Leu Thr Lys Cys Gly Ser Gln Ile Leu Ala Asn Val Ser Leu Ile Val
225 230 235 240

Val Ala Gly Lys Tyr His Ile Ile Asn Asn Lys Thr Asn Pro Lys Ile
245 250 255

Lys Ser Phe Thr Ile Lys Leu Leu Phe Asn Lys Asn Gly Val Leu Leu
260 265 270

Asp Asn Ser Asn Leu Gly Lys Ala Tyr Trp Asn Phe Arg Ser Gly Asn
275 280 285

Ser Asn Val Ser Thr Ala Tyr Glu Lys Ala Ile Gly Phe Met Pro Asn
290 295 300

Leu Val Ala Val Ser Lys Pro Ser Asn Ser Lys Lys Tyr Ala Arg Asp
305 310 315 320

Ile Val Tyr Gly Asn Ile Tyr Leu Gly Gly Lys Pro Asp Gln Pro Gly

325 330 335

Val Ile Lys Thr Thr Phe Asn Gln Glu Thr Gly Cys Glu Tyr Ser Ile
340 345 350

Thr Phe Asn Phe Ser Trp Ser Lys Thr Tyr Glu Asn Val Glu Phe Glu
355 360 365

Thr Thr Ser Phe Thr Phe Ser Tyr Ile Ala Gln Glu
370 375 380

<210> 48
<211> 391
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(391)
<223> Serotype 39 fiber protein

<220>
<221> MISC_FEATURE
<222> (43)
<223> 'Xaa' at position 43 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC_FEATURE
<222> (49)
<223> 'Xaa' at position 49 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC_FEATURE
<222> (97)
<223> 'Xaa' at position 97 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC_FEATURE
<222> (192)
<223> 'Xaa' at position 192 indicates an unidentified amino acid due to unidentified nucleotide(s)

<400> 48

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Xaa Thr Pro Pro Phe Val
35 40 45

Xaa Ser Asp Gly Phe Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asp Pro Ile Thr Ile Ala Asn Gly Asn Val Ser Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Thr Leu Glu Gln Asp Ser Gly Lys Leu Ile Val Asn
85 90 95

Xaa Lys Ala Pro Leu Gln Val Ala Asn Asp Lys Leu Glu Leu Ser Tyr
100 105 110

Ala Asp Pro Phe Glu Thr Ser Ala Asn Lys Leu Ser Leu Lys Val Gly
115 120 125

His Gly Leu Lys Val Leu Asp Glu Lys Asn Ala Gly Gly Leu Lys Asp
130 135 140

Leu Ile Gly Thr Leu Val Val Leu Thr Gly Lys Gly Ile Gly Val Glu
145 150 155 160

Glu Leu Lys Asn Ala Asp Asn Thr Asn Arg Gly Val Gly Ile Asn Val
165 170 175

Arg Leu Gly Lys Asp Gly Gly Leu Ser Phe Asp Lys Lys Gly Asp Xaa
180 185 190

Val Ala Trp Asn Lys His Asp Asp Arg Arg Thr Leu Trp Thr Thr Pro

			195				200				205			
Asp	Pro	Ser	Pro	Asn	Cys	Thr	Ile	Asp	Glu	Glu	Arg	Asp	Ser	Lys	Leu
	210					215					220				
Thr	Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Asn	Val	Ser
225					230					235					240
Leu	Leu	Val	Val	Lys	Gly	Lys	Phe	Ser	Asn	Ile	Asn	Asn	Asn	Thr	Asn
				245					250					255	
Pro	Thr	Asp	Lys	Lys	Ile	Thr	Val	Lys	Leu	Leu	Phe	Asn	Glu	Lys	Gly
			260					265					270		
Val	Leu	Met	Asp	Ser	Ser	Ser	Leu	Lys	Lys	Glu	Tyr	Trp	Asn	Tyr	Arg
		275					280					285			
Asn	Asp	Asn	Ser	Thr	Val	Ser	Gln	Ala	Tyr	Asp	Asn	Ala	Val	Pro	Phe
	290					295					300				
Met	Pro	Asn	Ile	Lys	Ala	Tyr	Pro	Lys	Pro	Thr	Thr	Asp	Thr	Ser	Ala
305					310					315					320
Lys	Pro	Glu	Asp	Lys	Lys	Ser	Ala	Ala	Lys	Arg	Tyr	Ile	Val	Ser	Asn
				325					330					335	
Val	Tyr	Ile	Gly	Gly	Leu	Pro	Asp	Lys	Thr	Val	Val	Ile	Thr	Ile	Lys
			340					345					350		
Leu	Asn	Ala	Glu	Thr	Glu	Ser	Ala	Tyr	Ser	Met	Thr	Phe	Glu	Phe	Thr
		355					360					365			
Trp	Ala	Lys	Thr	Phe	Glu	Asn	Leu	Gln	Phe	Asp	Ser	Ser	Ser	Phe	Thr
	370					375					380				
Phe	Ser	Tyr	Ile	Ala	Gln	Glu									
385					390										

<210> 49
<211> 339
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(339)
<223> Serotype 39 fiber protein

<400> 49

Ile Arg Ile Ser Pro Ser Ser Leu Pro Pro Leu Ser Pro Pro Met Asp
1 5 10 15

Ser Lys Thr Ser Pro Leu Gly Cys Tyr His Ser Asn Trp Leu Thr Gln
20 25 30

Ser Pro Ser Pro Met Gly Met Ser His Ser Arg Trp Glu Gly Gly Ser
35 40 45

Pro Trp Gln Glu Gly Thr Gly Asp Leu Lys Val Asn Ala Lys Ser Pro
50 55 60

Leu Gln Val Ala Thr Asn Lys Gln Leu Glu Ile Ala Leu Ala Lys Pro
65 70 75 80

Phe Glu Glu Lys Asp Gly Lys Leu Ala Leu Lys Ile Gly His Gly Leu
85 90 95

Ala Val Val Asp Glu Asn His Thr His Leu Gln Ser Leu Ile Gly Thr
100 105 110

Leu Val Ile Leu Thr Gly Lys Gly Ile Gly Thr Gly Arg Ala Glu Ser
115 120 125

Gly Gly Thr Ile Asp Val Arg Leu Gly Ser Gly Gly Gly Leu Ser Phe
130 135 140

Asp Lys Asp Gly Asn Leu Val Ala Trp Asn Lys Asp Asp Asp Arg Arg
145 150 155 160

Thr Leu Trp Thr Thr Pro Asp Pro Ser Pro Asn Cys Lys Ile Asp Gln
165 170 175

Asp Lys Asp Ser Lys Leu Thr Phe Val Leu Thr Lys Cys Gly Ser Gln
180 185 190

Ile Leu Ala Asn Met Ser Leu Leu Val Val Lys Gly Lys Phe Ser Met
195 200 205

Ile Asn Asn Lys Val Asn Gly Thr Asp Asp Tyr Lys Lys Phe Thr Ile
210 215 220

Lys Leu Leu Phe Asp Glu Lys Gly Val Leu Leu Lys Asp Ser Ser Leu
225 230 235 240

Asp Lys Glu Tyr Trp Asn Tyr Arg Ser Asn Asn Asn Asn Val Gly Ser
245 250 255

Ala Tyr Glu Glu Ala Val Gly Phe Met Pro Ser Thr Thr Ala Tyr Pro
260 265 270

Lys Pro Pro Thr Pro Pro Thr Asn Pro Thr Thr Pro Leu Glu Lys Ser
275 280 285

Gln Ala Lys Asn Lys Tyr Val Ser Asn Val Tyr Leu Gly Gly Gln Ala
290 295 300

Gly Asn Pro Val Ala Thr Thr Val Ser Phe Asn Lys Glu Thr Gly Cys
305 310 315 320

Thr Tyr Ser Ile Thr Phe Asp Phe Ala Trp Asn Lys Thr Tyr Glu Asn
325 330 335

Val Gln Cys

<210> 50
<211> 380
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(380)
<223> Serotype 42 fiber protein

<220>
<221> MISC FEATURE
<222> (237)
<223> 'Xaa' at position 237 indicates an unidentified amino acid due to unidentified nucleotide(s)

<400> 50

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val
35 40 45

Ser Ser Asp Gly Phe Lys Asn Phe Pro Pro Gly Val Leu Ser Leu Lys
50 55 60

Leu Ala Asn Pro Ile Ala Ile Thr Asn Gly Asp Val Ser Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Thr Leu Gln Asp Gly Thr Gly Lys Leu Thr Ile Asp
85 90 95

Thr Lys Thr Pro Leu Gln Val Ala Asn Asn Lys Leu Glu Leu Ala Phe
100 105 110

Asp Ala Pro Leu Tyr Glu Lys Asn Gly Lys Leu Ala Leu Lys Thr Gly
115 120 125

His	Gly	Leu	Ala	Val	Leu	Thr	Lys	Asp	Ile	Gly	Ile	Pro	Glu	Leu	Ile
	130					135					140				

Gly	Ser	Leu	Val	Ile	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Thr	Gly	Thr	Val
145					150					155					160

Ala	Gly	Gly	Gly	Thr	Ile	Asp	Val	Arg	Leu	Gly	Asp	Asp	Gly	Gly	Leu
				165					170					175	

Ser	Phe	Asp	Lys	Lys	Gly	Asp	Leu	Val	Ala	Trp	Asn	Lys	Lys	Asn	Asp
			180					185					190		

Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp	Pro	Ser	Pro	Asn	Cys	Arg	Val
		195					200					205			

Ser	Glu	Asp	Lys	Asp	Ser	Lys	Leu	Thr	Leu	Ile	Leu	Thr	Lys	Cys	Gly
	210					215					220				

Ser	Gln	Ile	Leu	Ala	Ser	Phe	Ser	Leu	Leu	Val	Val	Xaa	Gly	Thr	Tyr
225					230					235					240

Thr	Thr	Val	Asp	Lys	Asn	Thr	Thr	Asn	Lys	Gln	Phe	Ser	Ile	Lys	Leu
				245					250					255	

Leu	Phe	Asp	Ala	Asn	Gly	Lys	Leu	Lys	Ser	Glu	Ser	Asn	Leu	Ser	Gly
			260					265					270		

Tyr	Trp	Asn	Tyr	Arg	Ser	Asp	Asn	Ser	Val	Val	Ser	Thr	Pro	Tyr	Asp
		275					280					285			

Asn	Ala	Val	Pro	Phe	Met	Pro	Asn	Thr	Thr	Ala	Tyr	Pro	Lys	Ile	Ile
	290					295					300				

Asn	Ser	Thr	Thr	Asp	Pro	Glu	Asn	Lys	Lys	Ser	Ser	Ala	Lys	Lys	Thr
305					310					315					320

Ile Val Gly Asn Val Tyr Leu Glu Gly Asn Ala Gly Gln Pro Val Ala
325 330 335

Val Ala Ile Ser Phe Asn Lys Glu Thr Thr Ala Asp Tyr Ser Ile Thr
340 345 350

Phe Asp Phe Ala Trp Ser Lys Ala Tyr Glu Thr Pro Val Pro Phe Asp
355 360 365

Thr Ser Ser Met Thr Phe Ser Tyr Ile Ala Gln Glu
370 375 380

<210> 51
<211> 328
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(328)
<223> Serotype 43 fiber protein

<220>
<221> MISC FEATURE
<222> (4)
<223> 'Xaa' at position 4 indicates an unidentified amino acid due to unidentified nucleotide(s)

<220>
<221> MISC FEATURE
<222> (232)
<223> 'Xaa' at positions 232 and 233 indicate an unidentified amino acid due to unidentified nucleotide(s)

<400> 51

Asn Ile Pro Xaa Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe Lys
1 5 10 15

Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile Thr
20 25 30

Ile Thr Asn Gly Asp Val Ser Leu Lys Val Gly Gly Gly Leu Thr Val
35 40 45

Glu Lys Glu Ser Gly Asn Leu Thr Val Asn Pro Lys Ala Pro Leu Gln
50 55 60

Val Ala Lys Gly Gln Leu Glu Leu Ala Tyr Asp Ser Pro Phe Asp Val
65 70 75 80

Lys Asn Asn Met Leu Thr Leu Lys Ala Gly His Gly Leu Ala Val Val
85 90 95

Thr Lys Asp Asn Thr Asp Leu Gln Pro Leu Met Gly Thr Leu Val Val
100 105 110

Leu Thr Gly Lys Gly Ile Gly Thr Gly Thr Ser Ala His Gly Gly Thr
115 120 125

Ile Asp Val Arg Ile Gly Lys Asn Gly Ser Leu Ala Phe Asp Lys Asp
130 135 140

Gly Asp Leu Val Ala Trp Asp Lys Glu Asn Asp Arg Arg Thr Leu Trp
145 150 155 160

Thr Thr Pro Asp Thr Ser Pro Asn Cys Lys Met Ser Glu Ala Lys Asp
165 170 175

Ser Lys Leu Thr Leu Ile Leu Thr Lys Cys Gly Ser Gln Ile Leu Gly
180 185 190

Ser Val Ser Leu Leu Ala Val Lys Gly Glu Tyr Gln Asn Met Thr Ala
195 200 205

Asn Thr Lys Lys Asn Val Lys Ile Thr Leu Leu Phe Asp Ala Asn Gly
210 215 220

Val Leu Leu Ala Gly Ser Ser Xaa Xaa Lys Glu Tyr Trp Asn Phe Arg
225 230 235 240

Ser Asn Asp Ser Thr Val Ser Gly Asn Tyr Glu Asn Ala Val Gln Phe
245 250 255

Met Pro Asn Ile Thr Ala Tyr Lys Pro Thr Asn Ser Lys Ser Tyr Ala
260 265 270

Arg Ser Val Ile Phe Gly Asn Val Tyr Ile Asp Ala Lys Pro Tyr Asn
275 280 285

Pro Val Val Ile Lys Ile Ser Phe Asn Gln Glu Thr Gln Asn Asn Cys
290 295 300

Val Tyr Ser Ile Ser Phe Asp Tyr Thr Leu Ser Lys Asp Tyr Pro Asn
305 310 315 320

Met Gln Phe Asp Val Thr Leu Ser
325

<210> 52
<211> 341
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(341)
<223> Serotype 44 fiber protein

<400> 52

Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe Gln
1 5 10 15

Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile Thr
20 25 30

Ile Thr Asn Gly Asn Val Ser Leu Lys Val Gly Gly Gly Leu Thr Leu
35 40 45

Gln Glu Gly Thr Gly Asp Leu Lys Val Asn Ala Lys Ser Pro Leu Gln
50 55 60

Val	Ala	Thr	Asn	Lys	Gln	Leu	Glu	Ile	Ala	Leu	Ala	Lys	Pro	Phe	Glu
65					70					75					80

Glu	Lys	Asp	Gly	Lys	Leu	Ala	Leu	Lys	Ile	Gly	His	Gly	Leu	Ala	Val
				85					90					95	

Val	Asp	Glu	Asn	His	Thr	His	Leu	Gln	Ser	Leu	Ile	Gly	Thr	Leu	Val
			100					105					110		

Ile	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Thr	Gly	Ser	Ala	Glu	Ser	Gly	Gly
		115					120					125			

Thr	Ile	Asp	Val	Arg	Leu	Gly	Ser	Gly	Gly	Gly	Leu	Ser	Phe	Asp	Lys
	130					135					140				

Asp	Gly	Asn	Leu	Val	Ala	Trp	Asn	Lys	Asp	Asp	Asp	Arg	Arg	Thr	Leu
145					150					155					160

Trp	Thr	Thr	Pro	Asp	Pro	Ser	Pro	Asn	Cys	Lys	Ile	Asp	Gln	Asp	Lys
				165					170					175	

Asp	Ser	Lys	Leu	Thr	Phe	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu
			180					185					190		

Ala	Asn	Met	Ser	Leu	Leu	Val	Val	Lys	Gly	Lys	Phe	Ser	Met	Ile	Asn
		195					200					205			

Asn	Lys	Val	Asn	Gly	Thr	Asp	Asp	Tyr	Lys	Lys	Phe	Thr	Ile	Lys	Leu
	210					215					220				

Leu	Phe	Asp	Glu	Lys	Gly	Val	Leu	Leu	Lys	Asp	Ser	Ser	Leu	Asp	Lys
225					230					235					240

Glu	Tyr	Trp	Asn	Tyr	Arg	Ser	Asn	Asn	Asn	Asn	Val	Gly	Ser	Ala	Tyr
				245					250					255	

Glu Glu Ala Val Gly Phe Met Pro Ser Thr Thr Ala Tyr Pro Lys Pro
260 265 270

Pro Thr Pro Pro Thr Asn Pro Thr Thr Pro Leu Glu Lys Ser Gln Ala
275 280 285

Lys Asn Lys Tyr Val Ser Asn Val Tyr Leu Gly Gly Gln Ala Gly Asn
290 295 300

Pro Val Ala Thr Thr Val Ser Phe Asn Lys Glu Thr Gly Cys Thr Tyr
305 310 315 320

Ser Ile Thr Phe Asp Phe Ala Trp Asn Lys Thr Tyr Glu Asn Val Gln
325 330 335

Phe Asp Ser Ser Phe
340

<210> 53
<211> 345
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(345)
<223> Serotype 45 fiber protein

<400> 53

Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe Gln
1 5 10 15

Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile Ala
20 25 30

Ile Thr Asn Gly Asp Val Ser Leu Lys Val Gly Gly Gly Leu Thr Val
35 40 45

Glu Lys Asp Ser Gly Asn Leu Lys Val Asn Pro Lys Ala Pro Leu Gln
50 55 60

Val	Thr	Thr	Asp	Lys	Gln	Leu	Glu	Ile	Ala	Leu	Ala	Tyr	Pro	Phe	Glu
65					70					75					80

Val	Ser	Asn	Gly	Lys	Leu	Gly	Ile	Lys	Ala	Gly	His	Gly	Leu	Lys	Val
				85					90					95	

Ile	Asp	Lys	Ile	Ala	Gly	Leu	Glu	Gly	Leu	Ala	Gly	Thr	Leu	Val	Val
			100					105					110		

Leu	Thr	Gly	Lys	Gly	Ile	Gly	Thr	Glu	Asn	Leu	Glu	Asn	Ser	Asp	Gly
		115					120					125			

Ser	Ser	Arg	Gly	Val	Gly	Ile	Asn	Val	Arg	Leu	Ala	Lys	Asp	Gly	Val
	130					135					140				

Leu	Ala	Phe	Asp	Lys	Lys	Gly	Asp	Leu	Val	Ala	Trp	Asn	Lys	His	Asp
145					150					155					160

Asp	Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp	Pro	Ser	Pro	Asn	Cys	Thr
				165					170					175	

Ile	Asp	Gln	Glu	Arg	Asp	Ser	Lys	Leu	Thr	Leu	Val	Leu	Thr	Lys	Cys
			180					185					190		

Gly	Ser	Gln	Ile	Leu	Ala	Asn	Val	Ser	Leu	Leu	Val	Val	Lys	Gly	Lys
		195					200					205			

Phe	Ser	Asn	Ile	Asn	Asn	Asn	Ala	Asn	Pro	Thr	Asp	Lys	Lys	Ile	Thr
	210					215					220				

Val	Lys	Leu	Leu	Phe	Asn	Glu	Lys	Gly	Val	Leu	Met	Asp	Ser	Ser	Thr
225					230					235					240

Leu	Lys	Lys	Glu	Tyr	Trp	Asn	Tyr	Arg	Asn	Asp	Asn	Ser	Thr	Val	Ser
				245					250					255	

Gln Ala Tyr Asp Asn Ala Val Pro Phe Met Pro Asn Ile Lys Ala Tyr
260 265 270

Pro Lys Pro Ser Thr Asp Thr Ser Ala Lys Pro Glu Asp Lys Lys Ser
275 280 285

Ala Ala Lys Arg Tyr Ile Val Ser Asn Val Tyr Ile Gly Gly Leu Pro
290 295 300

Asp Lys Thr Val Val Ile Thr Ile Lys Phe Asn Ala Glu Thr Glu Cys
305 310 315 320

Ala Tyr Ser Ile Thr Phe Glu Phe Thr Trp Ala Lys Thr Phe Glu Asp
325 330 335

Val Gln Cys Asp Ser Ser Ser Phe Thr
340 345

<210> 54
<211> 340
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(340)
<223> Serotype 46 fiber protein

<400> 54

Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe Lys
1 5 10 15

Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile Ala
20 25 30

Ile Val Asn Gly Asp Val Ser Leu Lys Val Gly Gly Gly Leu Thr Leu
35 40 45

Gln Glu Gly Asn Leu Thr Val Asp Ala Lys Ala Pro Leu Gln Val Ala
50 55 60

Asn	Asp	Asn	Lys	Leu	Glu	Leu	Ser	Tyr	Ala	Asp	Pro	Phe	Glu	Val	Lys
65					70					75					80

Asp	Thr	Lys	Leu	Gln	Leu	Lys	Val	Gly	His	Gly	Leu	Lys	Val	Ile	Asp
				85					90					95	

Glu	Lys	Thr	Ser	Ser	Gly	Leu	Gln	Ser	Leu	Ile	Gly	Asn	Leu	Val	Val
			100					105					110		

Leu	Thr	Gly	Lys	Gly	Ile	Gly	Thr	Gln	Glu	Leu	Lys	Asp	Lys	Asp	Asp
		115					120					125			

Glu	Thr	Lys	Asn	Ile	Gly	Val	Gly	Ile	Asn	Val	Arg	Ile	Gly	Lys	Asn
	130					135					140				

Glu	Ser	Leu	Ala	Phe	Asp	Lys	Asp	Gly	Asn	Leu	Val	Ala	Trp	Asp	Asn
145					150					155					160

Glu	Asn	Asp	Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp	Thr	Ser	Ser	Lys
				165					170					175	

Phe	Val	Lys	Ile	Ser	Thr	Glu	Lys	Asp	Ser	Lys	Leu	Thr	Leu	Val	Leu
			180					185					190		

Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Ser	Val	Ser	Leu	Leu	Ala	Val
		195					200					205			

Ala	Gly	Ser	Tyr	Leu	Asn	Met	Thr	Ala	Ser	Thr	Gln	Lys	Ser	Ile	Lys
	210					215					220				

Val	Ser	Leu	Met	Phe	Asp	Ser	Lys	Gly	Leu	Leu	Met	Thr	Thr	Ser	Ser
225					230					235					240

Ile	Asp	Lys	Gly	Tyr	Trp	Asn	Tyr	Arg	Asn	Lys	Asn	Ser	Val	Val	Gly
				245					250					255	

Thr Ala Tyr Glu Asn Ala Ile Pro Phe Met Pro Asn Leu Val Ala Tyr
260 265 270

Pro Arg Pro Asn Thr Pro Asp Ser Lys Ile Tyr Ala Arg Ser Lys Ile
275 280 285

Val Gly Asn Val Tyr Leu Ala Gly Leu Ala Tyr Gln Pro Ile Val Ile
290 295 300

Thr Val Ser Phe Asn Gln Glu Lys Asp Ala Ser Cys Ala Tyr Ser Ile
305 310 315 320

Thr Phe Glu Phe Ala Trp Asn Lys Asp Tyr Val Gly Gln Phe Asp Thr
325 330 335

Thr Ser Phe Thr
340

<210> 55
<211> 389
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(389)
<223> Serotype 47 fiber protein

<400> 55

Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met Lys Arg
1 5 10 15

Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr Gly Tyr
20 25 30

Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser
35 40 45

Asp Gly Phe Lys Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala
50 55 60

Asp	Pro	Ile	Thr	Ile	Thr	Asn	Gly	Asp	Val	Ser	Leu	Lys	Val	Gly	Gly
65					70					75					80

Gly	Leu	Thr	Leu	Gln	Glu	Gly	Thr	Gly	Asn	Leu	Thr	Val	Asn	Ala	Lys
				85					90					95	

Ala	Pro	Leu	Gln	Val	Ala	Asp	Asp	Lys	Lys	Leu	Glu	Leu	Ser	Tyr	Asp
			100					105					110		

Asn	Pro	Phe	Glu	Val	Ser	Ala	Asn	Lys	Leu	Ser	Leu	Lys	Val	Gly	His
		115					120					125			

Gly	Leu	Lys	Val	Leu	Asp	Glu	Lys	Asn	Ser	Gly	Gly	Leu	Gln	Glu	Leu
	130					135					140				

Ile	Gly	Lys	Leu	Val	Ile	Leu	Thr	Gly	Lys	Gly	Ile	Gly	Val	Glu	Glu
145					150					155					160

Leu	Lys	Asn	Ala	Asp	Asn	Thr	Asn	Arg	Gly	Val	Gly	Ile	Asn	Val	Arg
				165					170					175	

Leu	Gly	Lys	Asp	Gly	Gly	Leu	Ser	Phe	Asp	Lys	Lys	Gly	Glu	Leu	Val
			180					185					190		

Ala	Trp	Asn	Lys	His	Asn	Asp	Thr	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp
		195					200					205			

Pro	Ser	Pro	Asn	Cys	Lys	Ile	Glu	Gln	Asp	Lys	Asp	Ser	Lys	Leu	Thr
	210					215					220				

Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Thr	Met	Ala	Phe
225					230					235					240

Gln	Val	Val	Lys	Gly	Thr	Tyr	Glu	Asn	Ile	Ser	Lys	Asn	Thr	Ala	Lys
				245					250					255	

Lys Ser Phe Ser Ile Lys Leu Leu Phe Asp Asp Asn Gly Lys Leu Leu
260 265 270

Glu Gly Ser Ser Leu Asp Lys Asp Tyr Trp Asn Phe Arg Asn Asp Asp
275 280 285

Ser Ile Met Pro Asn Gln Tyr Asp Asn Ala Val Pro Phe Met Pro Asn
290 295 300

Leu Lys Ala Tyr Pro Asn Pro Lys Thr Ser Thr Val Leu Pro Ser Thr
305 310 315 320

Asp Lys Lys Ser Asn Gly Lys Asn Thr Ile Val Ser Asn Leu Tyr Leu
325 330 335

Glu Gly Lys Ala Tyr Gln Pro Val Ala Val Thr Ile Thr Phe Asn Lys
340 345 350

Glu Thr Gly Cys Thr Tyr Ser Ile Thr Phe Glu Phe Gly Trp Ala Lys
355 360 365

Thr Tyr Asp Val Pro Ile Pro Phe Asp Ser Ser Ser Phe Thr Phe Ser
370 375 380

Tyr Ile Ala Gln Glu
385

<210> 56
<211> 343
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(343)
<223> Serotype 48 fiber protein

<400> 56

Ser Asp Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe
1 5 10 15

Gln Asn Phe Pro Pro Gly Val Leu Ser Leu Lys Leu Ala Asp Pro Ile
20 25 30

Thr Ile Thr Asn Gly Asn Val Ser Leu Lys Val Gly Gly Gly Leu Thr
35 40 45

Leu Gln Glu Gly Thr Gly Asp Leu Lys Val Asn Ala Lys Ser Pro Leu
50 55 60

Gln Val Ala Thr Asn Lys Gln Leu Glu Ile Ala Leu Ala Lys Pro Phe
65 70 75 80

Glu Glu Lys Asp Gly Lys Leu Ala Leu Lys Ile Gly His Glu Leu Ala
85 90 95

Val Val Asp Glu Asn Leu Thr His Leu Gln Ser Leu Ile Gly Thr Leu
100 105 110

Val Ile Leu Thr Gly Lys Gly Ile Gly Thr Gly Arg Ala Glu Ser Gly
115 120 125

Gly Thr Ile Asp Val Arg Leu Gly Ser Gly Gly Gly Leu Ser Phe Asp
130 135 140

Lys Asp Gly Asn Leu Val Ala Trp Asn Lys Asp Asp Asp Arg Arg Thr
145 150 155 160

Leu Trp Thr Thr Pro Asp Pro Ser Pro Asn Cys Lys Ile Asp Gln Asp
165 170 175

Lys Asp Ser Lys Leu Thr Phe Val Leu Thr Lys Cys Gly Ser Gln Ile
180 185 190

Leu Ala Asn Met Ser Leu Leu Val Val Lys Gly Lys Phe Ser Met Ile
195 200 205

Asn Asn Lys Val Asn Gly Thr Asp Asp Tyr Lys Lys Phe Thr Ile Lys

210 215 220

Leu Leu Phe Asp Glu Lys Gly Val Leu Leu Lys Asp Ser Ser Leu Asp
225 230 235 240

Lys Glu Tyr Trp Asn Tyr Arg Ser Asn Asn Asn Asn Val Gly Ser Ala
245 250 255

Tyr Glu Glu Ala Val Gly Phe Met Pro Ser Thr Thr Ala Tyr Pro Lys
260 265 270

Pro Pro Thr Pro Pro Thr Asn Pro Thr Thr Pro Leu Glu Lys Ser Gln
275 280 285

Ala Lys Asn Lys Tyr Val Ser Asn Val Tyr Leu Gly Gly Gln Ala Gly
290 295 300

Asn Pro Val Ala Thr Thr Val Ser Phe Asn Lys Glu Thr Gly Cys Thr
305 310 315 320

Tyr Ser Ile Thr Phe Asp Phe Ala Trp Asn Lys Thr Tyr Lys Met Ala
325 330 335

Phe Ile Pro Arg Phe Asn Phe
340

<210> 57
<211> 394
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(394)
<223> Serotype 49 fiber protein

<220>
<221> MISC FEATURE
<222> (262)
<223> 'Xaa' at position 262 indicates an unidentified amino acid due to unidentified nucleotide(s)

<400> 57

Ser	Cys	Ser	Cys	Pro	Ser	Ala	Pro	Thr	Ile	Phe	Met	Leu	Leu	Gln	Met
1				5				10						15	

Lys	Arg	Ala	Arg	Pro	Ser	Glu	Asp	Thr	Phe	Asn	Pro	Val	Tyr	Pro	Tyr
			20					25					30		

Gly	Tyr	Ala	Arg	Asn	Gln	Asn	Ile	Pro	Phe	Leu	Thr	Pro	Pro	Phe	Val
		35					40					45			

Ser	Ser	Asp	Gly	Phe	Gln	Asn	Phe	Pro	Pro	Gly	Val	Leu	Ser	Leu	Lys
	50					55					60				

Leu	Ala	Asp	Pro	Ile	Ala	Ile	Thr	Asn	Gly	Asn	Val	Ser	Leu	Lys	Val
65					70					75					80

Gly	Gly	Gly	Leu	Thr	Val	Glu	Gln	Asp	Ser	Gly	Asn	Leu	Lys	Val	Asn
				85					90					95	

Pro	Lys	Ala	Pro	Leu	Gln	Val	Ala	Thr	Asp	Asn	Gln	Leu	Glu	Ile	Ser
			100					105					110		

Leu	Ala	Asp	Pro	Phe	Glu	Val	Lys	Asn	Lys	Lys	Leu	Ser	Leu	Lys	Val
		115					120					125			

Gly	His	Gly	Leu	Lys	Val	Ile	Asp	Glu	Asn	Ile	Ser	Thr	Leu	Gln	Gly
	130					135					140				

Leu	Leu	Gly	Asn	Leu	Val	Val	Leu	Thr	Gly	Met	Gly	Ile	Gly	Thr	Glu
145					150					155					160

Glu	Leu	Lys	Lys	Asp	Asp	Lys	Ile	Val	Gly	Ser	Ala	Val	Asn	Val	Arg
				165					170					175	

Leu	Gly	Gln	Asp	Gly	Gly	Leu	Thr	Phe	Asp	Lys	Lys	Gly	Asp	Leu	Val
			180					185					190		

Ala	Trp	Asn	Lys	Glu	Asn	Asp	Arg	Arg	Thr	Leu	Trp	Thr	Thr	Pro	Asp
		195					200					205			

Pro	Ser	Pro	Asn	Cys	Lys	Val	Ser	Glu	Glu	Lys	Asp	Ser	Lys	Leu	Thr
	210					215					220				

Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile	Leu	Ala	Ser	Val	Ser	Leu
225					230					235					240

Leu	Val	Val	Lys	Gly	Lys	Phe	Ala	Asn	Ile	Asn	Asn	Lys	Thr	Asn	Pro
				245					250					255	

Gly	Glu	Asp	Tyr	Lys	Xaa	Phe	Ser	Val	Lys	Leu	Leu	Phe	Asp	Ala	Asn
			260					265					270		

Gly	Lys	Leu	Leu	Thr	Gly	Ser	Ser	Leu	Asp	Gly	Asn	Tyr	Trp	Asn	Tyr
		275					280					285			

Lys	Asn	Lys	Asp	Ser	Val	Ile	Gly	Ser	Pro	Tyr	Glu	Asn	Ala	Val	Pro
	290					295					300				

Phe	Met	Pro	Asn	Ser	Thr	Ala	Tyr	Pro	Lys	Ile	Ile	Asn	Asn	Gly	Thr
305					310					315					320

Ala	Asn	Pro	Glu	Asp	Lys	Lys	Ser	Ala	Ala	Lys	Lys	Thr	Ile	Val	Thr
				325					330					335	

Asn	Val	Tyr	Leu	Gly	Gly	Asp	Ala	Ala	Lys	Pro	Val	Ala	Thr	Thr	Ile
			340					345					350		

Ser	Phe	Asn	Lys	Glu	Thr	Glu	Ser	Asn	Cys	Val	Tyr	Ser	Ile	Thr	Phe
		355					360					365			

Asp	Phe	Ala	Trp	Asn	Lys	Thr	Tyr	Lys	Asn	Val	Pro	Phe	Asp	Ser	Ser
	370					375					380				

Ser	Leu	Thr	Phe	Ser	Tyr	Ile	Ala	Gln	Glu
385					390				

<210> 58
<211> 353
<212> PRT
<213> adenoviridae

<220>
<221> VARIANT
<222> (1)..(353)
<223> Serotype 51 fiber protein

<400> 58

Ser Cys Ser Cys Pro Ser Ala Pro Thr Ile Phe Met Leu Leu Gln Met
1 5 10 15

Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
20 25 30

Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile Asn Pro Gly Phe Ile
35 40 45

Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly Val Leu Thr Leu Asn
50 55 60

Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Pro Leu Gln Leu Lys Val
65 70 75 80

Gly Gly Gly Leu Ile Val Asp Asp Thr Asp Gly Thr Leu Gln Glu Asn
85 90 95

Ile Arg Val Thr Ala Pro Ile Thr Lys Asn Asn His Ser Val Glu Leu
100 105 110

Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn Lys Leu Cys Ala Lys
115 120 125

Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp Ile Cys Ile Lys Asp
130 135 140

Ser Ile Asn Thr Leu Trp Thr Gly Ile Lys Pro Pro Pro Asn Cys Gln

145				150				155				160
Ile	Val	Glu	Asn	Thr	Asp	Thr	Asn	Asp	Gly	Lys	Leu	Thr	Leu	Val	Leu
				165				170				175			
Val	Lys	Asn	Gly	Gly	Leu	Val	Asn	Gly	Tyr	Val	Ser	Leu	Val	Gly	Val
			180				185				190				
Ser	Asp	Thr	Val	Asn	Gln	Met	Phe	Thr	Gln	Lys	Ser	Ala	Thr	Ile	Gln
		195				200				205					
Leu	Arg	Leu	Tyr	Phe	Asp	Ser	Ser	Gly	Asn	Leu	Leu	Thr	Asp	Glu	Ser
	210				215				220						
Asn	Leu	Lys	Ile	Pro	Leu	Lys	Asn	Lys	Ser	Ser	Thr	Ala	Thr	Ser	Glu
225				230				235							240
Ala	Ala	Thr	Ser	Ser	Lys	Ala	Phe	Met	Pro	Ser	Thr	Thr	Ala	Tyr	Pro
				245				250				255			
Phe	Asn	Thr	Thr	Thr	Arg	Asp	Ser	Glu	Asn	Tyr	Ile	His	Gly	Ile	Cys
			260				265				270				
Tyr	Tyr	Met	Thr	Ser	Tyr	Asp	Arg	Ser	Leu	Val	Pro	Leu	Asn	Ile	Ser
		275				280				285					
Ile	Met	Leu	Asn	Ser	Arg	Thr	Ile	Ser	Ser	Asn	Val	Ala	Tyr	Ala	Ile
	290				295				300						
Gln	Phe	Glu	Trp	Asn	Leu	Asn	Ala	Lys	Glu	Ser	Pro	Glu	Ser	Asn	Ile
305				310				315							320
Ala	Thr	Leu	Thr	Thr	Ser	Pro	Phe	Phe	Phe	Ser	Tyr	Ile	Ile	Glu	Asp
				325				330				335			
Thr	Thr	Lys	Cys	Ile	Ser	Leu	Cys	Tyr	Val	Ser	Thr	Cys	Leu	Phe	Phe
			340				345				350				

Asn

Title: Infection with ~~chimaeric~~chimeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR).

~~Abstract~~ABSTRACT

The invention relates to the field of molecular genetics and medicine. The invention discloses a method for delivering a nucleic acid of interest to a host cell by means of a gene delivery vehicle based on adenoviral material, whereby ~~said~~ the gene delivery vehicle delivers the nucleic acid to the host cell by associating with a binding site and/or a receptor present on CAR-negative cells, said binding site and/or receptor being a binding site and/or a receptor for adenovirus subgroups D and/or F.

APPENDIX C

(CLEAN VERSION OF CLAIMS)

(Serial No. 10/040,949)

CLAIMS

1. A method for delivering a nucleic acid of interest to a host cell by means of a gene delivery vehicle based on adenoviral material, whereby said gene delivery vehicle delivers the nucleic acid to the host cell by associating with a binding site and/or a receptor present on CAR-negative cells, said binding site and/or receptor being a binding site and/or a receptor for adenovirus subgroups D and/or F.

3. A gene delivery vehicle being a chimera based on at least two adenoviruses, whereby a cell recognising element of said gene delivery vehicle is based on adenoviral material from a subgroup D and/or F adenovirus, which material confers the capability of infecting CAR negative cells.

4. A gene delivery vehicle according to claim 3, wherein said adenoviral material is based on a fiber, a penton and/or a hexon protein of a subgroup D and/or subgroup F adenovirus.

5. (Amended) The chimeric gene delivery vehicle of claim 3, further comprising: an element from adenovirus 35 responsible for at least partially avoiding an immune response against adenovirus 35 in man.

6. (Amended) The chimeric gene delivery vehicle of claim 5, comprising an adenoviral 16 element or a functional analogue thereof, said adenoviral 16 element conferring adenovirus 16 with an enhanced capability to infect smooth muscle cells and/or synoviocytes.

7. (Amended) The chimeric gene delivery vehicle of claim 3, further comprising adenoviral nucleic acid.

8. (Amended) The chimeric gene delivery vehicle of claim 3, further comprising adenoviral nucleic acid derived from at least two different adenoviral types.

9. (Amended) The chimeric gene delivery vehicle of claim 8, wherein said adenoviral nucleic acid comprises at least one sequence encoding a capsid protein comprising at

least a tissue tropism determining fragment of adenovirus subgroup D and/or adenovirus subgroup F capsid protein.

10. (Amended) The chimeric gene delivery vehicle of claim 9, wherein said adenoviral nucleic acid is modified to reduce or disable the ability of said adenoviral nucleic acid to replicate in a target cell.

11. (Amended) The chimeric gene delivery vehicle of claim 7, wherein said adenoviral nucleic acid has been modified to reduce or disable the capacity of a host immune system to mount an immune response against adenoviral proteins encoded by said adenoviral nucleic acid.

12. (Amended) The chimeric gene delivery vehicle of claim 7, comprising a minimal adenovirus vector or an integrating adenovirus.

13. (Amended) The chimeric gene delivery vehicle of claim 7 further comprising at least one non-adenoviral nucleic acid.

14. (Amended) The chimeric gene delivery vehicle of claim 8 wherein said adenoviral nucleic acid is produced by a process comprising:

welding together, through homologous recombination, two nucleic acid molecules comprising partially overlapping sequences wherein said partially overlapping sequences allowing essentially only a single homologous recombination event thus generating a physically linked nucleic acid comprising:

a nucleic acid of interest, at least two functional adenoviral inverted terminal repeats (ITRs), and a functional encapsulation signal, or functional parts, derivatives or analogues of said ITRs and/or encapsulation signal.

15. (Amended) A cell for producing the chimeric gene delivery vehicle of claim 3, said cell comprising:

first means for assemblying said gene delivery vehicle wherein said first means includes further means for producing of an adenovirus capsid protein, said capsid protein comprising at least a receptor and/or binding site binding fragment of adenovirus subgroup D and/or adenovirus subgroup F capsid protein.

16. A cell according to claim 15, wherein said cell is or is derived from a PER.C6 cell (ECACC deposit number 96022940).

18. A receptor and/or a binding site for adenoviruses type D and/or F, present on or associated with CAR negative cells.

19. A receptor and/or a binding site according to claim 18, present on K562 cells, amniotic fluid cells and/or primary fibroblast cells.

20. A capsid protein derived from a subgroup D and/or a subgroup F adenovirus or a functional part, derivative and/or analogue thereof.

21. A capsid protein according to claim 20, wherein said protein is a fiber protein.

22. (Amended) An isolated and/or recombinant nucleic acid encoding a capsid protein of claim 20.

23. An isolate and/or recombinant nucleic acid according to claim 22, wherein said nucleic acid comprises a sequence as depicted in Figure 7.

APPENDIX D

(VERSION OF CLAIMS WITH MARKINGS TO SHOW CHANGES MADE)

(Serial No. 10/040,949)

~~Claims~~CLAIMS

1. A method for delivering a nucleic acid of interest to a host cell by means of a gene delivery vehicle based on adenoviral material, whereby said gene delivery vehicle delivers the nucleic acid to the host cell by associating with a binding site and/or a receptor present on CAR-negative cells, said binding site and/or receptor being a binding site and/or a receptor for adenovirus subgroups D and/or F.

3. A gene delivery vehicle being a ~~chimaera~~chimera based on at least two adenoviruses, whereby a cell recognising element of said gene delivery vehicle is based on adenoviral material from a subgroup D and/or F adenovirus, which material confers the capability of infecting CAR negative cells.

4. A gene delivery vehicle according to claim 3, wherein said adenoviral material is based on a fiber, a penton and/or a hexon protein of a subgroup D and/or subgroup F adenovirus.

5. (Amended) The chimeric gene delivery vehicle of claim 3, further comprising: an element from adenovirus 35 responsible for at least partially avoiding an immune response against adenovirus 35 in man.

6. (Amended) The chimeric gene delivery vehicle of claim 5, comprising an adenoviral 16 element or a functional analogue thereof, said adenoviral 16 element conferring adenovirus 16 with an enhanced capability to infect smooth muscle cells and/or synoviocytes.

7. (Amended) The chimeric gene delivery vehicle of claim 3, further comprising adenoviral nucleic acid.

8. (Amended) The chimeric gene delivery vehicle of claim 3, further comprising adenoviral nucleic acid derived from at least two different adenoviral types.

9. (Amended) The chimeric gene delivery vehicle of claim 8, wherein said adenoviral nucleic acid comprises at least one sequence encoding a capsid protein comprising at

least a tissue tropism determining fragment of adenovirus subgroup D and/or adenovirus subgroup F capsid protein.

10. (Amended) The chimeric gene delivery vehicle of claim 9, wherein said adenoviral nucleic acid is modified to reduce or disable the ability of said adenoviral nucleic acid to replicate in a target cell.

11. (Amended) The chimeric gene delivery vehicle of claim 7, wherein said adenoviral nucleic acid has been modified to reduce or disable the capacity of a host immune system to mount an immune response against adenoviral proteins encoded by said adenoviral nucleic acid.

12. (Amended) The chimeric gene delivery vehicle of claim 7, comprising a minimal adenovirus vector or an integrating adenovirus.

13. (Amended) The chimeric gene delivery vehicle of claim 7 further comprising at least one non-adenoviral nucleic acid.

14. (Amended) The chimeric gene delivery vehicle of claim 8 wherein said adenoviral nucleic acid is produced by a process comprising:

welding together, through homologous recombination, two nucleic acid molecules comprising partially overlapping sequences wherein said partially overlapping sequences allowing essentially only a single homologous recombination event thus generating a physically linked nucleic acid comprising:

a nucleic acid of interest, at least two functional adenoviral inverted terminal repeats (ITRs), and a functional encapsulation signal, or functional parts, derivatives or analogues of said ITRs and/or encapsulation signal.

15. (Amended) A cell for producing the chimeric gene delivery vehicle of claim 3, said cell comprising:

first means for assemblying said gene delivery vehicle wherein said first means includes further means for producing of an adenovirus capsid protein, said capsid protein comprising at least a receptor and/or binding site binding fragment of adenovirus subgroup D and/or adenovirus subgroup F capsid protein.

16. A cell according to claim 15, wherein said cell is or is derived from a PER.C6 cell (ECACC deposit number 96022940).

18. A receptor and/or a binding site for adenoviruses type D and/or F, present on or associated with CAR negative cells.

19. A receptor and/or a binding site according to claim 18, present on K562 cells, amniotic fluid cells and/or primary fibroblast cells.

20. A capsid protein derived from a subgroup D and/or a subgroup F adenovirus or a functional part, derivative and/or analogue thereof.

21. A capsid protein according to claim 20, wherein said protein is a fiber protein.

22. (Amended) An isolated and/or recombinant nucleic acid encoding a capsid protein of claim 20.

23. An isolate and/or recombinant nucleic acid according to claim 22, wherein said nucleic acid comprises a sequence as depicted in ~~figure~~Figure 7.